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Summary 
Streptomycetes are known for their ability to produce a range of different secondary 
metabolites, including antibiotics, immunosuppressive, anti-fungals, and anti-cancer 
compounds. Of these compounds, antibiotics play an important role in the clinics for 
treatment of both mild and severe bacterial infections. However, with the rise of 
multi-resistant pathogens, the demand for new antibiotics or derivatives of old ones, 
with improved properties, is now higher than ever.  
Recent efforts in genome sequencing and mining have revealed a so far untapped 
potential of streptomycetes and related actinomycetes as evident from so-called 
“silent” biosynthetic gene clusters, whose products remain undetectable under 
standard laboratory conditions. These clusters harbour all information necessary for 
production of potentially novel bioactive compounds, and hence provide high priority 
candidates for engineering to activate their production. With this knowledge, the need 
for better molecular tools to harness the potential of the gifted microorganisms is now 
greater than ever. One such molecular tool, which has truly revolutionised the field of 
genome engineering, is the CRISPR-Cas9 genome engineering system.  
In this thesis, the CRISPR-Cas9 system for genome engineering of actinomycetes was 
expanded for future applications in a high-throughput semi-automatic setting. First, a 
toolbox and workflow for construction of CRISPR plasmids, for a range of different 
engineering purposes was developed, including the computational prediction of 
suitable 20 bp protospacers for the single guide RNAs and a USER-cloning method 
for construction of the CRISPR plasmids. Additional improvement to the system was 
achieved through the development of an optimised USER assembly workflow for 
cheaper and faster plasmid construction. The workflow was verified by manual 
knock-down of two biosynthetic gene clusters in model organism Streptomyces 
coelicolor A3(2), which confirmed the applicability of the system.  
A second part of the thesis was devoted to engineering of Streptomyces collinus Tü 
365, which is a known producer of the narrow-spectrum antibiotic kirromycin.  
While there exists several studies addressing the PKS scaffold biosynthesis of 
kirromycin, knowledge about the supply of the precursor ethylmalonyl-CoA and most 
of the tailoring reactions remained scarce. In this thesis, the role of the gene kirN, 
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believed to be involved in precursor supply, and the six genes kirM, kirHIV, kirHV, 
kirHVI, kirOI and kirOII, all predicted to be involved in tailoring reactions, were 
investigated by gene inactivations, complementations, and characterisation of the 
biosynthetic products of the generated mutants. Within our studies, four novel 
kirromycin derivatives were generated and characterised. Our investigations allowed 
for closing some of the missing gaps in the biosynthesis of kirromycin, along with 
providing us with a toolbox of new mutants, which produce derivatives of the original 
compound. These derivatives could serve as scaffolds for future bioderivatization 
efforts.  
This thesis lays the groundwork for future engineering of streptomycetes to improve 
secondary metabolite production. For the USER-CRISPR-Cas9 platform, the next 
logical step will be to implement the workflow in a robotic setting. Furthermore, the 
mutants of S. collinus Tü 365 will be included in a derivatization platform to produce 
new kirromycin analogues with improved pharmacokinetic properties. 
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Sammenfatning 
Streptomyceter er kendt for deres evne til at fremstille forskellige bioaktive stoffer, 
deriblandt antibiotika, immunsuppresive, anti-svampe, og anti-cancer stoffer. Særligt 
antibiotika har en vigtig klinisk rolle, idet de har gjort det muligt at behandle både 
simple og mere seriøse bakterielle infektioner hurtigt og effektivt og med minimale 
bivirkninger. I de seneste år er efterspørgsel på nye og forbedrede antibiotika i 
mellemtiden steget, idet fremdriften af multiresistente bakterier vil komme til at 
udgøre en seriøs trussel for fremtidens samfund. 
Heldigvis har genomsekventering af disse talentfulde bakterier afsløret flere såkaldte 
kryptiske eller tavse gen clusters, der besidder potentialet for fremstilling af nye 
klinisk relevante stoffer, men forbliver udetektérbare under normale vækstforhold. En 
måde at udnytte dette skjulte potentiale og aktivere produktionen af de potentielt nye 
bioaktive stoffer er gennem brugen af molekylære værktøjer, såsom det nyudviklede 
CRISPR-Cas9 værktøj, til at ændre det kodende materiale i bakterierne.   
Denne afhandling søger at lægge et fundament for fremtidig engineering af 
streptomyceter med henblik på at fremme deres produktion af klinisk relevante 
bioaktive stoffer. Vores tilgang til dette kan deles op i to hovedprojekter.  
I første del af afhandlingen præsenteres udviklingen og optimeringen af en USER-
kloningsmetode til fremstilling af plasmider til CRISPR-Cas9 genome engineering. 
Kloningssystemet blev søgt optimeret for at fremme metodens brug i fremtidige high-
throughput, semi-automatisk systemer. Anvendeligheden af platformen blev testet 
manuelt i to proof-of-concept studier, hvor produktion af to bioaktive stoffer fra  
model-organismen Streptomyces coelicolor A3(2) blev hæmmet som følge af brugen 
af det nye plasmid-system. Med de lovende resultater fra den manuelle test af system 
bliver det næste store skridt at implementere kloningsmetoden på en robot og dermed 
teste anvendeligheden af hele arbejdsprocessen i en high-throughput baggrund.   
Anden del af afhandlingen omhandler genetiske studier og engineering af 
Streptomyces collinus Tü 365, som er kendt for at fremstille antibiotikummet 
kirromycin. Grundet uønskede bivirkninger kan kirromycin på nuværende tidspunkt 
ikke bruges til behandling i klinikken. Dette gør stoffet til en ideel kandidat for 
bioderivatisering, idet ændringer i den molekylære sammensætning kan ændre et stofs 
virkningsmekanisme drastisk.  
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Adskillige studier i biosyntesen af kirromycin har ført til detaljeret viden om 
systemet, men til dato mangler der stadig information om precursor forsyning og de 
sidste tailoring reaktioner, der sammen fører til det endelig molekyle. Vores arbejde 
med syv gener, hvoraf ét var formodet involveret i precursor forsyning og seks i 
tailorings, har gjort det muligt for os at udfylde nogle af de manglende huller i 
biosyntesen af kirromycin. Ydermere resulterede vores studier i en samling af fire nye 
genetiske mutanter, der producerer nye kirromycin derivater, og en mutant med lavere 
produktion af kirromycin. Særligt den sidste mutant har høj interesse idet den kan 
indgå i en bioderivatiserings-platform til fremstilling af nye analoge stoffer af 
kirromycin med forbedrede egenskaber.  
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Outline of the Ph.D. thesis 
The following Ph.D. thesis with the title “Engineering of secondary metabolite 
production in streptomycetes” contains four manuscripts organised in three main 
sections.  Besides the manuscripts, an introduction and discussion, which both sum up 
the general themes of the thesis, are included in the dissertation. 
After a brief introduction to metabolic engineering, the review (manuscript I) with 
the title “Towards Systems Metabolic Engineering of Streptomycetes”, which was 
recently published in Biotechnology Journal, is presented. 
Manuscript II contains the method “CRISPR-Cas9 Toolkit for Actinomycete 
Genome Editing”, in which the overall workflow developed for genome-to-
knockout/down of actinomycetes is presented, which was recently published as a 
chapter in the book entitled “Synthetic Metabolic Pathways”.    
Following this, manuscript III entitled “An improved USER-CRISPR-Cas9 platform 
for high-throughput genome editing in streptomycetes” is presented. The draft 
manuscript describes an optimised USER-cloning system developed for fast and 
efficient construction of CRISPR-(d)Cas9 constructs, which should serve as a 
platform to improve our future efforts in semi-automatic, high-throughput gene and 
gene cluster cloning of streptomycetes.  
A case in which the CRISPR-Cas9 technology proved unsuitable for genome editing 
appeared during our work on kirromycin biosynthesis in Streptomyces collinus Tü 
365. Instead, an alternative method was used for constructing the genetic mutants in 
this strain and the results from this work are presented in manuscript IV with the title 
“Filling the Gaps in the Kirromycin Biosynthesis: Deciphering the Role of Genes 
Involved in Ethylmalonyl-CoA Supply and Tailoring Reactions”. 
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Introduction 
Biology of streptomycetes 
Streptomycetes are gram-positive, soil-dwelling bacteria, which belong to the order of 
Actinomycetales. Actinomycetes bear morphological resemblance to fungi as evident 
from the formation of mycelia, which is the result of growth by tip extension and 
branching of the hyphae. Under sufficient growth conditions, streptomycetes form a 
dense vegetative mycelium1, in which cell division occurs by cross-wall separation of 
the hyphae into individual compartments2. As a result, each compartment can contain 
multiple copies of the chromosome, making streptomycetes multicellular organisms3. 
When encountering nutrient depletion or other stress signals, the hyphae develop into 
aerial hyphae, which due to their hydrophobic surface can rise into the air and further 
segregate into mature spores4. The dormant spores can readily spread in the 
environment and ensure the survival of the bacteria. Once vegetative growth 
conditions are encountered again germination of the spores are initiated5,6 (Fig. 1).  
 
Figure 1 Schematic overview of the life cycle of streptomycetes. From Barka et al.6 
Another interesting feature of streptomycetes is their abundance and importance in 
soil. Accounting for 95 % of Actinomycetales isolates from soil, streptomycetes 
produce a range of different exoenzymes, which are used to break down polymers to 
release carbon7. In addition, streptomycetes harbour the potential to produce a 
multitude of bioactive secondary metabolites, including, but not limited to, 
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antibiotics, immunosuppressants, antifungals, and anti-cancer compounds8. In fact, in 
the so-called “golden era” of antibiotic discovery, ranging from the 1940s until the 
early 1950s, 70 to 80 % of all newly identified natural antibiotics were isolated from 
Streptomyces species9. These clinically relevant compounds are produced from 
biosynthetic gene clusters (BGCs) encoded in the linear chromosomes of the bacteria 
as a part of their secondary metabolism. Although not a part of primary metabolism, 
the biosynthesis of bioactive secondary metabolites is believed to be of great 
importance to cell survival as means of self-protection in response to external stimuli, 
such as nutrient depletion or when faced with a competitive niche6.  
Since the discovery of several “cryptic” gene clusters in the model strain 
Streptomyces coelicolor A3(2)10, the field saw the need for understanding the 
biosynthetic logic behind secondary metabolism. As a result, acquisition of high-
quality data from the large, G+C-rich genomes of streptomycetes is now becoming a 
routine practice in many laboratories as a means of uncovering the hidden potential of 
the strains through genome mining11–13. For additional information on this topic, the 
reader is referred to manuscript I of this thesis.  
 
Biosynthesis of secondary metabolites in streptomycetes 
The genes required for biosynthesis of secondary metabolites are often clustered in 
the genomes of streptomycetes, a feature which has enabled the discovery of several 
natural products using genome mining tools such as antiSMASH14 or PRISM15. The 
overall principle behind biosynthesis from BGCs can be divided into three main 
phases: basic building block supply, assembly of the building blocks, and tailoring of 
the precursor molecule to yield the final product16. For many of the complex 
secondary metabolites, the building blocks, which are supplied from primary 
metabolism or through feedings, are assembled by enzymatic machineries encoding 
all information required for synthesis, transport, and resistance. The genetic 
information stored in these mega-enzymatic complexes is often organised by an 
assembly line principle, in which each gene encodes modules that are further divided 
into separate enzymatic domains. Here, the gathered enzymatic actions of the domains 
in the modules are responsible for the activation and attachment of one extender unit. 
Complexity in biosynthesis of secondary metabolites is achieved through variations in 
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the three biosynthetic phases, including variation in and linkage of the building blocks 
and in the type of tailoring reactions encoded in the BGC. 
 
Polyketides 
The biosynthesis of polyketides is facilitated by polyketide synthases (PKSs). 
Polyketides are composed of simple carboxylic acid monomers, which are assembled 
in a manner similar to that of fatty acid (FA) biosynthesis. Assembly of the activated 
acyl-CoA monomers is facilitated by iterative decarboxylative Claisen-like 
condensation. The polyketide precursor can then undergo a series of reductive steps, 
which is facilitated by ketoreductases (KRs), dehydratases (DHs), and enoyl 
reductases (ERs). In contrast to FA biosynthesis, the degree of reduction is subject to 
variation in PKSs, a feature which gives rise to higher complexity of the polyketides. 
Upon assembly, the precursor molecule is released from the PKS by, most commonly, 
a thioesterase (TE), at which point the molecule can be subjected to additional 
enzymatic tailoring reactions, such as methylations, hydroxylations, halogenations, 
and ring formations.  
Depending on their domain architecture, PKSs are further grouped into three different 
types (type I-III PKSs), that can be either modular (type I) or iterative (types I, II, III), 
which determines whether the domains are used in a single or repetitive fashion, 
respectively.  
Type I PKSs are the most complicated and versatile of the three PKS classes17 and are 
divided into the iterative and modular type. The simplest structure is that of the 
iterative type I PKS, in which one module is used repeatedly for chain elongation. 
The presence of iterative type I PKSs is relatively rare in prokaryotes and only gives 
rise to small, aromatic compounds such as the “warhead” structures of enediynes 
anticancer antibiotics18,19.  
In contrast to the iterative type I PKSs, modular type I PKS can give rise to larger and 
more complex polyketides such as the antibiotics erythromycin and pikromycin or the 
anti-cancer compound chartreusin. The “minimal PKS module”, which is responsible 
for the chain elongation with one extender unit at a time, is composed of three 
essential domains, namely the acyltransferase (AT), ketosynthase (KS) and the acyl 
carrier protein (ACP). During each round of chain elongation, the AT selects and 
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loads the extender unit onto the ACP from which the formation of C-C-bond, 
catalysed by the KS, takes place. The optional presence of β-keto-processing 
enzymes, KR, DH, and ER, determines the level of reduction in each module. 
Recently, the use of cryogenic electron microscopy (cryo-EM) on the pikromycin 
type I PKS module five, encoded by pikAIII, has helped to understand the 
organisational changes occurring during assembly20,21 (Fig. 2). During chain 
elongation, the ACP, carrying the intermediate chain, is moved between the 
enzymatic domains to interact with these and finally is ejected out to interact with the 
sixth module in the pikromycin assembly line.  
  
 
Figure 2 Cryo-EM of pikromycin PKS module five (holo-PikAIII) (left figure)21 and schematic overview of 
substrate processing of the same module PikAIII (right figure)20. During the transition from state 1 to 2, the KR 
(purple) undergoes an end-to-end flip, which places the ACP (orange) close to the AT (green) domain. Upon 
loading of methylmalonyl (MM, red line), the ACP is moved to the bottom entrance of the KS (blue) (state 3). The 
extension of the pentaketide (yellow and red lines) moves the precursor bound to the ACP to the KR domain (state 
4). In the final two states, the ACP is ejected out of the central pocket of the complex (state 5) to interact with the 
next module PikAIV in the assembly line (state 6). ACP, acyl carrier protein; AT, acyltransferase; KR, 
ketoreductase; KS, ketosynthase; MM, methylmalonyl; NADPH, Nicotinamide adenine dinucleotide phosphate. 
The modular organisation of type I PKSs often follows the rule of “colinearity”, 
which is the result of one-to-one correspondence of PKS architecture and metabolite 
structure. This feature has been successfully applied for bioinformatic predictions of 
molecular structures based on BGC architecture or vice versa19. However, the 
presence of duplicated or inactive domains complicates discovery efforts22, as in the 
case of rapamycin biosynthesis in Streptomyces hygroscopicus. In the rapamycin 
BGC, four DH domains were identified as inactive based on deletions in the 
characteristic active site sequence, however, further sequence analysis failed to 
provide any explanation for the missing activities of two additional DH domains, of 
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two KR domains, and of one ER domain, located in two separate modules (module 3 
and 6)23,24.    
Furthermore, the presence of so-called trans-AT PKSs, which, unlike cis-AT PKSs, 
use freestanding AT enzymes, which has the ability to load extender units to several 
different modules in the same type I PKS assembly line, can bring extra complexity to 
the molecule, which is the case for the antibiotic kirromycin25–27. 
Type II and III PKSs synthesise mostly aromatic molecules, albeit using different 
enzymatic approaches17. Type II PKSs are exclusively found in bacteria, in which 
they iteratively synthesise aromatic polyketides19, such as the antibiotic actinorhodin28 
and the anti-cancer compound doxorubicin29. For these PKSs, the minimal set of 
enzymes needed for assembly is restricted to two KSs, KSα and KSβ, and the ACP. 
During chain elongation, the thioester is tethered to the ACP while the KSαKSβ-
complex is responsible for elongation of the chain with malonyl-CoA units 
exclusively. Based on the current working hypothesis, an additional enzymes should 
be included as a component of the minimal PKS, namely the malonyl-CoA:ACP 
transferase (MCAT), which is believed to recruit the malonate extender units from 
primary metabolism. Since most clusters of type II PKSs do not encode any MCAT, 
the homologous enzyme from FA biosynthesis has been speculated to be capable of 
interacting with the PKS by loading the malonate units to the ACP30. However, 
contradictory examples exist to this hypothesis as exemplified by the well-studied 
biosynthetic pathway of actinorhodin in Streptomyces coelicolor, in which the 
chemically synthesised variant of ACP was capable of undergoing self-malynation in 
the absence of any MCAT activity31. 
To avoid spontaneous cyclisation of the polyketide intermediate upon release from the 
enzymatic complex, additional cyclases (CYCs) and KRs are often encoded in the 
BGCs of type II PKSs to act as chaperons and reductive agents, respectively, in order 
to facilitate the correct cyclisation. In addition, the presence of aromatases (AROs) 
results in the biosynthesis of the aromatic ring systems. 
Type III PKSs distinguish themselves from other PKSs by their lack of ACPs and 
instead the presence of a single KS-like enzyme responsible for condensation of 
acetate units to CoA-derivatized starter units17. Within the same PKS active site 
cavity, the linear chain is then further processed through intramolecular condensation 
and aromatisation. Diversity is added to the polyketide chain through variations in 
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choice of acyl-CoA starter units, the number of elongation rounds, and the mechanism 
of folding of the final molecule17,19. 
Although previously thought to be exclusive to plants, type III PKSs can also be 
found in bacteria32,33. Examples of bacterial type III PKSs involved in biosynthesis 
are found in the biosynthetic pathway of balhimycin in Amycolatopsis bahlimycina32 
and for the 1,3,6,8-tetrahydroxynaphthalene (THN) precursor, which can undergo 
spontaneous oxidation to yield the pigment flaviolin found in many 
streptomycetes33,34. For balhimycin biosynthesis, the type III PKS is encoded by the 
DpgA enzyme, responsible for provision of the non-proteinogenic amino acid 3,5-
dihydroxy-phenylglycine, which is essential for biosynthesis of the antibiotic32.  
 
Figure 3 Schematic representations of the biosynthetic cycles of a minimal NRPS (a) and PKS (b) assembly line, 
depicting both initiation and extension modules. A, adenylation domain; AA, amino acid; ACP, acyl carrier 
protein; AT, acyltransferase; C, condensation domain; NRP, non-ribosomal peptide; KS, ketosynthase; PCP, 
peptidyl carrier protein; PK, polyketide; TE, thioesterase domain. From Weissman22. 
 
Non-ribosomally synthesised peptides 
Another important group of secondary metabolites are the peptide-derived 
compounds, which are composed of proteogenic or non-proteogenic amino acids, 
assembled by non-ribosomal peptide synthetases (NRPSs) (Fig. 3). For NRPSs, 
selection and loading of amino acid extender units are catalysed by the adenylation 
(A) domain, which also activates the bound amino acid at the expense of ATP. The 
activated amino acid is in turn tethered to the peptidyl carrier protein (PCP) through a 
thiolation reaction resulting in an amino-acid-PCP-thioester. Due to this reaction, the 
PCP domain is also referred to as the thiolation (T) domain. Peptide bond formation 
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and further chain elongation are catalysed by the condensation (C) domain. Two 
common modification reactions can occur in NRPS assembly lines. The first is 
epimerisation (E) to convert the L-aminoacyl and L-peptidyl thioesters into their 
corresponding D-forms before being transferred to the next module. The second type 
of common modification arises from the actions of methyltransferase (MT) domains, 
responsible for N-methylation of the NRPS intermediate35. Finally, in bacteria the TE 
domain is most often encoded in the last module of the megaenzyme and is 
responsible for chain termination and release from the NRPS assembly line.  
Recently, structural insight on the distinct conformations of the two NRPS modules 
AB3403 from the pathogen Acinetobacter baumannii and EntF from Escherichia coli 
has helped to elucidate the dynamics behind two essential catalytic states in the NRPS 
cycle36. More specifically, during the four states in the catalytic cycle, the module 
undertakes three distinct conformations, in which the initial amino acid adenylation 
(AA-AMP) (state I) is followed by delivery of the AA-AMP to the A domain for 
thioester-formation to load the PCP (state II). Upon activation, the NRPS complex 
converts back to the initial conformation I to deliver the PCP to the C domain to 
receive the upstream peptide (state III). In the final conformation (state IV) the 
peptide is delivered to a downstream C, TE, or reductase domain (Fig. 4)36. 
 
Figure 4 The NRPS catalytic cycle involving four states (I – IV)36. In state (I), the incoming amino acid (AA) is 
activated by the adenylation (A) domain. During (II), the peptidyl carrier protein (PCP) moves to the A domain 
resulting in thioester bond formation between co-factor and AA. In (III), the activated AA bound to PCP is moved 
to the condensation (C) domain at which point it can interact with an upstream peptide. Finally, in state (IV) the 
peptide chain is moved to a new C domain or released by a thioesterase (TE) or reductase domain. AA, amino 
acid; PCP, peptidyl carrier protein; Pep, peptide. 
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Hybrid PKS/NRPSs 
As a result of the similarity between their biosynthetic machineries (Fig. 3), PKSs and 
NRPSs can collaborate to assemble hybrid polyketide-peptide metabolites22. Excellent 
examples exist of hybrid PKS/NRPS assembly lines, including that of the 
immunosuppressant ascomycin (FK520), which is composed of 11 PKS modules 
distributed on the three proteins FkbB, FkbC and FbkA, followed by one NRPS 
module on the protein FkbP37. The opposite situation also exists where polyketide 
units are incorporated in NRPS-derived peptides, as exemplified by the biosynthesis 
of the anti-cancer compound bleomycin. For bleomycin biosynthesis, the hybrid 
assembly line is composed of ten NRPS modules and one PKS module, which result 
in the incorporation of a single malonyl-CoA unit in the molecule38. In both of the 
aforementioned cases, what remains to be studied in these hybrid assembly lines is 
how translocation of the growing chain between the PKS/NRPS and NRPS/PKS 
interfaces is facilitated39. 
 
Kirromycin 
The antibiotic kirromycin (Fig. 5) is an excellent example of how complex Nature’s 
own biosynthetic machinery can be. Kirromycin was first isolated from Streptomyces 
collinus Tü 365 in 1972 by Wolf and Zähner in Tübingen, Germany40.  
 
Figure 5 Structure of kirromycin. 
Kirromycin is a narrow-spectrum antibiotic with activity against gram positive and 
gram negative bacteria, including Enterococcus faecium, E. faecalis, Haemophilus 
influenzae type B, Neisseria gonorrhoeae, and the malaria parasite Plasmodium 
falciparum41–43. The molecule belongs to the class of elfamycin antibiotics, which are 
grouped based on their ability to interact with prokaryote elongation factor (EF) Tu44. 
Interestingly, this group of antibiotics shows little toxicity against the mitochondrial 
elongation factor in eukaryotes45. Kirromycin binds to the interface of domains I and 
III of the EF Tu in complex with either GDP or GTP (Fig. 6), although with highest 
affinity for the latter46,47. The binding induce the EF Tu to maintain the conformation 
O
OH
NH
O
O
O
O
N
H
O
OH
HH
OH
OH
OH
OH
 10 
it would adopt when bound to GTP, which then prevents release of the complex from 
the ribosome and ultimately results in the stalling of protein translation.  
 
 
Figure 6 Crystal structure of elongation factor (EF) Tu. Kirromycin binds between domains I and III in the 
complex, which has been marked in the illustration. Adapted from Carelli et al.48 
Kirromycin suffers from poor pharmacokinetics, which has limited its use in the 
clinics. However, with increased reports of resistant isolates of N. gonorrhoeae 
arising in the clinic, the group of elfamycin antibiotics might experience revitalisation 
in future years. In this sense, kirromycin with a reported minimal inhibitory 
concentration (MIC) of 0.06 µg/mL might be subject to new studies to change 
properties of the molecule and improve its pharmacokinetics41.  
In addition to the studies on the mode of action and clinical value of kirromycin, the 
molecule has also been subject to detailed biosynthetic studies. As a result, the full 
BGC of kirromycin was characterised in 2008, revealing an 82 kb DNA region 
composed of 28 genes involved in synthesis and transport (Fig. 7). Furthermore, 
genome mining of S. collinus Tü 365 later revealed the presence of two copies of the 
kirromycin BGC on the arms of the chromosome49,50. 
 
Figure 7 Schematic representation of the biosynthetic gene cluster of kirromycin. Red, PKS-related genes; Blue, 
NRPS-related genes; Black, hypothetical proteins; Orange, dehydrogenases and hydroxylases; Light blue, genes 
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involved in precursor supply; Light brown, O-methyltransferase; Light green, transport-related genes; Purple, 
resistance-related genes; Light grey, genes not involved in kirromycin biosynthesis. Modified from Weber et al. 
200825. 
Kirromycin is synthesised and assembled by a hybrid type I PKS/NRPS assembly line 
in which kirAI, kirAII, and kirAIV – AVI encode PKS modules, kirB an NRPS module, 
and finally kirAIII is composed of both NRPS- and PKS-related modules (Fig. 8). 
Based on the studies of Weber et al.25, loading of the acetyl-CoA starter unit onto 
KirAI might be facilitated by the putative Gcn5-related N-acetyltransferase (GNAT) 
KirE, although no experimental data is available. Further extension of the precursor 
molecule is achieved from the PKS modules KirAII and KirAIV – AVI, which 
amounts to the addition of 15 extender units consisting of 13 malonyl-CoA, one 
methylmalonyl-CoA, and one ethylmalonyl-CoA extender unit. The two NRPS 
modules, KirAIII and KirB, account for incorporation of the glycine and β-alanine 
residue, respectively. Post-translational activation of the ACPs and PCPs is catalysed 
by the putative Sfp-type phosphopantetheinyl transferase (PPTase) encoded by kirP51. 
Besides its ability to activate both ACP and PCP, KirP also has a relaxed substrate 
specificity with respect to CoA substrates and has been found to accept both malonyl- 
and methylmalonyl-CoA.  
 
Figure 8 Schematic overview of the hybrid PKS type I/NRPS assembly line for kirromycin. ACP, acyl carrier 
protein; AT, acyltransferase; KS, ketosynthase; DH, dehydrogenase; KR, ketoreductase; ER, enoylreductase; MT, 
methyltransferase; C, condensation domain; A, adenylation domain; PCP, peptidyl carrier protein; KirCI/KirCII, 
trans-ATs; kirHI, Dieckmann cyclase; kirM, O-methyltransferase; kirHVI, phytanoyl-CoA dioxygenase; 
kirOI/kirOII, cytochrome P450-dependent hydroxylases. Modified from Weber et al. 200825 
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Several interesting features of the kirromycin BGC have led to additional studies to 
elucidate the logic behind its biosynthesis. Most intriguingly, only KirAVI contains 
the classical cis-AT domains responsible for selecting and loading of extender units 
onto the ACPs. Instead, KirAI to KirAV are trans-AT PKSs, making kirromycin the 
first described biosynthetic pathway combining both types of PKS. The extender units 
for the trans-AT type PKSs are provided by the two discrete ATs, KirCI and KirCII. 
More specifically, KirCI accepts and loads malonyl-CoA extender units onto all 
modules except for M1 (starter unit) and M5, while KirCII is responsible for loading 
of ethylmalonyl-CoA onto ACP5 in M5. In vitro assays of both enzymes have 
enabled the characterisation of the enzyme specificities. Despite the three-domain 
architecture of KirCI (AT1-AT2-ER), only the AT2 domain is responsible for loading 
of malonyl-CoA extender units onto ACPs in the kirromycin assembly line27. Unlike 
KirCI, which has a high specificity towards malonyl-CoA extender units, KirCII is 
more promiscuous when it comes to substrate loading, in that it was found to accept 
non-malonyl-CoA extender units, such as allyl- and propargyl-malonyl-CoA at the 
ACP526,52. Here, the chemical nature of propargyl-kirromycin has allowed for its use 
in Copper(I)-dependent azide-alkyne cycloaddition (CuAAC), in popular term “click” 
chemistry, which allows for the exchange of functional groups on a molecule under 
mild aqueous conditions. In an eGFP transcription/translation in vitro assay of 
kirromycin, allyl-kirromycin, and coumarin-kirromycin, the latter generated by 
“click” chemistry, a lowered inhibition of EF-Tu was observed for coumarin-
kirromycin (IC50 = 7.3 µM) compared to kirromycin (IC50 = 0.9 µM) (Fig. 9). This 
observation strengthened the incentive to use this polyketide derivatization tool for 
changing the pharmacokinetic properties of kirromycin52.  
 
 
Figure 9 Structures of kirromycin analogues allyl-kirromycin (2) and coumarin-kirromycin (4) and the in vitro 
translation assay with eGFP inhibition as a result of increasing concentrations of kirromycin (1) and the two 
kirromycin analogues (2) and (3). Modified from Musiol-Kroll et al.52 
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Another interesting feature of the kirromycin assembly line is its missing TE domain. 
Instead, the precursor molecule of kirromycin is released from the megaenzymatic 
complex by KirHI, which was recently found to belong to a new class of Dieckmann 
cyclases responsible for tetramic acid and pyridine scaffold biosynthesis53.  
Although much is known about the core genes involved in the biosynthesis of 
kirromycin, knowledge about host resistance and tailoring steps remain scarce. From 
the initial studies of Weber et al.25, no genes within the cluster boundaries could be 
assigned to be involved in resistance. Interestingly, S. collinus Tü 365 has a 
kirromycin-sensitive EF Tu, but as the strain does not suffer during production of the 
antibiotic, alternative resistance mechanisms must be present and are yet to be 
characterised54. In the case of the tailoring reactions, enzymes responsible for 
oxygenations, hydroxylations, formation of the tetrahydrofuran ring, and O-
methylation are expected to be encoded by genes within the BGC of kirromycin as 
well, although they remain to be characterised.   
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Manuscript I 
Metabolic engineering of streptomycetes  
Streptomycetes possess a huge potential to produce valuable natural products, 
however, many of the BGCs encoding the biosynthesis remain silent under standard 
growth conditions. Through the years, several approaches have been employed for 
unraveling the hidden potential of these gifted microorganisms. These include 
systematic manipulation of the fermentation conditions, also known as the One 
Strain-Many Compounds (OSMAC) approach55, and mutagenesis procedures56 to 
isolate novel mutants with improved production, increased tolerance to the end 
product, or with other traits rendering the strain superior to the parental strain.  
In recent years, more systematic and rational approaches are being pursued in order to 
unlock the hidden potential of streptomycetes. One such focused approach presents 
itself with metabolic engineering, which builds on de novo assembly or modifications 
of metabolic pathways within a strain to improve flux towards a desired end 
product57.  
Metabolic engineering of well-established hosts such as Escherichia coli and 
Saccharomyces cerevisiae have already resulted in numerous successful examples of 
titer improvements for biofuels, bulk chemicals, proteins, and natural products58–62. 
Some key examples include the establishment and improvement of production of the 
erythromycin precursor 6-deoxyerythronolide B (6dEB) in E. coli59 and the 
antimalerial drug precursor artemisinic acid in S. cerevisiae58. 
Despite the obvious benefits of using these model organisms as production hosts, they 
suffer from inherent limitations when it comes to production of the often complex 
secondary metabolites produced by actinomycetes and fungi. These limitations 
include incompatibility between the expression systems of the host and the natural 
producer, including insufficient precursor supplies, and poor growth of the production 
host caused by sensitivity towards the end product.  
Heterologous hosts of streptomycetes origin overcome some of these limitations, of 
which Streptomyces coelicolor M1154, Streptomyces avermitilis, and Streptomyces 
albus J1074 are some noteworthy mentions63. More on this topic and the recent 
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advances made in the transition to systems metabolic engineering of streptomycetes 
for improved production of secondary metabolites are presented in manuscript I, a 
review entitled “Towards systems metabolic engineering of streptomycetes for 
secondary metabolites production”, which was recently published in Biotechnology 
Journal64. 
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Toward Systems Metabolic Engineering of
Streptomycetes for Secondary Metabolites Production
Helene Lunde Robertsen, Tilmann Weber,* Hyun Uk Kim, and Sang Yup Lee*
Streptomycetes are known for their inherent ability to produce pharmaceuti-
cally relevant secondary metabolites. Discovery of medically useful, yet novel
compounds has become a great challenge due to frequent rediscovery of
known compounds and a consequent decline in the number of relevant
clinical trials in the last decades. A paradigm shift took place when the first
whole genome sequences of streptomycetes became available, from which
silent or “cryptic” biosynthetic gene clusters (BGCs) were discovered. Cryptic
BGCs reveal a so far untapped potential of the microorganisms for the
production of novel compounds, which has spurred new efforts in under-
standing the complex regulation between primary and secondary metabolism.
This new trend has been accompanied with development of new computa-
tional resources (genome and compound mining tools), generation of various
high-quality omics data, establishment of molecular tools, and other strain
engineering strategies. They all come together to enable systems metabolic
engineering of streptomycetes, allowing more systematic and efficient strain
development. In this review, the authors present recent progresses within
systems metabolic engineering of streptomycetes for uncovering their hidden
potential to produce novel compounds and for the improved production of
secondary metabolites.
1. Introduction
Streptomycetes are ﬁlamentous gram-positive bacteria pre-
dominantly found in soil and water environments. The bacteria
are recognized for their capabilities to produce secondary
metabolites with clinically relevant applications, some of which
include antibiotics such as streptomycin and daptomycin,
anthelmintic compound avermectin, immunosuppressant
tacrolimus (FK-506), and anti-cancer agents bleomycin and
doxorubicin (for review, see Ref. [1]). Despite the proven clinical
effects of secondary metabolites, drug
discovery in streptomycetes has witnessed
a decline in success rate ever since the
golden age of antibiotics experienced
from late 1940s to 1960s.[2] A paradigm
shift begun in the early 2000s when the
complete genome sequences of a model
organism Streptomyces coelicolor[3] and an
industrial strain Streptomyces avermitilis[4]
were published. In the case of S. coelicolor,
the 8.6Mb linear chromosome was found
to harbor several cryptic or silent biosyn-
thetic gene clusters (BGCs) in addition to
already known BGCs of actinorhodin,
undecylprodigiosin, and calcium-depen-
dent antibiotic (CDA). These silent BGCs
showed indications of possible biosynthe-
sis of secondary metabolites, but interest-
ingly, no corresponding compounds were
detected under standard laboratory
growth conditions. In the following years,
many of these silent BGCs were success-
fully activated and their corresponding
secondary metabolites were characterized,
including iron-chelators desferriox-
amine[5] and coelichelin,[6,7] sesquiter-
pene antibiotic albaﬂavenone,[8] and polyketide (PK) alkaloid
coelimycin.[9] The initial successes in identifying novel
secondary metabolites from silent BGCs have led to the
subsequent increases in the genome sequencing of strepto-
mycetes in the last decade (Figure 1).
Availability of genome data has spurred advances in relevant
technologies covering computational resources (in particular,
genome and compound mining tools), high-throughput (omics)
techniques aswell asmolecular tools.Genomemining tools suchas
antibiotics and Secondary Metabolites Analysis SHell (anti-
SMASH)[10–12] and Prediction Informatics for Secondary Metab-
olomes (PRISM)[13,14] havegreatly improvedour ability to survey the
genomic potential of strains, and allowed for initial prioritization of
engineeringefforts.Also, omics techniques suchas transcriptomics
and proteomics have contributed to understanding the complex
regulatorynetworksemployedbystreptomycetes tobalanceprimary
and secondary metabolism.[15,16] Availability of such genome and
expression data has further enabled construction of genome-scale
metabolicmodels (GSMMs)ofstreptomycetes todescribemetabolic
pathwaysandpredict optimal routes for theproductionof secondary
metabolites.[17]
With high-quality whole genome sequences and an array of
suitable genome/compound mining and molecular cloning
tools readily at hand, the secondary metabolite research is now
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moving toward systems metabolic engineering of streptomy-
cetes in order to fully harness their potential to produce
medically valuable secondary metabolites.[18] Systems metabolic
engineering brings in recent developments experienced in the
ﬁelds of systems and synthetic biology, and provides a more
systematic and efﬁcient approaches for strain engineering.[19]
However, streptomycetes and other secondary metabolite-
producing microbes require additional sophisticated analyses
concerned with secondary metabolite BGCs before strains are
engineered at the systems level for the novel compound
production and the improved production titers.[17] To this end,
here we review recent progress within the ﬁeld of systems
metabolic engineering of streptomycetes with focuses on the
additional sophisticated analyses unique to streptomycetes as
well as recent successful studies on streptomycetes engineering
(Figure 2).
2. Unique Considerations for Systems
Metabolic Engineering of Streptomycetes
The established framework of systems metabolic engineering[19]
can serve as a guideline for the optimal production of secondary
metabolites using streptomycetes (Figure 3). However, systems
metabolic engineering of streptomycetes has additional special
considerations that are not necessarily relevant to popular model
organisms such as Escherichia coli and Saccharomyces cerevisiae.
In this context, we ﬁrst focus on these “unique considerations”
for streptomycetes, including characterization of BGCs, their
encoding secondary metabolites and regulations involved in the
secondary metabolite biosynthesis as well as molecular tools
speciﬁcally adapted for the streptomycetes engineering.
2.1. Characterization of BGCs and Their Secondary
Metabolites Through Computational Resources
Due to the complex nature of secondary metabolism, computa-
tional resources are needed to better understand working
mechanisms of secondary metabolisms many of which are still
unknown. Secondary metabolite biosynthetic pathways are also
not sufﬁciently covered by existing general metabolic databases
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Figure 1. Cumulative number of whole genome sequences of Streptomy-
ces species published in National Center for Biotechnology Information
(NCBI) from 2001 to September 2017.
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(e.g., KEGG and MetaCyc). Fortunately, advances in high-quality
genome sequences of Streptomyces isolates (Figure 1) and other
secondary metabolite-producing organisms have sparked the
development of such specialized computational resources,
including databases and genome/compound mining tools,
and the representative ones are presented herein. First, BGC
databases allow for easy access and evaluation of curated and
predicted BGCs, such as the Minimum Information on
Biosynthetic Gene Clusters (MIBiG),[20] the Integrated Microbial
Genomes Atlas of Biosynthetic gene Clusters (IMG-ABC),[21]
and the antiSMASH database.[22] For the secondary metabolite
compounds, several comprehensive databases exist as well,
including NORINE[23] speciﬁcally for non-ribosomal peptides
(NRPs), Antibiotic’ome[24] for the predicted molecular targets of
antibiotics, and StreptomeDB,[25] which presents information on
compounds produced by streptomycetes.
Second, genome mining tools continue to develop with more
features, which allow for predicting and assigning functions to
enzymes involved in the biosynthesis of secondary metabolites.
antiSMASH[12] and PRISM[14] are two of the most well-
established tools, which both base their predictions on
identiﬁcation of signature genes or domains known to be
speciﬁc for secondary metabolite BGCs.[20] Another recently
released approach called EvoMining employs phylogenomic
analysis to identify repurposed enzymes, originating from
primary metabolism, which has been recruited to secondary
metabolism for the secondary metabolite biosynthesis.[26]
Using this EvoMining approach, Cruz-Morales et al. identiﬁed
a new clade of biosynthetic enzymes involved in the
biosynthesis of arseno-organic metabolites.[26] In addition, an
alternative way of mining BGCs is found in the Antibiotics
Resistant Target Seeker (ARTS) (https://arts2.ziemertlab.com),
which evaluates BGCs based on self-resistance mechanisms of
antibiotic producers.[27] ARTS scans genomes for promising
BGCs based on known resistances and the presence of
duplicated, co-localized housekeeping genes that display an
evidence of horizontal gene transfer. In the context of systems
metabolic engineering, the identiﬁed resistance genes can be
used as probes to ﬁnd novel BGCs without requiring detailed
information on the BGC. The Gene Cluster Family (GCF)
network (http://www.igb.illinois.edu/labs/metcalf/gcf/index.
html)[28] is another useful approach for BGC identiﬁcation,
which groups gene clusters and assigns functions of previously
uncharacterized BGCs.
For the compound mining, further prioritization of BGCs in
promising strains can be achieved through cheminformatic
analyses of the metabolome data generated from liquid
chromatography (LC) tandem mass spectrometry (MS/MS) or
Figure 2. Schematic representation of the workflow of systems metabolic engineering for streptomycetes. Characterization of BGCs, their encoding
secondary metabolites and biosynthesis regulations involved is critical in engineering streptomycetes for the production of novel compounds and the
higher yields of a known end product. Genome and compound mining, omics techniques, molecular tools as well as the use of elicitors play important
roles in this process.
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nuclear magnetic resonance (NMR).[13,29] Upon LC-MS/MS-
guided identiﬁcation of new compounds, following compound
mining (or cheminformatic) tools enable automated compound
characterization and dereplication: Global Alignment for
natuRaL-products chemInformatiCs (GARLIC) in combination
with Generalized Retrobiosynthetic Assembly Prediction Engine
(GRAPE) platform[30]; and the open-access MS/MS database
Global Natural Products Social Molecular Networking
(GNPS).[31] The GARLIC pipeline allows for both linking
orphaned products to their corresponding BGCs and for
identiﬁcation of novel compounds by aligning bacterial PK
and NRP BGCs predicted by PRISM to a comprehensive library
of natural products from GRAPE.[30] The applicability of this
pipeline consisting of PRISM, GRAPE, and GARLIC was
Figure 3. Workflow of systems metabolic engineering for the optimal production of secondary metabolites. The workflow shown includes tools and
methods used within the individual steps. The workflow can be applied in an iterative fashion as illustrated by the design-build-test-learn cycle. The use of
the entire workflow is exemplified by the production of ascomycin using Streptomyces hygroscopicus var. ascomyceticus. Here, (1) and (2) illustrates the two
separate rounds of engineering applied for the optimization of ascomycin production.
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demonstrated by identifying a new compound, potensibactin,
isolated fromNocardiopsis potensDSM 45234, and also by linking
three previously orphaned natural products, lucensomycin,
octacosaminin, and bogorol, to their respective BGCs in
Streptomyces achromogenes NRRL 3125, Amycolatopsis sp. NAM
50, and Brevibacillus laterosporus DSM 25, respectively. Mean-
while, the GNPS platform contains a comprehensive compound
data collection curated by the natural product community.[31] As
this community-driven knowledge-sharing database constantly
expands, it allows for continuous screening of newly uploaded
data sets against the established database. Besides its applicabil-
ity in the discovery and characterization of natural products and
their BGCs, the network can be used to identify structural
analogs of a knownmolecule as exempliﬁed from the analysis of
a broad-spectrum antibiotic stenothricin from Streptomyces
roseosporus. Based on the molecular networking and dereplica-
tion features of the platform, GNPS identiﬁed a subnetwork of
ﬁve stenothricin analogs produced by Streptomyces sp. DSM5940,
all with different structural properties compared to the original
molecule stenothricin.
More detailed descriptions beyond these computational
resources discussed herein can be found from several review
papers.[32–34] In addition, to aid scientists within the ﬁeld in
prioritizing the individual tools, The Secondary Metabolite
Bioinformatics Portal (SMBP) at http://www.secondary
metabolites.org was recently launched.[35] For each tool or
database, SMBP provides the users with links and short
descriptions, allowing for quick and easy browsing. SMBP can
especially be useful for metabolic engineers who plan to produce
secondary metabolites, but are not familiar with secondary
metabolism biochemistry.
2.2. Characterization of the Regulation of Secondary
Metabolites Biosynthesis in Streptomycetes – Use of Omics
Techniques as an Example
The data obtained from genome mining often provides little
information on the regulation of secondary metabolites
biosynthesis in streptomycetes. An additional level of informa-
tion from omics techniques can be used to clarify the complex
regulations involved.[36] Transcriptomics is the most accessible
and most frequently adopted omics approach which monitors
changes in the gene expression levels over a course of time, or as
a result of external stimuli or genetic manipulation.[16] In this
context, Nieselt et al.[37] conducted microarray analyses of time-
point samples of S. coelicolor M145 taken during a 60 h
fermentation, and established changes in the expression proﬁles
of clustered genes during the metabolic switch from primary to
secondary metabolism. Here, the general change in expression
proﬁles observed between the 35 and 36 h especially marked the
metabolic switch, which was an interval for the depletion of
phosphate from the medium. More recently, multi-omics
techniques were deployed to determine the transcriptional
and translational landscape of S. coelicolor M145 using
differential RNA-sequencing (dRNA-seq) and strand-speciﬁc
RNA-seq (ssRNA-seq) ﬁrst, followed by ribosome proﬁling (Ribo-
seq).[38] In particular, the use of Ribo-seq shed light on the level of
translational control on genes involved in both primary and
secondary metabolism, and revealed a general decline in the
translation efﬁciency of BGCs in S. coelicolor after the cell’s
transition to growth phase. Furthermore, translation efﬁciency
was negatively correlated with transcription, hence revealing the
extra level of regulation to account for when embarking on the
quest of strain optimization.
In addition to transcriptomics, proteomics can provide
additional and complementary information on regulations
associated with the transition to antibiotic production. Proteome
data of S. coelicolor M145 were collected at three developmental
stages ranging from compartmentalized mycelium (12 h) to the
multinucleated mycelium (24 h and 72 h), which revealed that
hypha differentiation from substrate to aerial hypha was found to
be correlated with a change in proteome composition.[39] Based
on LC-MS/MS, 626 proteins were identiﬁed, of which 345
proteins were further quantiﬁed to reveal that proteins involved
in primary metabolism were the most abundant in the cells in
the compartmentalized mycelium, whereas proteins involved in
secondary metabolism were found to predominate the cells in
the multinucleated mycelium. Such omics studies will allow us
to better understand metabolic characteristics and complex
regulations involved in biosynthesis of desired secondary
metabolites.
2.3. Molecular Tools for Streptomycetes Engineering
A remarkable progress recently made in the computational ﬁeld
has been accompanied with concurrent advances in molecular
tools in order to overcome challenges associated with strepto-
mycetes engineering: high GC contents, relatively long cultiva-
tion times and occasional (or frequent in some strains)
reluctance towards introduction of recombinant DNA.[40] To
circumvent the limitations encountered when using the
standard restriction- and ligation-based cloning for genetic
manipulation, the E. coli-derived λ Red system was applied for
faster and more efﬁcient gene disruption, in-frame deletion,
gene replacement, and refactoring of entire gene clusters in
Streptomyces strains.[41] To aid genetic engineering effort even
further in streptomycetes, an alternative to this classical method
was reported using the S. cerevisiae I-SceI homing endonuclease
for DNA double strand break (DSB)-based genome editing.[42,43]
This meganuclease differs from conventional restriction
enzymes by its longer recognition site of 18 bp and with a
lower risk of off-targets for gene editing purposes. Using a two-
plasmid system, the I-SceI recognition sequence and a suitable
resistance marker are introduced into a deﬁned site on the
genome of the recipient streptomycete via a single crossover
event using the ﬁrst plasmid. Double crossover is induced upon
introduction of the second plasmid, which harbors the synthetic
codon-optimized I-SceI under the control of either the
constitutive ermE! or thiostrepton-inducible tipA promoter. To
facilitate marker-free gene deletions, plasmids derived from
pSG5[44] with temperature sensitive replicons can be used.When
using the I-SceI system for gene replacement in Streptomyces sp.
Tu ̈ 6071, I-SceI-mediated homologous recombination (HR) was
found to be 25 times more efﬁcient than spontaneously
occurring HR, hence, establishing its use for more systematic
gene editing in streptomycetes.[42]
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More recently, an even more efﬁcient and ﬂexible system for
genome engineering in streptomycetes has made its way to the
ﬁeld, namely the type II Clustered Regularly Interspaced Short
Palindromic Repeats (CRISPR)-CRISPR associated protein
(Cas9) system from Streptococcus pyogenes. The CRISPR-Cas9
technique can be applied for deletion of genes and gene
clusters[45–47] in a multiplex manner,[45] reversible gene expres-
sion control,[47] and induction.[48] The optimized system relies on
two components: the single guide RNA (sgRNA), which is a
synthetic RNA consisting of a CRISPR RNA (crRNA) and trans-
activating crRNA (tracrRNA) complex, and is required for
guiding Cas9 to modify the targeted genome sequence; and the
endonuclease Cas9 or catalytically inactive dCas9, which upon
interaction with the sgRNA, scans the genome for protospacer
adjacent motif (PAM) sequences and the corresponding 20 bp
recognition site. Upon recognition of the target DNA sequence,
Cas9 binds to and cleaves the speciﬁc site in the genome whereas
the inactive dCas9 will bind to the target DNA without sequence
modiﬁcations. Here, the dCas9 presents an easy-to-clone tool for
reversible control of gene expression, and thus is useful for
investigating regulation without the risk of off-target effects or
subjecting the cells to the stress associated with gene replace-
ments or mutagenesis procedures.[47] CRISPR-Cas9-mediated
mutagenesis can be used in the absence of templates for HR. In
this case, the repair mechanism is dependent on the non-
homologous end joining (NHEJ) of the DNA in Streptomyces
species. However, efﬁciency and speciﬁcity are greatly improved
if a homology template for HR is provided.[45–47] This has been
demonstrated in independent studies, in which Cobb et al.[45]
and Huang et al.[46] reported 60!100% and 70!100% efﬁcien-
cies, respectively, whereas Tong et al.[47] reported near 100%
efﬁciency for their studies on the actinorhodin gene cluster in S.
coelicolor.
For speciﬁc applications, the CRISPR-Cas9 system has proven
suitable for identiﬁcation and examination of putative genes and
BGCs for secondary metabolism in several Streptomyces species.
One example is the use of the system for discovery and
examination of the BGC encoding the antibiotics formicamycins
in a new isolate Streptomyces formicae.[49] Using the pCRISPo-
myces-2 vector, which harbors both the codon-optimized Cas9
from S. pyogenes and the sgRNA cassette, the only type II
polyketide synthase (PKS) BGC in S. formicae was deleted,
resulting in a mutant incapable of producing any formicamy-
cins. Using the same vector, the authors proceeded to elucidate
the biosynthetic pathway by knocking out single genes in the
putative BGC, and ultimately proposed a preliminary biosyn-
thetic route for the production of this group of antibiotics.[49]
Similarly, CRISPR-Cas9 was used to determine that the LuxR
family cluster-situated regulator FscRI was necessary for the
activation of antimycins biosynthesis in Streptomyces albus S4.[50]
Using this information, heterologous production of antimycins
in S. coelicolor M1146 was achieved when the BGC was co-
expressed with its activator FscRI. The general versatility of the
CRISPR-Cas9 system has been further exempliﬁed by its
application for genome editing of rare actinomycetes, one of
which is Actinoplanes sp. SE50/110.[51]
The CRISPR-Cas9 was applied in an alternative fashion for
the knock-in strategy in order to activate silent BGCs in multiple
Streptomyces strains.[48] Replacing native promoters with the
strong, constitutive promoter kasOp" using the CRISPR-Cas9
system led to the production of new compounds in S. roseosporus,
Streptomyces venezuelae, and Streptomyces viridochromogenes.
Furthermore, the compound isolated from S. viridochromogenes
was found to be a novel pigmented PK produced from an
otherwise silent BGC of the type II PKS. Although this activation
strategy bears striking similarity to a technique previously
reported for the activation of ﬁve gene clusters in S. albus
J1074,[52] the incentive to use the CRISPR-Cas9 system is the
increased efﬁciency of HRs, presenting an improved method for
genetic manipulation of strains suffering from the low efﬁciency
of natural recombination.
The use of synthetic or natural strong promoters has also been
proven useful in activating BGCs with low or no expression
levels.[53–55] Based on the xylE reporter gene and RNA-seq, 32
promoters from S. albus J1034 were identiﬁed and characterized,
revealing 10 promoters with strengths 200!1300% higher than
that reported for the standard, constitutive promoter ermE"p.[55]
Using a similar screening approach, Siegl et al.[54] evaluated their
collection of synthetic promoters, and reported strengths of
2!319% in comparison with that of ermE"p.
In addition to the newly adapted molecular tools discussed
above, various systems metabolic engineering strategies for the
model organisms can also be deployed to refactor secondary
metabolites biosynthesis in native hosts, including removal of
competing pathways to change the ﬂux distribution or increase
the pool of precursors, deletion of repressors, and over-
expression of activators.[56] With further advances in the ﬁeld,
systems metabolic engineering strategies will also be employed
for establishment and optimization of secondary metabolites
production in heterologous hosts in the future (see Section 2.4).
2.4. Additional approaches that facilitate streptomycetes
engineering
Besides the molecular tools discussed above, several additional
approaches exist, which may further facilitate streptomycetes
enginering and the secondary metabolite production. First, if the
native host is reluctant toward any genome engineering efforts,
heterologous expression might prove a helpful alternative.[40,57]
Strains such as S. albus, S. avermitilis, S. coelicolor, and
Streptomyces lividans are readily amenable to cloning and
expression, and therefore, their use as heterologous hosts
circumvents native host limitations.[58] Also, the construction of
genome-minimized hosts, which have had one or more BGCs
removed from their genomes, might improve titers of a given
product by avoiding the use of common precursors for other
secondary metabolites.[56,58] One such example is the minimized
host S. coelicolor M1154 which had four of its BGCs deleted in
addition to the introduction of point mutations in rpoB and rpsL,
and is known to have an improved antibiotic production
performance. Using this host, Gomez-Escribano and Bibb
reported 30- and 40-fold increases in the production titers of
congocidine and chloramphenicol, respectively, compared to the
control strain S. coelicolor M145 as the production host.[59] An
even further reduction of the S. coelicolor genome was obtained
by Zhou et al.[60] who, using PCR-targeting of cosmids for the
gene disruption, sequentially deleted all the 10 BGCs encoding
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PKS and non-ribosomal peptide synthetases (NRPS) in addition
to a 900-kb subtelomeric region. A series of mutants were
generated as a result, one of which had 14% of its genome
deleted. Furthermore, a physiological comparison of the
constructed genome-minimized mutants to the wild-type
showed no differences in growth rates. Hence, this strategy
can provide new hosts suitable for heterologous expression of a
wide variety of BGCs.
Thedevelopment of a smallmolecule activation approach could
also prove helpful whenworkingwith the troublesome isolates. In
this regard, chemical elicitation which uses small molecules to
induce themetabolites production in a given strain has been used
with positive outcomes.[61,62] Using the GFP- and LacZ-based
reporter systems tomonitor activationof gene expression, a library
of 640 elicitors was screened to ﬁnd nine of them eliciting
production of two otherwise silent BGCs in Burkholderia
thailandensis E264.[61] Similarly, in a study on the effects of rare
earth elements on secondarymetabolite production inS. coelicolor,
scandium and lanthanum were found to induce gene expression
for the actinorhodin BGC in addition to four otherwise silent
BGCs.[63] More recently, a library of 30 569 small molecules was
screened for their effects on actinorhodin production in S.
coelicolor M145.[64] This led to the isolation of a group of four
antibiotic-remodeling compounds (ARCs), of which ARC2 was
found capable of eliciting secondary metabolism in related
Streptomyces species as well. Following these ﬁndings, the
synthetic derivative Cl-ARC was used for the stronger elicitation
of BGCs encodingmolecules at a low abundance in a panel of ﬁfty
Actinomycete strains.[65] This resulted in the identiﬁcation of
several CI-ARC-induced compounds including oxohygrolidin
from Streptomyces ghanaensis, not previously known to produce
thismolecule.[66] Furthermore, basedonbioactivity-guided assays,
it was shown that while the extracts of the elicitor-treated S.
ghanaensis failed to provide detectable inhibition, puriﬁed
oxohydrolidin displayed activity against S. cerevisiae Y7092. The
latter ﬁnding provides strong incentives to focus future work on
puriﬁed compounds in order to avoid masking of low abundance
molecules in complex sample mixtures. Furthermore, such
systematic analyses show a great promise in high-throughput
screening approaches in that they allow for both screening
multiple elicitors on one strain, or, as reported by Craney et al.,[64]
screening one elicitormolecule against a collection of strains. The
major limitation to such an approach, however, remains in the
massive amount of samples generated, which all require time-
consuming subsequent analytics studies.
3. Recent Examples of Systems Metabolic
Engineering of Streptomycetes for the
Optimized Production of Secondary
Metabolites
The framework of systems metabolic engineering continues to
be adopted to improve the production of secondary metabolites
in streptomycetes, as seen from the many recent successful
examples reported (Table 1). Some noteworthy examples include
the production of tacrolimus (FK506) using Streptomyces
tsukubaensis,[67–69] ascomycin (FK520) using Streptomyces hygro-
scopicus var. ascomyceticus,[70–72] avermectin using S.
avermitilis,[73] and pristinamycin I (PI) and II (PII) using
Streptomyces pristinaespiralis.[74,75]
To solve the issue of low production yield of tacrolimus in the
natural producer, Wang et al.[67] ﬁrst determined the intracellular
responseofS. tsukubaensis to exogenous feedingof fourprecursors
known to promote the tacrolimus biosynthesis. Using a weighted
correlation network analysis (WGCNA) on a dataset containing 93
different intracellular metabolites measured with gas chromatog-
raphy (GC)-MS and LC-MS/MS, metabolites highly associated
with the tacrolimus biosynthesis were identiﬁed. Furthermore,
time-point sampling led to the identiﬁcation of three pronounced
pathways involved in the tacrolimus biosynthesis, namely pentose
phosphate, shikimate, and aspartate pathways. Using this
information and the GSMM of S. tsukubaensis, the genes aroC
and dapA, involved in the biosynthesis of chorismate and lysine,
respectively, were identiﬁed for overexpression, and the effects of
overexpression of these genes were experimentally validated. As a
result, amutantoverexpressing thearoCanddapAgenesproduced
1.64-fold higher yields of tacrolimus, compared to the wild-type
strain.
Ascomycin, an ethyl analog of tacrolimus, is another important
immunosuppressant. To optimize the production of this com-
pound, the natural producer S. hygroscopicus var. ascomyceticus has
undergone several rounds of metabolic engineering. Early strain
development efforts have so far included femtosecond laser
irradiation mutagenesis combined with a shikimic acid enduring
screening. Although shikimic acid was found to have a positive
effect on the ascomycin production, themutant strain FS35, from
themutagenesis screen, also displayedhigh sensitivity toward this
substrate. To overcome this negative effect, an endurance
screening with shikimic acid was carried out, resulting in the
isolation of a shikimic acid-resistant mutant strain SA68 with
ascomycin yield of 330mgL!1 (270mgL!1 for the parent
strain).[70,71] More recently, systems metabolic engineering[72]
was employed to obtain a high-yield ascomycin producing strain,
which showed 84.8% titer improvement, compared to the parent
strain. Prior to the strain engineering, 13C-labelling experiments
and metabolic ﬂux analysis (MFA) were employed in parallel to
construct and validate an ascomycin metabolic network. Elemen-
tary ﬂux mode analysis (EFMA) on the model allowed the
identiﬁcation of chorismatase FkbO and pyruvate carboxylase Pyc
as overexpression and inactivation targets, respectively. Further-
more, from the fed-batch fermentationof the high-producer strain
TD-ΔPyc-FkbO, ethylmalonyl-CoAwas found to be limited toward
the end of fermentation, which opens up for future engineering
efforts.
Similarly, industrial producer strains have undergone extensive
systems metabolic engineering to improve their production titers
of a group of avermectins.[73] As avermectin biosynthesis is under
the tight control of several regulators,much focus has been put on
relieving such regulators. The pathway-speciﬁc regulator AveR,
which is involved in the activation of avermectin biosynthesis, is
itself subject to both negative and positive regulation.[73] Here, the
two TetR family transcriptional regulators (TFRs) encoded by the
genes SAV576 and SAV577were found to indirectly downregulate
the avermectin biosynthesis through binding to the promoter
region of SAV575; SAV575 is known to be involved in providing
acetate and propionate extender units required for the avermectin
production.[76,77] Using a combination of microarray analysis,
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Table 1. Examples of metabolic engineering strategies used for the optimization of secondary metabolite production in streptomycete hosts.
Secondary
metabolite Streptomyces host Metabolic engineering strategies
Highest yield increase
(compared to control strain) References
Actinorhodin Streptomyces coelicolor A3(2) Construction of two comprehensive GSMMs: iIB711
and iMK1208. The latest iMK1208 comprises 1208 genes,
1643 reactions, and 1246 metabolites
52-fold [83–85]
Construction of a mutant strain with improved yields
13C-MFA and transcriptional analysis of mutant and parental
strains to compare their fluxes and gene expression patterns, respectively
FSEOF on iMK1208 to identify additional gene target for overexpression
and subsequent experimental verification
Ascomycin Streptomyces hygroscopicus
var. ascomyceticus
Parallel 13C labeling and MFA to construct metabolic network model 84.8% [70–72]
EFMA on the ascomycin network model for target predictions
Strain engineering by overexpression and inactivation of genes
Addition of resin HP20 in the growth medium
Avermectin Streptomyces avermitilis Increasing flux through precursor pathways 3-fold [73,76,77]
Microarray analysis and ChIP assays for the analysis of expression levels
Identification and deletion of regulators with inhibitory effect on production
Daptomycin Streptomyces roseosporus
LC-511
MFA to identify potential bottlenecks in biosynthesis 43.2% [86,87]
Identification of three genes for overexpression to increase fluxes
through
rate-limiting pathway
Construction of a triple overexpression mutant with improved titers
Transcriptional analysis to evaluate gene expression patterns of parental
and mutant strains
Addition of glucose to fed-batch fermentations of the triple mutant strain
to improve yields further
Pristinamycin Streptomyces pristinaespiralis Transcriptional analysis by RT-PCR for the evaluation of regulatory
network
involved in biosynthesis
2.4-fold (PI) [74,75]
Strain engineering by introduction of extra copies of the BGC, deletion of
repressors, and overexpression of activators
5.26-fold (PII)
Addition of resins to bioreactors
Rapamycin Streptomyces hygroscopicus
ATCC 29253
Construction of a GSMM with 1003 reactions and 711 metabolites 142.3% [88]
FBA and MOMA analyses to evaluate gene targets for improving
production
Construction of a mutant strain with one gene knock-out and
overexpression of
two genes showing higher fluxes through key primary metabolism
pathways
Spinosad Streptomyces albus J1074 Construction of a Saccharopolyspora spinosa NRRL 18395 bacterial
artificial chromosome library
1000-fold [89]
Establishment of heterologous expression of spinosyn BGC in
Streptomyces lividans TK24 and S. albus J1074
Transcriptional and translational (proteomics) analyses to evaluate
heterologous and native hosts
Metabolomics to identify the best suited candidate host for the
expression of spinosyn BGC
Pathway refactoring including promoter engineering and overexpression
of synthetic modules in S. albus mutant
(Continued)
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genetic studies, and chromatin immunoprecipitation (ChIP)
assays, the expression levels of the TFRs and SAV575 were
determined for both mutant and wild-type strains as well as the
binding sites of SAV575 for theTFRs. This observation allowed for
proposing the regulatory role of the TFRs in the avermectin
production. Based on this information, a double deletion mutant
(ΔSAV576 andΔSAV577)was constructed,which showed!3-fold
higher production of avermectin, compared to the wild-type.[77]
A more recent example of using a combinatorial metabolic
engineering approach has been presented for the production of
streptogramin-like antibiotic pristinamycin, which consists of
two chemically unrelated compounds PI and PII.[78] As the
native host S. pristinaespiralis suffers from low yields, additional
copies of the two BGCs responsible for the production of PI and
PII were introduced in addition to the deletion of repress-
ors.[74,75]. The metabolic engineering efforts were strongly aided
from previous ﬁndings of the regulatory cascade governing the
biosynthesis of both PI and PII in S. pristinaespiralis.[79] For PII,
the deletion of the two cluster-speciﬁc repressors PapR3 and
PapR5 along with overexpression of the activators PapR4 and
PapR6 resulted in a 1.5-fold higher production of PII in a mutant
harboring an additional copy of the PII BGC, compared to the
wild-type. Furthermore, the addition of resins to relieve both
feedback inhibition and toxicity of PII resulted in the 5.26-fold
higher production, compared to wild-type, when grown in 5 L
bioreactors.[74] For PI, the highest production was observed in a
mutant in which the BGC of PII was removed, an additional copy
of the PI BGC introduced, and the repressor PapR3 deleted.
Besides the 2.4-fold increased production of PI compared to the
wild-type, interestingly, the mutant with only the PII BGC
removed showed 20–40% lowered PI production, compared to
the wild-type, revealing a possible role of PII as a coactivator or
inducer of PI production.[75] Further characterization efforts are
needed to unravel the regulatory mechanism behind this
observation and to additionally engineer the strain accordingly.
Additional examples on the use of bothmetabolic engineering
and more general engineering strategies for the optimization of
secondarymetabolites production in actinobacteria have recently
been reviewed elsewhere.[56]
4. Conclusions
The expansions and improvements witnessed within the ﬁelds
of genome and compound mining, omics, and molecular
cloning techniques are paving the way for systems metabolic
engineering to harness the production potential of streptomy-
cetes. Systematic and global analyses that have been undertaken
will continue to improve, and, as a result, will foster faster and
better decision making when re-designing a given strain for the
optimal production of a target secondary metabolite and
discovery of new secondary metabolites. However, it should
be noted that, despite all these resources available, a certain
amount of iterations of the design-build-test-learn cycle are still
necessary as demonstrated for other microbial metabolic
engineering cases, especially taking into account the complex
regulation between primary and secondary metabolism in
streptomycetes. Implementation of molecular cloning methods
in an automated, high-throughput setting, such as iBioFab,[80]
biosensors for detecting expression of secondary metabolite
biosynthesis genes,[81] or biosensors for the production of a
desired secondary metabolite[82] might further reduce time and
efforts needed to optimize the production of secondary
metabolites using streptomycetes. It is expected that the tools
and strategies of systems metabolic engineering of streptomy-
cetes will advance rapidly to harness full biotechnological
potentials of this important class of bacteria.
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Table 1. (Continued)
Secondary
metabolite Streptomyces host Metabolic engineering strategies
Highest yield increase
(compared to control strain) References
Tacrolimus Streptomyces tsukubaensis Proteomic and metabolomic analyses of an overproducer strain fed with
soybean oil
1.64-fold [67–69]
WGCNA for the identification of pronounced precursor pathways
Identification of key limiting steps in the pronounced pathways using a
GSMM
Gene overexpression to increase fluxes through two precursor pathways
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Manuscripts II and III 
The CRISPR-Cas9 system 
The clustered regularly interspaced short palindromic repeats (CRISPR) – CRISPR-
associated nuclease (Cas9) system was first recognised as a part of the adaptive 
immune response in bacteria and archeae65–67. Upon encountering foreign DNA or 
RNA, the host organism stores short fragments of genetic information, termed 
protospacers, between identical repeats in so-called CRISPR arrays. Following this 
adaption phase, the host enters the expression phase in which precursor CRISPR RNA 
(pre-crRNA) is transcribed and further processed to yield short crRNAs. During the 
final phase of interference, the crRNAs can bind to the complementary protospacer 
sequences present on the invading viral or plasmid target at which point the Cas 
proteins are recruited66,68 (Fig. 10). To date, three different CRISPR-Cas systems (I, 
II, III) have been characterised69. Of these, the CRISPR type II has received special 
attention, in that it relies only on three distinct components; the crRNA, trans-
activating crRNA (tracrRNA), and a single Cas9 protein68,70. The role of the 
tracrRNA is dual in that it both catalyses the processing of pre-crRNA into crRNA 
and is involved in formation of the complex of Cas9 and crRNA:tracrRNA. Upon 
binding of this complex to the complementary sequence in the target DNA, Cas9 
undergoes conformation changes71, leading to activation of the HNH and RuvC 
endonuclease domains and with that the introduction of double stranded breaks 
(DSBs) in the target DNA.  
The versatility of the CRISPR-Cas9 system potentiates its use in numerous 
applications, including strain genotyping, epidemiological studies, strain 
improvements, and transcriptional modulation66,72. Strain improvement in particular 
has been subject to much progress. The development of a single guide RNA (sgRNA), 
composed of the crRNA:tracrRNA complex, has enabled genetic modification of a 
wide range of hosts, including bacteria, yeast, human cell lines, mouse, zebrafish, and 
others73. In addition, the construction of a catalytically “dead” Cas9 (dCas9), mutated 
in the HNH (D10A) and RuvC (H840A) domains, has facilitated the use of the protein 
as a transcriptional modulator, in that the dCas9 retains its ability to bind to DNA, 
however, lacks the endonuclease activity68. 
 30 
 
Figure 10 The three stages of CRISPR-Cas adaptive immunity in prokaryotes including acquisition (1), expression 
(2), and interference (3). In (1), the bacteria is challenged with viral or plasmid DNA resulting in acquisition of 
unique protospacers (coloured squared with PAM (red) upstream), which are stored between the repetitive 
sequences (grey ellipses) in the CRISPR array. During (2), the leader region (light grey box) of the CRISPR array 
is transcribed into pre-crRNA, which is further processed by Cas proteins into crRNAs, containing single spacers 
and partial repeats. When challenged with viral or plasmid DNA (3) with strong similarity to the acquired 
protospacers, the incoming DNA is cleaved by the Cas proteins. This general scheme is based on the well-studied 
and relatively simple CRISPR-Cas system of Streptococcus thermophiles65,74. Cas, CRISPR-associated; CRISPR, 
clustered regularly interspaced short palindromic repeats; crRNA, CRISPR RNA; Pre-crRNA, precursor CRISPR 
RNA; PAM, protospacer-adjacent motif. 
The development of a CRISPR-Cas9 technology suitable for genome editing in 
actinomycetes75–77 has opened up new ways of engineering the strains for production 
of secondary metabolites as evident from recent publications78–81.  
To promote the use of the CRISPR-Cas9 system for scientist working in the field of 
streptomycetes, our group has published a “CRISPR-Cas9 Toolkit for Actinomycete 
Genome Editing”. The method, which is a chapter in the Springer Protocol series 
“Synthetic Metabolic Pathways”, is presented as manuscript II in this dissertation. 
To further expand the applicability of the USER-CRISPR-Cas9 cloning platform, an 
optimised USER cloning protocol, compatible with a high-throughput setting, for 
vector construction was developed. The development and proof-of-concept (PoC) of 
the optimised workflow are presented in manuscript III entitled “An improved 
USER-CRISPR-Cas9 platform for high-throughput genome editing in 
streptomycetes”.  
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Chapter 11
CRISPR-Cas9 Toolkit for Actinomycete Genome Editing
Yaojun Tong, Helene Lunde Robertsen, Kai Blin, Tilmann Weber,
and Sang Yup Lee
Abstract
Bacteria of the order Actinomycetales are one of the most important sources of bioactive natural products,
which are the source of many drugs. However, many of them still lack efficient genome editing methods,
some strains even cannot be manipulated at all. This restricts systematic metabolic engineering approaches
for boosting known and discovering novel natural products. In order to facilitate the genome editing for
actinomycetes, we developed a CRISPR-Cas9 toolkit with high efficiency for actinomyces genome editing.
This basic toolkit includes a software for spacer (sgRNA) identification, a system for in-frame gene/gene
cluster knockout, a system for gene loss-of-function study, a system for generating a random size deletion
library, and a system for gene knockdown. For the latter, a uracil-specific excision reagent (USER) cloning
technology was adapted to simplify the CRISPR vector construction process. The application of this toolkit
was successfully demonstrated by perturbation of genomes of Streptomyces coelicolor A3(2) and Streptomyces
collinus T€u 365. The CRISPR-Cas9 toolkit and related protocol described here can be widely used for
metabolic engineering of actinomycetes.
Key words CRISPR-Cas9, CRISPRi, Uracil-specific excision reagent (USER) cloning, Synthetic
biology, Actinomycetes, Genome editing, Double-strand break (DSB), Homology directed repair
(HDR), Non-homologous end joining (NHEJ)
1 Introduction
1.1 Actinomycetes Actinomycetes are Gram-positive bacteria with high GC content
genomes, belonging to the order of Actinomycetales. They are well
known for their ability to produce medically and industrially rele-
vant secondary metabolites (natural products) [1–3], including,
but not limited to antibiotics, herbicides, chemotherapeutics, and
immunosuppressants, such as vancomycin, bialaphos, doxorubicin,
and rapamycin, respectively. However, after being studied over half-
century, it becomes more and more challenging to find novel
secondary metabolites with meaningful properties by traditional
Michael Krogh Jensen and Jay D. Keasling (eds.), Synthetic Metabolic Pathways: Methods and Protocols, Methods in Molecular
Biology, vol. 1671, https://doi.org/10.1007/978-1-4939-7295-1_11, © Springer Science+Business Media, LLC 2018
The authors have filed a patent (EP15160126.7) on the actinomycete CRISPR toolkit.
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methods. However, modern genome mining techniques [4–7]
have revealed that those bacteria still possess a huge unexploited
potential to produce secondary metabolites with novel structures
[8]. Unfortunately, in comparison with model organisms like E. coli
and S. cerevisiae, there are only few genetic manipulation tools
available for actinomycetes. In addition, the high GC content
(sometimes>72%) impedes genetic manipulation even if actinomy-
cete DNA is manipulated in other hosts like E. coli. With the help of
the recently developed CRISPR-Cas9 technology, we now have
more tools to address and overcome these challenges for efficient
genetic manipulation of actinomycetes.
1.2 CRISPR-Cas9 Themodules of Clustered Regularly Interspaced Short Palindromic
Repeats (CRISPR)/CRISPR-associated (Cas) proteins are present
in most archaea and many bacteria as adaptive immune systems for
defense against foreign DNA [9–11] or RNA [12]. Based on the
number of Cas proteins involved, CRISPR-Cas systems can be
divided into “class 1” and “class 2.” Class 1 systems have multiple
Cas9 proteins, while class 2 systems only need one single Cas
protein, for instance, type II CRISPR system, also known as
CRISPR-Cas9 system [13]. The currently well-studied and widely
used CRISPR-Cas9 system is originally from Streptococcus pyogenes.
The target sequences of the Cas9 endonuclease are defined in the
CRISPR loci containing short repeats separated by “spacer”
sequences that exactly match the sequences of the targeted foreign
genetic element. Introducing double-strand breaks (DSBs) into
these DNAs offers adaptive immunity against foreign genetic ele-
ments [9, 14–17]. In the native CRISPR-Cas9 system, the spacer
sequence of the CRISPR array transcribes to a CRISPR RNA
(crRNA). Subsequently, an associated trans-activating CRISPR
RNA (tracrRNA) hybridizes with the crRNA, forming an RNA
duplex, which is cleaved and further processed by endogenous
RNase III and possibly other, yet unknown nucleases [18]. The
crRNA-tracrRNA duplex, which was later artificially designed as a
chimera named “single guide RNA” (sgRNA) [17], interacts with
Cas9 to form a complex, then scans the foreign genetic elements for
the presence of trinucleotide protospacer adjacent motifs (PAMs).
When this complex finds a PAM that has a 50 sequence (normally
around 20 nt) complementary to the spacer sequence in the
crRNA-tracrRNA duplex, it binds to this position and then triggers
the conformational change of Cas9 to activate the HNH and RuvC
endonuclease domains [19, 20], which causes DNA double-strand
break (DSB). The DNA DSB of a chromosome is lethal, and cells
can only survive if the lesion is repaired. The two major routes for
DNA repair are (1) non-homologous end joining (NHEJ), in
which no editing template is needed, and (2) homology-directed
repair (HDR), in which an editing template for homologous
recombination is needed [21, 22] (Fig. 1).
164 Yaojun Tong et al.
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Using the feature of introducing DNA DSBs, which then get
repaired by cellular mechanisms such as NHEJ or HDR, allows the
use of CRISPR-Cas9 for genome editing in many different organ-
isms, from E. coli to human cells [23–31]. NHEJ is a complicated
process that involves several proteins. It has been best described in
eukaryotic cells to repair the DNA DSB in an error-prone manner
[32, 33]; however, it is also found in prokaryotes [34, 35]. Inter-
estingly, in S. coelicolor we found that the NHEJ in contrast to other
bacteria, e.g., Mycobacterium tuberculosis [34], is missing a DNA
ligase function. In this strain, the activity of this enzyme can be
partially restored by other yet unknown enzymes, albeit with a
lower efficiency. In S. coelicolor and other streptomycetes lacking
the ligase gene, the native “incomplete” NHEJ repair pathway
usually leads to larger deletions around the site of the DSB. This
phenomenon can be exploited to trigger deletions between the
nearest two essential genes, thus leading to “random size deletion
libraries” [36, 37].
A study of S. pyogenes Cas9 nuclease domain revealed that
mutating the HNH and RuvC domains (D10A and H840A)
resulted in a catalytically dead Cas9 (dCas9) variant that does not
have endonuclease activity, but could still form a complex with
sgRNA and efficiently bind to the target DNA [17]. This effect
can be used to sequence-specifically interfere with transcription and
thus control gene expression. In analogy to eukaryotic RNA inter-
ference (RNAi), this system was named as CRISPRi [38].
Fig. 1 CRISPR-Cas9 schematics. CRISPR-Cas9 genome editing working model
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1.3 USER Cloning Construction of CRISPR-Cas9 vectors using ligation-based
approach is still relatively time consuming, and is difficult to be
implemented in high-throughput and automation settings.
Nowadays, PCR-based cloning is a commonly used method for
de novo gene assembly in metabolic engineering [39]. USER
friendly cloning is one of those modern cloning methods, and it
represents an alternative to conventional ligation-based cloning in
that it allows for simultaneous scarless assembly of multiple PCR
products into USER-compatible vectors (Fig. 2). This allows for
easy and versatile vector construction [40]. We introduced USER
friendly cloning to facilitate CRISPR-Cas9 vectors construction, as
well as to meet the demands for further high-throughput and
automated genome editing purposes.
USER assembly relies on the generation of complementary
overhangs in the PCR products and destination vector and can be
divided into three distinct steps. First, genes of interest (GOIs) are
PCR amplified with primers containing between 7 and 12 nucleo-
tides overhangs flanked by uracil bases (dU) [41]. The directional
assembly of the PCR fragments is facilitated through the over-
hangs, which are designed either manually or using an online tool
such as AMUSER 1.0 (at http://www.cbs.dtu.dk/services/
AMUSER/) [42]. In addition, a proofreading DNA polymerase
such as PfuX7 (Norholm, see [43]) or the commercially available
Phusion U Hot Start DNA Polymerase (Thermo Fisher Scientific,
Waltham, US) is required for the recognition of the uracil bases and
incorporation of adenosine residues on the complementary strand;
second, the destination vector is linearized and with that comple-
mentary overhangs generated using a combination of a restriction
and a nicking enzyme. The enzymes required for linearization and
generation of single-stranded overhangs depend on the USER
cassette in the destination vector. Examples of USER cassettes
include the PacI/Nt.BbvCI, AsiSI/Nb.BsmI, and AsiSI/Nb.BtsI
cassettes [44]; in the third step, PCR fragments are assembled in
the linearized vector by means of the USER™ kit (New England
Biolabs) that contains a mixture of the E. coli uracil DNA glycosy-
lase and DNA glycosylase-lyase endonuclease VIII, both of which
recognize and remove uracil bases. Following uracil excision, the
reaction is kept at the melting temperature of the single-stranded
overhangs for several minutes to facilitate the assembly of the PCR
fragments in the destination vector [45].
During the past 2 years, independent laboratories have estab-
lished modular and efficient genetic manipulation tools for strep-
tomycetes based on CRISPR-Cas9. These tools significantly
facilitated the processes of gene/gene cluster deletion, point muta-
genesis, gene replacement, as well as repression of gene transcrip-
tion in Streptomyces [36, 46–48]. In this chapter, we describe
protocols using the toolkit developed in our lab [36, 37] and a
workflow combining of in silico primer design for sgRNA construc-
tion, USER-based cloning, and CRISPRi.
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Fig. 2 USER cloning schematics. Schematic overview of the steps involved in USER assembly of PCR-
generated fragments in a linearized USER-compatible destination vector
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2 Materials
Milli-Q water (18.2 MΩ cm at 25 !C) is used for preparation of all
media and solutions. All kits and reagents are used according to the
manufacturer’s instructions, unless the modifications are indicated.
Diligently follow all waste disposal regulations when disposing
waste materials.
2.1 Strains One Shot® ccdB Survival™ 2 T1R chemically competent cells
(Thermo Fisher Scientific) are used for the construction of the
USER-compatible vectors. Chemically competent E. coli cells,
e.g., NEB5-α (New England Biolabs), and One Shot® Mach1™
T1 Phage-Resistant (Thermo Fisher Scientific) are used for routine
cloning. Non-methylating E. coli ET12567/pUZ8002 [49] is used
for conjugation. Streptomyces coelicolor A3(2), and Streptomyces col-
linus T€u365 are used as example strains in these protocols.
2.2 Plasmids Plasmids pGM1190 [50], pGM1190-Cas9, pCRISPR-Cas9,
pCRISPR-dCas9, pCRISPR-Cas9-ScaligD [36], and pCRISPR-
USER-(d)Cas9 are used in the following protocols. All oligonu-
cleotides and gBlocks are purchased from Integrated DNA Tech-
nologies (IDT).
2.3 Media All components for media preparation are purchased from Sigma-
Aldrich, unless indicated otherwise.
SOC medium (20 g/L Tryptone, 5 g/L Yeast extract, 4.8 g/L
MgSO4, 3.603 g/L Dextrose, 0.5 g/L NaCl, 0.186 g/L KCl), LB
medium (10 g/L Tryptone, 5 g/L Yeast extract, 5 g/L NaCl,
20 g/L Agar is added for solidification), ISP2 medium (Yeast
extract 4 g/L, Malt extract 10 g/L, Dextrose 4 g/L, 20 g/L
Agar is added for solidification), and Soya Flour Mannitol agar
(MS, or SFM, or Cullum agar) (20 g/L Mannitol, 20 g/L Soya
flour with low fat (W. Schoenenberger GmbH & Co.), 20 g/L
Agar) supplemented with 10 mM MgCl2. Appropriate antibiotics
are added to the media when needed. Their working concentra-
tions are: apramycin, 50 μg/mL; nalidixic acid, 50 μg/mL; thios-
trepton, 1 μg/mL; kanamycin, 25 μg/mL; and chloramphenicol,
25 μg/mL.
2.4 Reagents
and Kits
Phusion Hot Start II DNA Polymerase (2 U/μL), DreamTaq
Green PCR Master Mix (2"), PCR Master Mix (2"), PfuX7
DNA polymerase [43], Phusion U Hot Start DNA Polymerase
(2 U/μL), T4 DNA Ligase (1 U/μL), GeneJET Plasmid Miniprep
Kit, CloneJET PCR Cloning Kit, GeneJET PCR Purification Kit,
and all restriction enzymes are purchased from Thermo Fisher
Scientific; USER™ Enzyme, and Gibson Assembly® Cloning Kit
are purchased from New England Biolabs. Blood & Cell Culture
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DNA Kit is from Qiagen. NucleoSpin® Gel Clean-up kit is from
Macherey-Nagel.
2.5 Equipment NanoDrop 2000 (Thermo Scientific) is used to measure DNA
concentrations, and Concentrator plus (Eppendorf) is used for
concentrating DNA solutions.
3 Methods
All the procedures are carried out at room temperature unless other-
wise specified, allDNAs are elutedbynuclease-freewater (pH8). The
annealing temperature (Ta) is calculated with the Thermo Fisher
Scientific Tm calculator: http://www.thermofisher.com/dk/en/
home/brands/thermo-scientific/molecular-biology/molecular-
biology-learning-center/molecular-biology-resource-library/
thermo-scientific-web-tools/tm-calculator.html.
The plasmids within our CRISPR-Cas9 toolkit are based on
one single temperature sensitive vector pGM1190, which is a deri-
vate of the replicon pSG5 [50]. All necessary elements are
integrated into one single construct, where Cas9/dCas9 is under
control of the thiostrepton inducible tipA promoter, while the
sgRNA is driven by a constitutive ermE* promoter. The editing
template, NHEJ missing component(s), and other element(s) can
be inserted via the singular StuI site of the vector [36] (seeNote 1).
3.1 Identification of
Suitable 20 nt Spacers
with CRISPy-Web
For successful CRISPR/Cas9 experiments it is essential to define
good 20 nt spacer sequences within the desired target region of the
genome. One prerequisite for these 20 nt spacers is that they match
the 20 nt upstream of a PAM close to the desired target. In
addition, it is important to avoid off-target effects: If the same or
a very similar 20 nt spacer sequence is found close to a PAM
elsewhere on the genome, Cas9 will introduce a DSB there as
well. To reduce the probability of unwanted side effects even fur-
ther, spacers that match many other spacers with a mismatch of one
or two bases should be avoided.
For this reason, it is recommended to use computational tools
to design the guide RNAs. While many programs exist for design-
ing sgRNAs for model organisms, only few tools can be used with
user-supplied genomes [51]. The CRISPy-web tool [52] assists
researchers in this task by identifying appropriate 20 nt spacer
regions for sgRNAs in any user-supplied microbial genome
sequence. CRISPy-web is available at http://crispy.
secondarymetabolites.org/.
1. To run CRISPy-web for a genome region of interest, a
GenBank-formatted file can be uploaded by clicking the
“Browse” button and selecting the appropriate file on the
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start page of CRISPy-web. Alternatively, CRISPy-web sup-
ports directly using the results from the antiSMASH secondary
metabolite biosynthetic gene cluster mining platform [4, 5], by
simply selecting “Get sequences from antiSMASH” and
providing the antiSMASH job id that is included in the anti-
SMASH result email. The search is started by clicking the
“Start” button.
2. Once the sequence has been uploaded, the user has to select a
target region to scan for suitable spacers. The region selection
page gives a short summary of the uploaded genome and a
search field below the summary can be used to specify the
target region.
Regions can be selected by entering a range of nucleotide
coordinates (like 12,345–67,890), a gene name, or a locus tag
from the annotated genome.
The search field will autocomplete for gene and cluster name
as well as locus tags. If the data were directly transferred from
antiSMASH and secondary metabolite biosynthetic gene clus-
ter has been identified, these are also shown in a summary table
below the search field.
A help screen for the syntax is displayed by clicking on
“Usage hints.”
3. Once a target region is selected, a click on the “Find targets”
button starts the actual scan for spacers. Depending on the size
of the selected region and the overall genome size, this process
usually takes between few—for small—to around 15 min for
large genomes.
4. Once the scan has completed, the user will be presented with a
page showing an overview of the scanned region. In this over-
view, genes are displayed as gray arrows and potential 20 nt
spacers are indicated as red boxes. It is possible to zoom in to a
specific gene by clicking the gene arrow and selecting “Show
results for this gene only” from the pop-up.
5. Potential spacers are displayed sorted by the number of identi-
cal off-target hits, the number of off-target hits allowing for
one or twomismatches, and the location on the genome.When
hovering over the table, the currently active spacer is high-
lighted in the visualization, and vice versa.
6. Clicking on a table row adds the corresponding spacer to the
download basket, a second click deselects the spacer again. The
basket icon on the upper right of the screen displays the num-
ber of selected spacers.
7. Clicking the download basket icon takes the user to the down-
load page. Here, a summary of the selected spacers is shown,
and it is possible to download the selection as a comma-
separated table that can be opened from a spreadsheet applica-
tion or text editor.
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3.2 Generation of a
Random Size Deletion
Library in
Actinomycetes Using
pCRISPR-Cas9 with
Native NHEJ (See
Note 2)
1. Digest the pCRISPR-Cas9 with Fast Digest NcoI and SnaBI or
Eco105I restriction enzyme (Thermo Fisher Scientific, Wal-
tham, US, Waltham, US). To prepare a stock of vector, a
100 μL reaction is used. Mix 5 μg (up to 10 μg) plasmid,
10 μL 10! Fast Digest Buffer, 5 μL of each of the Fast Digest
restriction enzymes, and nuclease-free Milli-Q water to
100 μL. Incubate at 37 "C for 60 min. The digested plasmid
is purified by GeneJET PCR Purification Kit (seeNote 3). Then
use NanoDrop 2000 to measure the concentration, and then
Concentrator plus for concentrating the DNA solution when
needed. The NcoI and SnaBI double-digested pCRISPR-Cas9
backbone solution can be stored in small aliquots at#20 "C for
up to 6 months for multiple usages.
2. Identify spacers for functional sgRNA cassettes using CRISPy-
web tool as described in Subheading 3.1; for each gene of
interest, pick two spacers with minimal off-target effects.
3. Design primers for functional sgRNA cassette amplification,
the forward primer can be designed as sgRNA-F:
50-CATGCCATGGN20GTTTTAGAGCTAGAAATAGC-30
(N20 represents the 20 nt spacer sequence);
the reverse primer stays the same as sgRNA-R:
50-ACGCCTACGTAAAAAAAGCACCGACTCGGTGCC-30.
The restriction enzyme sites are underlined.
4. PCR is used to amplify the functional sgRNA cassette from
pCRISPR-Cas9. 50 μL PCR reaction is used. Mix 20 ng (up to
100 ng) plasmid DNA, 10 μL 5! HF Buffer, 1 μL 10 mM
dNTP mix, 0.5 μM of designed primers, 1.5 μL DMSO, 1 U
Phusion Hot Start II DNA Polymerase, and nuclease-free
Milli-Q water to 50 μL on ice, flip the PCR tubes by fingers,
spin down the mixture. The PCR conditions are 98 "C for 30 s;
35 cycles of 98 "C for 10 s; Ta (up to 72 "C, calculated by
Thermo Fisher Scientific Tm calculator from both primers) for
30 s; 72 "C for 10 s (1 kb/15–30 s); and finally 72 "C for
10 min, afterward keep at 4 "C.
5. Analyze the PCR products using 2% agarose gel on 1! TAE
running buffer, the positive PCR product is purified by
GeneJET PCR Purification Kit. Then use NanoDrop 2000 to
measure the concentration, and Concentrator plus for concen-
trating the DNA solution when needed.
6. The purified PCR products are double digested by Fast Digest
NcoI and SnaBI restriction enzymes, with the same condition
of the plasmid double digestion.
7. Mix 100 ng of the double-digested pCRISPR-Cas9 backbone
from step 1, fivefold of double-digested functional sgRNA
cassette PCR product (from step 6), 1 μL 10! T4 Buffer,
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and 1 U T4 DNA ligase in a total of 10 μL reaction volume,
then incubate at 25 !C for 60 min.
8. Transform 50 μL of One Shot® Mach1™ T1 Phage-Resistant
competent E. coli cells with 10 μL the ligation mixture, heat
shock at 42 !C for 70 s, recover the cells in 300 μL SOC
medium at 37 !C, 200 rpm for 1 h. Plate 200 μL of the
recovered cells on selective LB agar plates with 50 μg/mL
apramycin, and incubate at 37 !C overnight (around 16 h).
9. On the next day, pick 3–5 colonies into 0.5 mL selective LB
liquid medium with 50 μg/mL apramycin in 1.5 mL Eppen-
dorf tubes, incubate at 37 !C, 200 rpm for 4 h. 1 μL of each
culture is used as a template for colony PCR validation of the
ligation in step 7.
10. The colony PCR is carried out in a 20 μL reaction using Taq-
based DNA polymerase. Mix 1 μL of the culture from step
8 (20 ng of non-digested pCRISPR-Cas9 as a negative con-
trol), 10 μL of the PCR Master Mix (2"), 0.5 μM of the
primers (sgRNA check-F: 50-AATTGTACGCGGTCGAT
CTT-30 and sgRNA check-R: 50-TACGTAAAAAAAGCACCG
AC-30), and nuclease-free Milli-Q water to 20 μL on ice, flip
the PCR tubes by fingers, spin down the mixture. Colony PCR
conditions are 94 !C for 4 min; 35 cycles of 94 !C for 30 s;
50 !C for 30 s; 72 !C for 20 s (1 kb/1 min); and finally 72 !C
for 10 min, then keep at 4 !C.
11. Analyze the PCR products using 4% agarose gel (see Note 4)
on 1" TAE running buffer. Randomly pick two positive clones
of each construct for 10 mL overnight culture using selective
LB liquid medium with 50 μg/mL apramycin, at 37 !C.
12. On the next day, isolate the plasmids from the 10 mL culture of
step 10, and confirm the results by Sanger sequencing using
primer sgRNA check-F.
13. Transform ET12567/pUZ8002 competent E. coli cell with
100 ng of the validated plasmid using the same protocol as in
step 8. Plate 100 μL of the recovered cells on selective LB
agar plates with 50 μg/mL apramycin, 50 μg/mL kanamycin,
and 25 μg/mL chloramphenicol, and incubate at 37 !C for
around 24 h.
14. Randomly pick one clone (known as the donor strain for
conjugation) from the selective LB plate of step 12, inoculate
it into 10 mL of the same selective LB liquid medium, incubate
at 37 !C overnight (around 24 h).
15. Wash the above culture twice with 10 mL LB liquid medium
without antibiotics supplementation and then suspend the cell
pellet with 1 mL (1/10 volume of the culture) LB liquid
medium.
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16. Mix 100 μL ET12567/pUZ8002 culture from step 15 with
50 μL S. coelicolor A3(2) spores (see Note 5), and plate the
mixture onto Cullum agar plates, inoculate the plates at 30 !C
overnight (around 16 h).
17. On the next day, overlay the conjugation plates with 1 mL of
sterilized Milli-Q water containing 1 mg nalidixic acid and
1 mg apramycin.
18. Incubate the plates at 30 !C for 3–5 days to let the exconju-
gants grow.
19. Pick customized number of exconjugants (the library size) and
re-streak them onto ISP2 plates with 1 μg/mL thiostrepton,
50 μg/mL apramycin, and 50 μg/mL nalidixic acid for
5–7 days (see Note 6).
20. Inoculate the step 19 strain into 20 mL non-antibiotic ISP2
liquid medium and incubate at 30 !C, 180 rpm for 3–5 days.
21. Isolate genomic DNA of the strains from step 20 using Blood
& Cell Culture DNA Kit.
22. The isolated genomic DNA can be used to analyze the random
size deletion library.
3.3 Highly Efficient
Gene Loss-of-Function
Studies in
Actinomycetes
Using pCRISPR-Cas9-
ScaligD (See Note 7)
Steps of 1–18 are identical to Subheading 3.2, except the backbone
plasmid is pCRISPR-Cas9-ScaligD instead of pCRISPR-Cas9. The
protocol diverges at step 19, when exconjugants can be seen from
the conjugation plates.
19. Pick 10–20 exconjugants and re-streak them onto ISP2 plates
with 1 μg/mL thiostrepton, 50 μg/mL apramycin, and 50 μg/
mL nalidixic acid for 5–7 days.
20. Scratch some mycelia of the clones from step 19 using a sterile
toothpick into 10 μL pure DMSO (Sigma-Aldrich, St. Louis,
US) in PCR tubes. Shake tubes vigorously for 10 min at
100 !C in a shaking heating block, vortex vigorously for
another 1 min at room temperature, spin down the pellet at
top speed for 10 s. Then 2 μL of the supernatant is used as a
PCR template in a 50 μL reaction in step 22.
21. Design primers for amplifying an approximately 500 bp frag-
ment, around the expected DSB site of mutation.
22. Mix 2 μL supernatant from step 20, 10 μL 5"GC Buffer, 1 μL
10 mM dNTP mix, 0.5 μM of designed primers from step 21,
1 U Phusion Hot Start II DNA Polymerase and nuclease-free
Milli-Q water to 50 μL on ice, flip the PCR tubes by fingers,
spin down the mixture. The PCR conditions are 98 !C for 30 s;
35 cycles of 98 !C for 10 s; Ta (up to 72 !C, is calculated by
Thermo Fisher Scientific Tm calculator from both the primers)
for 30 s; 72 !C for 10 s (1 kb/15–30 s); and finally 72 !C for
10 min, 4 !C forever.
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23. Subclone the PCR products of step 22 into pJET1.2/blunt
vector from CloneJET PCR Cloning Kit, use pJET1.2 For-
ward Sequencing Primer from the kit for Sanger sequencing.
24. The desired mutations from step 23 can be used for gene loss-
of-function study.
3.4 Generation of In-
Frame Gene/Gene
Cluster Deletions or
Replacements in
Actinomycetes Using
pCRISPR-Cas9 with
Homologous
Recombination
Templates
As the homologous recombination is widely used for gene deletion
and replacement in many organisms including Streptomyces [53].
We provide an editing template within the same plasmid,
pCRISPR-Cas9 for HDR of the DSB caused by Cas9, to achieve
scar-less genome editing.
Almost all the steps are the same as Subheading 3.2 (steps
1–11 are exactly the same). The main different steps of this proto-
col are homologous recombination templates design and cloning.
12. Digest the pCRISPR-Cas9 that carries the designed spacer (the
plasmid from step 11 of Subheading 3.3) with Fast Digest StuI
or Eco147I restriction enzyme. A 100 μL reaction volume is
used. Mix 5 μg (up to 10 μg) plasmid, 10 μL 10! Fast Digest
Buffer, and 5 μL of Fast Digest StuI restriction enzyme. Then
incubate at 37 "C for 30 min. The linearized plasmid is purified
by GeneJET PCR Purification Kit. Then use NanoDrop 2000
to measure the concentration and Concentrator plus for con-
centrating the DNA solution when needed.
13. Design primers for amplifying ~1 kb of both 50 and 30 frag-
ments of the target gene (gene cluster), with 20 nt overhang at
the end of both the fragments for later Gibson Assembly.
14. PCR amplify around 1 kb homologous recombination tem-
plates from genomic DNA of the WT strain. The 50 μL PCR
reaction is used. Mix 150 ng (up to 500 ng) genomic DNA,
10 μL 5! GC Buffer, 1 μL 10 mM dNTP mix, 0.5 μM of
designed primers, 1.5 μL DMSO, 1 U Phusion Hot Start II
DNA Polymerase, and nuclease-free Milli-Q water to 50 μL on
ice, flip the PCR tubes by fingers, spin down the mixture. The
PCR conditions are 98 "C for 30 s; 35 cycles of 98 "C for 10 s;
Ta (up to 72 "C, is calculated by Thermo Fisher Scientific
Tm calculator from both the primers) for 30 s; 72 "C for 30 s
(1 kb/15–30 s); and finally 72 "C for 10 min, then keep
at 4 "C.
15. A 3-fragment Gibson assembly of 10 μL reaction volume is
used to assemble the two homologous recombination tem-
plates into StuI site of pCRISPR-Cas9 with designed spacer.
Mix 100 ng linearized plasmid (backbone), three- to fivefold of
each of the two ~1 kb homologous recombination templates,
5 μL 2! Gibson Master Mix, and nuclease-free Milli-Q water
to 10 μL in a PCR tube on ice. Flip the tube, spin down the
mixture, incubate at 50 "C in a PCR block for 60 min.
174 Yaojun Tong et al.
 44 
 
 
 
  
16. Transform 50 μL of One Shot® Mach1™ T1 Phage-Resistant
competent E. coli cells with 10 μL of each assembly reaction.
Apply heat shock at 42 !C for 70 s, recover the cells in 300 μL
SOC medium at 37 !C for 1 h. Plate 200 μL of the recovered
cells on selective LB agar plates with 50 μg/mL apramycin, and
incubate at 37 !C overnight (around 16 h).
17. On the next day, pick 3–5 colonies into 0.5 mL selective LB
liquid medium with 50 μg/mL apramycin in 1.5 mL Eppen-
dorf tubes, incubate at 37 !C, 200 rpm for 4 h for colony PCR
using the designed primers which can cross both homologous
recombination templates to validate the assembly in step 15.
18. The colony PCR is carried out in a 20 μL reaction, the same
protocol as step 9 of Subheading 3.3. Check the PCR products
using 1% agarose gel on 1" TAE running buffer. Randomly
pick two positive clones of each construct for 10 mL overnight
culture. The following steps are the same as steps 11–18.
19. Randomly pick 3–5 exconjugants and restreak them onto ISP2
plates with 1 μg/mL thiostrepton, 50 μg/mL apramycin, and
50 μg/mL nalidixic acid for 5–7 days.
20. Inoculate the step 19 strains into the 20 mL non-antibiotic
ISP2 liquid medium and incubate at 40 !C, 180 rpm for 7 days
to eliminate the CRISPR plasmid (see Note 8).
21. A proper (can be 1000- to 10,000-fold, dependents on the
culture density) diluted fraction of step 20 cultures is plated on
non-antibiotic ISP2 plates to isolate single colonies.
22. Randomly pick 10–20 colonies of each strain from step 21 and
replica plate on ISP2 agar with and without 50 μg/mL apra-
mycin. The clones with restored apramycin sensitivity have
successfully eliminated the temperature-sensitive pCRISPR-
Cas9 plasmid with the homologous recombination templates.
23. Scratch some mycelia of the plasmid-free clones from step 22
using a sterile toothpick into 10 μL pure DMSO in PCR tubes.
Let the tubes shake vigorously for 10 min at 100 !C in a
shaking heating block, vortex vigorously for 1 min at room
temperature, spin down the pellet at top speed for 10 s, 2 μL of
the supernatant is used as the PCR template in a 50 μL reaction
in step 24 (see Note 9).
24. Mix 2 μL supernatant from step 23, 10 μL 5"GC Buffer, 1 μL
10 mM dNTP mix, 0.5 μM of designed primers from step 17,
1 U Phusion Hot Start II DNA Polymerase, and nuclease-free
Milli-Q water to 50 μL on ice, flip the PCR tubes with fingers,
spin down the mixture. The PCR conditions are 98 !C for 30 s;
35 cycles of 98 !C for 10 s; Ta (annealing temperature, up to
72 !C, was calculated by Thermo Fisher Scientific Tm calculator
from the primers) for 30 s; 72 !C for X seconds (depends on
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the amplicon size) (1 kb/15–30 s); and finally 72 !C for
10 min, keep on 4 !C.
25. Subclone the PCR products of step 24 into pJET1.2/blunt
vector from CloneJET PCR Cloning Kit, and use pJET1.2
Forward Sequencing Primer from the kit for Sanger
sequencing.
26. The desired in-frame deletions can be identified from step 25
(see Note 10).
3.5 pCRISPR-dCas9
for Gene Knockdown in
Actinomycetes
For bacterial CRISPRi application, there are two locations of the
DNA that can be targeted by dCas9:sgRNA complex to suppress
the transcription; the gene coding region, and the region upstream
of the start codon, which often includes the promoter. However,
caused by a yet unknown mechanism, for sgRNAs targeting the
coding region, only those sgRNAs that bind to the non-template
DNA strand have the suppression effect, while no such strand bias is
observed when the sgRNAs are targeting on the 50-UTR [36, 38].
A simple illustration is shown in Fig. 3a, while a detailed example is
in Fig. 3b [36].
The steps are the same as steps 1–19 of Subheading 3.2.
Except the spacer from the coding region of the sgRNAs needs to
target on the non-template DNA strand.
20. The strains from step 19 can be used for gene knock-down
validation, either by measuring the final product or the mRNA
level.
3.6 Introduction of
USER Cassette (See
Notes 11 and 12) into
pCRISPR Serials
Vector for the
Facilitation of the
CRISPR Vector
Construction
The vector pGM1190-Cas9 is used to exemplify the de novo
construction of a USER-compatible vector. In general, the USER
vector contains a USER cassette composed of the ccdB gene-
chloramphenicol resistance marker flanked by a restriction and a
nicking enzyme. For the CRISPR-Cas9 system, thiostrepton and
apramycin resistance markers are included in the vector for positive
selection in actinomyces hosts. Two USER-compatible vectors are
currently available in our lab: the pCRISPR-USER-Cas9 for gene
knockout (in), and the pCRISPR-USER-dCas9 for gene
knockdown.
1. The ccdB-chloramphenicol resistance marker cassette is ampli-
fied from the Gateway® Vector of the “Gateway® Vector Con-
version System with One Shot® ccdB Survival Cells”-kit. For
the PCR, mix 20 μL 5" Phusion® HF Buffer, 2 μL 10 mM
dNTP mix, 1 μM of each primer (50-AAAACGCCGGCGGA
ATGCGTGCGATCGCAG-30 and 50-AAAAGGGCCCGAA
TGCACGCGATCGCTG-30) (see Note 13), 2 U Phusion®
HF DNA Polymerase, and nuclease-free Milli-Q water to
100 μL on ice, flip the PCR tubes by fingers, spin down the
mixture. The PCR conditions are 98 !C for 30 s; 35 cycles of
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98 !C for 10 s; 71 !C for 30 s; 72 !C for 1 min; and finally
72 !C for 10 min, keep on 4 !C.
2. Analyze the PCR product on 1% agarose gel with 1" TAE
running buffer and purify the fragment using a gel cleanup kit.
3. Digest vector pGM1190-Cas9 and the PCR-amplified USER
cassette with MreI and Bse120I. To ensure sufficient yields,
digest up to 10 μg of the destination vector with 5 U of each
enzyme in a total volume of 100 μL. For the PCR-amplified
USER cassette, a 50 μL reaction with up to 3 μg DNA and 2 U
of each enzyme normally is sufficient. The digestions are car-
ried out at 37 !C. It is recommended to run the digestions
overnight.
4. Analyze the digestions on 1% agarose gel with 1" TAE running
buffer and purify the fragments with a gel cleanup kit.
5. For the ligation, mix digested vector and USER cassette in the
ratio 1:3 (see Note 14). Mix 2 μL T4 DNA Ligase Reaction
Fig. 3 Prokaryotic CRISPRi working model. (a) An overview of the prokaryotic CRISPRi working model. (b)
Specific example of CRISPRi, the sgRNA is targeting on (binding to) the nontemplate DNA strand of the coding
region of the SCO5092 gene in S. coelicolor [36]
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Buffer, 1 U T4DNA Ligase, and nuclease-free Milli-Q water in
a total volume of 20 μL. The reaction can be carried out either
at 25 !C for 1 h or 16 !C overnight and should be terminated
by heating at 65 !C for 10 min.
6. Use 10 μL of the ligation mix for transformation of 50 μL One
Shot® ccdB Survival™ 2 T1R chemically competent cells. To
account for variations in transformation efficiency, plate both
100 and 250 μL on pre-warmed selective LB plates with 50 μg/
mL apramycin and 25 μg/mL chloramphenicol.
7. Verify clones by colony PCR and Sanger sequencing with pri-
mers covering the entire USER cassette (see Note 15). For the
colony PCR, use 2 μL 10" DreamTaq buffer, 0.4 μL 10 mM
dNTP mix, 0.1 μM of each primer (see Note 15), 2 μL colony
(dissolved in 20 μL nuclease-freeMilli-Q water), 0.2 UDream-
Taq DNA Polymerase, and nuclease-free Milli-Q water to
20 μL on ice, flip the PCR tubes by fingers, spin down the
mixture. PCR conditions are 95 !C for 3 min; 40 cycles of
95 !C for 30 s; 64 !C for 30 s; 72 !C for 2 min; and finally
72 !C for 5 min, keep on 4 !C. Analyze colony PCRs on 1%
agarose with 1" TAE running buffer. Successful integration of
the USER cassette should result in a PCR product of ~1.9 kb.
Colonies with correct size of PCR product are subjected to
Sanger sequencing. The final vector is named pCRISPR-
USER-Cas9.
8. Linearize between 10 and 15 μg USER-compatible pCRISPR-
USER-Cas9 with 20 U and 10 U Nb.BsmI in a total volume of
50 μL. Add 5 μL of the NEB3.1 or CutSmart® buffer and run
the digestion at 37 !C for 2 h, followed by the inactivation of
the enzymes at 65 !C for 1 h.
9. Run the 50 μL-reaction directly on 1% agarose gel with 1"
TAE running buffer until a clear separation of the linearized
vector and the ccdB þ chloramphenicol resistance marker cas-
sette (size of 1.7 kb).
10. Purify the vector with a gel cleanup kit (see Note 16).
11. GOIs are amplified using USER-compatible primers specific
for the AsiSI/Nb.BsmI USER cassette. 7 to 12 nucleotides
USER overhangs is sufficient for successful assembly [41]:
50-CGTGCGAU-[GOI_1]-30.
50-CACGCGAU-[GOI_1]-30.
Use 20 ng gBlock DNA, and up to 200 ng genomic DNA
as PCR template. For the PCR, mix 10 μL 5" Phusion GC
Buffer with 1 μL 10 mM dNTP mix, 0.1 μM of each oligonu-
cleotide, 1 U PfuX7 (seeNote 17) or 1 U Phusion UHot Start
DNA Polymerase, and nuclease-free Milli-Q water to 50 μL on
ice, flip the PCR tubes by fingers, spin down the mixture. The
178 Yaojun Tong et al.
 48 
 
 
 
  
PCR conditions are 98 !C for 3 min; 40 cycles of 98 !C for
10 s; Ta (up to 72 !C, is calculated by Thermo Fisher Scientific
Tm calculator from both the primers) for 50 s; 72 !C for 10 s
(1 kb/15–30 s); and finally 72 !C for 10 min, keep on 4 !C.
12. Analyze the PCR products on 1% agarose gel with 1" TAE
running buffer and purify the right using a gel cleanup kit (see
Note 18).
13. Mix the linearized USER-compatible vector with PCR frag-
ments in the ratio 1:3 or 1:6. For PCR fragments <1000 bp
use ratio 1:6 and for PCR fragments >1000 bp use ratio 1:3.
Mix 1 μL USER™ enzyme mix and 0.5 μL 10" CutSmart®
buffer with nuclease-free Milli-Q water in a total volume of
10 μL.
14. The USER excision is carried out at 37 !C for 15 min followed
by 15 min at Tm of the USER overhang (if using AMUSER for
USER overhang prediction software tools, then the Tm is
26 !C). Keep the mix at 10 !C for another 10 min to allow
the DNA fragments be assembled into the vector.
15. For transformation, mix all 10 μL USER reaction with 90 μL
NEB5-α competent E. coli cells and incubate the mixture on ice
for 20 min before performing the heat-shock at 42 !C for 45 s.
Incubate the transformation mixture on ice for 2 min followed
by the addition of 250 μL pre-warmed (37 !C) SOC medium
for recovering at 37 !C, 250 rpm for 1 h. Plate 100 and 250 μL
(see Note 19) of the recovered cells on pre-warmed (37 !C)
selective LB plates with appropriate antibiotics (in our case
50 μg/mL apramycin) and incubate at 37 !C overnight
(about 16 h).
16. Perform colony PCR as described in step 7.
4 Notes
1. Before using the CRISPR-Cas9 toolkit in the strain of interest,
please check that the pGM1190-based plasmid can replicate
and that the strain codes for a tipA homologue that is required
to activate the tipA-promoter.
2. This feature can only be used in the host with a defective
NHEJ. The strain of interest needs to be checked first if there
is a defective NHEJ and which component(s) are missing. For
example, S. coelicolor A3(2) does not contain a gene encoding
the ligase LigD.
3. The NcoI and SnaBI double digestion of pCRISPR-Cas9 gen-
erates two fragments, ~11 kb and 90 bp, because 90 bp is too
small to be caught by the GeneJET PCR Purification Kit, we
normally directly use GeneJET PCR Purification Kit to purify
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the ~11 kb backbone, which will give you a higher yield. Of
course, gel purification can be used to recycle the ~11 kb
backbone.
4. Because the differences of successful ligation and self-ligation
or the non-digested pCRISPR-Cas9 plasmid PCR are only
20 bp, which needs a high concentration of agarose gel to
distinguish.
5. The amounts of ET strain and spore are highly case dependent,
in this case, for S. coelocolor A3(2), 108 ET strains and 107–108
spore per plate are sufficient to generate enough exconjugants,
for other actinomyces strains, the conjugation condition needs
to be customized.
6. Because the tipA promoter is leaky, we have observed that in
some cases no induction with thiostrepton is required to pro-
vide sufficient Cas9 in the targeted cells.
7. This system, pCRISPR-Cas9-ScaligD, can only be functional in
the host that is lack of DNA ligase component of NHEJ
pathway.
8. For those actinomycetes that are high temperature sensitive:
To eliminate the CRISPR plasmid, carry out step 20 under
30 !C at least two times and then plate a proper diluted fraction
of the culture on nonselective ISP2 plate to isolate single
colonies. Check for apramycin sensitivity of these clones. If
no candidate shows apramycin sensitivity, additional rounds
of nonselective culture may be applied.
9. If colony PCR did not give you any positive bands, which may
indicate that the colony PCR did not work, the genomic DNA
needs to be isolated for PCR template.
10. If the two homologous recombination templates are outside
the gene cluster, then this system can be used for the deletion
of whole gene clusters/genomic regions. Alternatively, they
can be designed to generate in frame deletions within single
genes or used to introduce additional genes/DNA fragments
at the targeted DNA region.
11. Instead, a simpler USER cassette can be designed in which the
ccdB and chloramphenicol resistance marker cassette is omit-
ted. For a detailed protocol on how to construct this type of
cassette, see [54].
12. We use the ccdB-chloramphenicol resistance marker cassette as
positive control for digestion but other systems might apply.
The cassette can be amplified from the Gateway® Vector found
in the Gateway® Vector Conversion System with One Shot®
ccdB Survival Cells.
13. For de novo design of the USER cassette, design oligonucleo-
tides with overhangs for AsiSI and Nb.BsmI as follows:
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50-AAAA-[MCS_enzyme1]-[Nb.BsmI]-[nt*]-[AsiSI]-30.
50-AAAA-[MCS_enzyme2]-[Nb.BsmI]-[nt*]-[AsiSI]-30.
*The variable nucleotide (nt) ensures directional assembly
during cloning.
14. To calculate the molar ratios, use a ligation calculator such as
the one found at http://nebiocalculator.neb.com/#!/.
15. Examples of colony PCR and sequencing primers for the
pCRISPR-Cas9/dCas9 constructs:
USERseq_F: 50-CGAGCGTCCGCCGGCG-30.
USERseq_internal_F: 50-GCTAGTGTCATAGTCCTGAAA
ATCATCTG-30.
USERseq_internal_R: 50-CTGGGTGAGTTTCACCAGTTT
TGATTTAAAC-30.
USERseq_R: 50-GCGTACCGCTTCGGGCCC-30.
Use USERseq_F and USERseq_R for colony PCRs and
USERseq_internal_F and USERseq_internal_R for Sanger
sequencing of the USER cassette.
16. To improve titers, elute DNA in smaller volumes and repeat
the last elution step.
17. The PfuX7 DNA polymerase is prepared in-house by expres-
sing the his-tagged protein followed by Ni-NTA chromatogra-
phy. Hence, concentration of the enzyme can vary between
batches and preliminary titrations are advised. Otherwise, the
USER-compatible polymerase Phusion U is commercially
available from Thermo Fisher Scientific.
18. We experience a higher frequency of correct transformants
when gel purifying the PCRs prior to the USER assembly.
However, for gBlock fragments it might prove sufficient with
direct PCR purification using for example the GeneJET PCR
Purification Kit.
19. Efficiency of the USER assembly depends on the number and
sizes of the fragments for the assembly. If experiencing low
efficiencies, consider plating all of the USER mixture on one
plate.
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Abstract 
Streptomycetes possess a great potential for production of clinically relevant 
secondary metabolites. However, in comparison to other industrial microorganisms, 
the molecular tools available for manipulating streptomycetes are still a limiting 
factor for large-scale metabolic engineering efforts.  
The advent of the CRISPR-Cas9 genome engineering tool for actinomycetes has 
revitalised the field by now allowing for fast and efficient targeted editing of defined 
genes and gene clusters. The ease of handling and the general applicability of the tool 
favour its use in large-scale, high-throughput cloning settings, which allow for much 
greater output in terms of harnessing the full potential of promising isolates. 
Here, we report the optimisation of a recently published cloning methodology termed 
the USER-CRISPR-Cas9 toolbox, suitable for fast and easy vector construction for 
targeted gene and gene cluster engineering in actinomycetes. Proof-of-concept was 
established for the optimised method based on the actinorhodin and 
undecylprodigiosin biosynthetic gene clusters in Streptomyces coelicolor A3(2). The 
improved cloning platform is compatible with an automated setting, which 
strengthens its applicability for future semi-automatic high-throughput genome 
engineering efforts in streptomycetes for improved production of valuable secondary 
metabolites. 
 56 
Introduction 
The gram-positive bacteria streptomycetes constitute the most well-described genus 
within the order of Actinomycetales1. Streptomycetes are primarily found in soil 
environments1, however, other niches, such as freshwater and marine environments, 
have also been reported2. The bacteria are distinguished by several characteristics, 
including GC-rich genomes and a gifted secondary metabolite production profile, of 
which between 20 and 50 biosynthetic gene clusters (BGCs), spread on 0.8 – 3.0 Mb 
of the coding DNA, can be found in their genomes3. However, despite the genetic 
potential to synthesise multiple complex metabolites, only a fraction of the 
compounds are detected in routine fermentations. Instead, most of the BGCs, 
responsible for production of the secondary metabolites, remain silent under standard 
growth conditions. Although the reasons behind the silent nature of some clusters 
remain to be fully understood, the complex regulatory network used by these 
microorganisms to balance metabolism could play a role4,5. These regulatory circuits 
comprise global regulators, which can affect several pathways as a response to 
nutrient limitations or other environmental stresses, and local regulators, which act on 
specific pathways6,7. As more studies are undertaken to gain a greater understanding 
of the logic behind secondary metabolism in streptomycetes, more rational and 
targeted engineering solutions to close the gap between potential and actual 
production of novel compounds are becoming possible8.  
In addition to the increased understanding of secondary metabolite production and its 
regulation, the molecular toolbox used for genome manipulation of streptomycetes 
has also experienced great progress in recent years. 
One of the more recent additions to the toolbox is the clustered regularly interspaced 
short palindrome repeats (CRISPR)-CRISPR-associated nuclease (Cas) system. 
CRISPR-Cas was first discovered as a part of the adaptive immune system in 
prokaryotes and archaea and displays similarities to the eukaryotic RNA interference 
(RNAi) mechanism9. The adaptive immunity is acquired based on the ability of the 
host to recognise incoming foreign DNA and store fragments, or protospacers, of this 
between short repetitive sequences in so-called CRISPR arrays in the host’s 
genome10. The presence of a protospacer associated motif (PAM) upstream of the 
protospacer, found only in the foreign DNA and not in the CRISPR array, is believed 
to play a role in the acquisition stage as well11. Upon exposure to a virus or plasmid, 
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harbouring a protospacer sequence identical to a protospacer found in the CRISPR 
array, the foreign DNA is cleaved by the Cas proteins, which are guided by CRISPR 
RNA (crRNA), the mature form of precursor crRNA (pre-crRNA). The mechanism 
behind cleavage depends on the type of CRISPR system (type I – III) encoded in the 
host10. The type II CRISPR-Cas system is the most simple of the three types in that it 
requires only a limited set of components for interference10,12. This set includes the 
crRNA, trans-encoded small crRNA (tracrRNA), and the Cas9 protein. Here, the 
tracrRNA is responsible for the cleavage of pre-crRNA into crRNA, which then can 
form a complex with Cas9.  
Recently, the type II CRISPR-Cas9 system has been adapted as a tool for genome 
engineering13 and so far it has been implemented in a range of species, including, but 
not limited to, bacteria, yeast, mice, and human cell lines14. The CRISPR-Cas9 system 
has also been adapted for genome engineering of actinomycetes15–17.  
The two main components of the CRISPR-Cas9 editing system are the single guide 
RNA (sgRNA), which contains the 20 bp protospacer specific for a defined target 
sequence, and the endonuclease Cas9. Once the sgRNA binds to matching 20 bp 
sequence in the target DNA, Cas9 is recruited to cut the DNA, leaving a double strand 
break (DSB), which is repaired by the host by either non-homologous end joining 
(NHEJ) or homologous recombination (HR)18. The applicability of the system for 
genome engineering of actinomycetes has already been proven by successful 
deletions of genes as well as gene clusters15–17, also in a multiplex manner15, gene 
induction19, and reversible repression of gene expression17. Here, the latter application 
relies on the catalytically inactive variant of Cas9 (dCas9), in which two point 
mutations (D10A and H840A) have been introduced in the RuvC and HNH domains 
of Cas9. As a result, the dCas9 can bind to the target DNA but lacks the endonuclease 
activity13,20.   
The potential of targeting any gene of interest (GOI) based on very few changes in the 
sgRNA makes the CRISPR-Cas9 system a highly valuable tools for generating 
libraries of mutants. However, despite the high efficiency of the system, the process 
of generating the constructs needed for the specific genome editing purposes can still 
be time-consuming. Hence, implementation of the plasmid construction in a semi-
automatic high-throughput setting would improve the current experimental workflow 
and improve overall output. In this sense, the CRISPR-Cas9 system presents a highly 
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suitable system for automation in that it only requires co-expression of the sgRNA 
and the Cas9 protein, making the plasmid construction relatively straightforward.  
So far, the exchange of 20 bp protospacers and HR templates, needed for the specific 
CRISPR-Cas9 constructs, has been achieved by different approaches, including 
Golden Gate assembly15, Gibson assembly16,17, and digestion and ligation-based 
cloning15–17. The uracil-specific excision reagent (USER)-cloning technique presents 
an excellent alternative to the current PCR-based cloning methods available for 
construction of the CRISPR-Cas9 constructs. The ligase-free USER-cloning 
technique is a highly efficient tool for directional, seamless assembly of multiple 
fragments in one step21–23. USER assembly requires only three components; 
fragments with PCR-generated 7 – 12 nucleotide (nt) overhangs flanked by uracil 
(dU) bases, a linearised vector with overhangs compatible to the fragment overhangs, 
and the USER™ enzyme, which is a mixture of a uracil DNA glycosylase (UDG) and 
the DNA glycosylase-lyase Endonuclease VIII24,25. Upon mixing, the USER™ 
enzyme recognises and cleaves dUs from the overhangs of the PCR-amplified 
fragments, leaving sticky ends compatible to those of the linearised vector (Fig. 1). 
The applicability of the USER assembly system has been greatly strengthened by the 
development of the commercial high-fidelity PfuTurbo® Cx Hotstart DNA 
polymerase26 and the mutant PfuX7 DNA polymerase27, which are both capable of 
reading through the dU bases without loss of fidelity. The latest improvement to the 
system is the AMUSER 1.0  (http://www.cbs.dtu.dk/services/AMUSER/)28, which is 
an in silico tool for designing oligonucleotides for the USER assembly. This web 
application and the simple features of the USER method makes it a suitable tool for 
construction of plasmids in a high-throughput manner in which a library of 
exchangeable control elements, such as promoters and terminators, can be introduced 
with genes of interest (GOIs) to generate new constructs ready for genome editing of 
a strain of interest. 
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Here we report the development of an optimised USER cloning platform for 
construction of CRISPR-Cas9 plasmids suitable for genome engineering of 
streptomycetes. Prior to implementation of the optimised system in an automated 
setting, the workflow was tested manually and evaluated based on the successful 
knock-down of actinorhodin (ACT) and undecylprodigiosin (RED) production in 
Streptomyces coelicolor A3(2) using the CRISPR-dCas9 construct. The next step will 
be to implement the system in a programmable automated workflow, which will allow 
for high-throughput plasmid construction.  
With this optimised cloning platform we hope to strongly encourage future genome 
engineering efforts in streptomycetes in order to harness their full potential for 
production of novel and valuable secondary metabolites.  
 
 
Figure 1 Schematic overview of USER assembly, which can be broken down into three main steps; First, the 
gene of interest (GOI) is PCR-amplified with oligonucleotides with 7 – 12 nucleotide overhangs flanked by a 
uracil (U) base. In parallel, the destination vector is linearisation with a restriction and a nicking enzyme, 
leaving overhangs complementary to those of the PCR-amplified fragments. In the third step, the GOI and 
linearised vector are mixed with the USER™ enzyme, yielding an assembled vector. GOI; gene of interest, 
USER; uracil-specific excision reagent. 
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Materials and Methods 
Bacterial strains and growth conditions 
Plasmids and strains used in this study are listed in Supplementary Table S1.   
All Escherichia coli transformations were carried out according to manufacturer’s 
instructions and always included a 1 h recovery step in Super Optimal broth with 
Catabolite repression (S.O.C.) medium.   
One Shot® ccdB Survival™ 2 T1R chemically competent cells (Thermo Fisher 
Scientific, Waltham, US) were used for propagation of pUSER plasmids harbouring 
the ccdB and chloramphenicol (CmR) gene cassette. Cells were propagated in Luria 
Broth (LB) medium supplemented with 50 µg/mL apramycin and 25 µg/mL 
chloramphenicol.  
E. coli DH5-α cells were used for propagation of actinorhodin (ACT)- and 
undecylprodigiosin (RED)-CRISPR-dCas9 clones in LB supplemented with 50 
µg/mL apramycin. 
Prior to conjugation in Streptomyces coelicolor A3(2), plasmid DNA of ACT- and 
RED-CRISPR-dCas9 clones were introduced into E. coli ET12567(pUZ8002) 
chemically competent cells by calcium chloride transformation. ET12567 strains were 
propagated in LB medium supplemented with 50 µg/mL apramycin, 25 µg/mL 
kanamycin, and 25 µg/mL chloramphenicol for maximum 16 h.  
S. coelicolor A3(2) was grown on modified SFM agar (2 % mannitol, 2 % full fat soy 
flour, 20mM MgCl2, 20mM CaCl2, tap water) for 5 – 7 days for sporulation. 
Intergeneric conjugation was carried out according to a standard protocol29. 
 
Construction of optimised USER-compatible pCRISPR vectors 
Primers used in this study are listed in Supplementary Table S2. Furthermore, the 
sequence of gBlock® gene fragments, UC1 and UC2, and plasmid maps of pUSER1-
dCas9, pUSER2-dCas9, pUSER2-Cas9, and pUSER2-Cas9/ScaLigD can be found in 
Supplementary Notes S1 and S2.  
The USER-compatible destination vectors pUSER1-Cas9, pUSER1-dCas9, and 
pUSER1-Cas9/ScaLigD were previously constructed according to30. To facilitate the 
use of the USER-compatible vectors in an automated setting, an alternative USER 
cassette (UC2) was introduced to replace the original cassette in the pUSER1 
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plasmids, yielding the three new plasmids pUSER2-Cas9, pUSER2-dCas9, and 
pUSER2-Cas9/ScaLigD. In the following, the plasmid construction will be 
exemplified with pUSER2-dCas9, since this plasmid was used for the proof-of-
concept (PoC) studies reported here. To construct pUSER2-dCas9, UC2 was PCR-
amplified using primers UP1/UP2 and introduced into the MreI (Sse232I)/Bsp120I-
linearised pUSER1-dCas9. Ligation was carried out using T4 DNA ligase (New 
England Biolabs, NEB, Ipswich, US) following the manufacturer’s instructions. 
Correct clones were verified by colony PCR using primers UP1/UP2 followed by 
Sanger sequencing with primers UP1 – UP4 to cover the entire USER cassette.   
 
Construction of pUSER2-dCas9 plasmids for ACT and RED   
The pUSER2-dCas9 plasmids for the knock-down of genes involved in biosynthesis 
of ACT and RED in S. coelicolor A3(2) were constructed as reported previously30. In 
brief, the 20 bp spacers specific for either SCO5087 (ActIorf1 in ACT) or SCO5878 
(RedX in RED) were identified using CRISPy-web online tool31 and corresponding 
primers for the USER assembly were predicted using AMUSER 1.028. 
For the three ACT constructs ActIorf1-NT1, ActIorf1-NT2, and ActI-nontarget the 
sgRNA core sequence was PCR-amplified from UC1 using primers UP6/UP7/UP8 
and UP11, of which the three forward primers contained the new 20 bp spacers to be 
introduced in front of the core sgRNA. For the RED constructs, UP9 – UP11 were 
used to PCR-amplify the sgRNAs containing the new 20 bp spacer specific for RedX 
(UP9) and a non-target spacer (UP10). The non-target 20 bp spacers were included 
for both ACT and RED to serve as negative controls. Destination vector pUSER2-
dCas9 was linearised with restriction enzyme AsiSI and nicking enzyme Nb.BsmI 
(New England Biolabs, NEB, Ipswich, US). For the USER assembly, the sgRNA 
fragments and linearised pUSER2-dCas9 were mixed in the ratio 6:1 together with 1 
unit USER™ enzyme (New England Biolabs, NEB, Ipswich, US). The mix was 
incubated at 37°C for 15 min, 25°C for 15 min, and finally 10°C for 10 min, upon 
which the mix was used for E. coli DH5α transformation. Correct clones were 
identified by colony PCR and verified by Sanger sequencing using primers 
UP12/UP13 (see Supplementary Fig. S1).  
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Detection of ACT and RED production in S. coelicolor A3(2) and pUSER2-
dCas9 mutants 
For induction of dCas9, exconjugants harbouring the ACT-CRISPR-dCas9 plasmids 
were streaked onto ISP2 agar containing 50 µg/mL apramycin, 25 µg/mL nalidixic 
acid, and 1 µg/mL thiostrepton, and incubated at 30°C for 7 days or until colonies 
became visible. ACT production of wild type strain S. coelicolor A3(2) and mutants 
A3(2)::ΔACT-orf1NT1/NT2 and A3(2)::ΔACT-nontarget were evaluated directly on 
the ISP2 plates containing 1 µg/mL thiostrepton for induction of the dCas9. Inhibition 
was confirmed by loss of the blue pigment characteristic for ACT production.   
To evaluate RED production, wild type S. coelicolor A3(2), A3(2)::ΔRED-SCO5878, 
and A3(2)::ΔRED-nontarget strains were grown in 100 mL minimal medium29 for 5 
days with 1 µg/mL thiostrepton induction for the two mutant strains. RED production 
was determined using a modified protocol of Kang et al.32. 10 mL culture was spun 
down and cell pellet extracted with equal volume of absolute methanol. Extraction 
was carried out at 37°C for 1 h, shaking at 250 rpm, upon which cell debris was 
removed by centrifugation at 5000 g for 5 min.  RED production was measured using 
an Orbitrap Fusion equipped with a Dionex Ultimate 3000 Ultra high performance 
liquid chromatography (UHPLC) pumping system (ThermoFisher Scientific, 
Waltham, MA, USA). Samples were held in the autosampler under 10°C during the 
analysis. 2 µL of each sample was injected to a C18 Acquity UPLC F5-3 HPLC 
column (2.1 × 100 mm, 1.8 µm,), at a flow rate of 0.4 mL/min, 30.0°C. Mobile phases 
A and B were 0.1 % formic acid in water and acetonitrile, respectively. Elution was 
done with a 30 min multistep system. After 5 % B for 1 min, a linear gradient started 
from 5 % B to 100% B in 21 min, which was held for another 5 min and followed by 
re-equilibration to 5 % B until 30 min. Profile data was collected in both positive and 
negative ion modes with a scan range of (m/z) = 100 – 1600. Further processing was 
carried out using Thermo Xcalibur™ 3.0 software. 
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Results 
Construction of new CRISPR destination vectors allows for an optimised USER-
cloning platform compatible with high-throughput settings  
To take advantage of the simple features of USER assembly and CRISPR-(d)Cas9 
genome engineering, three new plasmids were constructed. Prior to this study, the 
three USER-compatible vectors pUSER1-Cas9, pUSER1-dCas9, and pUSER1-
Cas9/ScaLigD had already been constructed based on the backbones of pCRISPR-
Cas9, pCRISPR-dCas9, and pCRISPR-Cas9-ScaLigD17, respectively, and the 
protocol described by Tong, Robertsen et al.30.  
As the pUSER1 constructs required the exchange of the entire sgRNA (462 bp) for 
every new 20 bp protospacer chosen, the system had to be optimised to reduce costs 
and facilitate a standard assembly scheme. This was achieved by exchanging the 
original USER cassette (UC1), present in the pUSER1 constructs, with a new cassette 
(UC2), which was ordered as a gBlock® gene fragment (see Supplementary Note 
S1). In addition to the ccdB suicide gene and the chloramphenicol resistance marker 
(CmR), present in the original UC1, UC2 was expanded to include the sgRNA core 
flanked by the ermE* promoter and the to terminator. The replacement of UC1 with 
UC2 in the original plasmids was facilitated through the MreI and Bsp120I sites 
flanking the cassettes. This resulted in the three new destination vectors pUSER2-
Cas9, pUSER2-dCas9, and pUSER2-Cas9/ScaLigD (see Supplementary Note S2). 
With the new system, exchanging the 20 bp spacer sequences is now facilitated 
through the USER primers (Fig. 2), in which the 20 bp are inserted directly after the 7 
nt-dU overhangs. As a result, the organisation of the functional sgRNA is kept 
according to the original constructs17 with the 20 bp spacer immediately downstream 
the constitutively expressed ermE* promoter and upstream of the core sgRNA.  
Using this new system, the price for the individual construct is drastically reduced. 
Instead of a 462 bp synthetic DNA fragment, the improved system only requires one 
generic reverse oligonucleotide (UP11) and one custom oligonucleotide containing 
the 20 bp spacer, the 7 nt-dU overhang, and 19 bp sequence complementary to the 
core sgRNA. pUSER2-Cas9 in addition can include the HR templates interspaced by 
the ermE* promoter.  
The optimised system, developed here, is suitable for high-throughput cloning in that 
the overall workflow requires limited operator interference and most of the individual 
 64 
steps can be automated. Once supplied with the primers, templates, and linearised 
plasmid, the PCRs, USER assemblies, and transformations can be programmed on 
robotic equipment. 
 
 
 
 
Figure 2 Schematic representation of the optimised USER-cloning method for construction of CRISPR 
knock-down (dCas) or knock-out (Cas9/Cas9-ScaLigD) plasmids. 20 bp recognition sequences (spacers) are 
predicted using CRISPy-web online tool. AMUSER 1.0 is used for prediction of the primers needed for the 
USER assembly of the sgRNA and the homologous recombination (HR) templates (the latter only for 
pUSER2-Cas9). Destinations vectors are linearised with a restriction and a nicking enzyme, leaving overhangs 
compatible with those of the USER-overhangs (upstream of uracil (U) base). Linearised vector and PCR-
amplified uracil-containing fragments are assembled using the USER™ enzyme, which removes the dUs, 
resulting in generation of single-stranded overhangs compatible with the vector. CmR, chloramphenicol 
resistance marker; CRISPR, clustered regulatory interspaced short palindromic repeats; GOI, gene of interest; 
sgRNA, single-guide RNA; U, uracil; USER, uracil-specific excision reagent. 
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Repression of core genes involved in biosynthesis of ACT and RED in S. 
coelicolor A3(2) using engineered pUSER2-dCas9 constructs  
To demonstrate the functionality of the new vector system, a proof-of-concept (PoC) 
was devised using pUSER2-dCas9 for gene knock-down of actinorhodin (ACT) 
production in S. coelicolor A3(2). The gene actIorf1 (SCO5087), which encodes the 
ketosynthase (KS) and is a part of the minimal polyketide synthase (PKS) of ACT, 
was chosen as gene target. Two 20 bp spacers were tested; NT1, which had 
previously been used for successful gene knock-out17, and NT2, predicted by 
CRISPy-web31. The results of the CRISPY-web prediction of protospacers for both 
SCO5087 and SCO5878 can be found in Supplementary Fig. S2-I and S2-II, 
respectively. Only spacers targeting the non-template strand of the genes actorfI and 
redX were chosen. Furthermore, spacers with few off-targets (defined as mis-matches 
in CRISPy-web) were preferred (see Supplementary Fig. S2-I and S2-II). 
Using the optimised USER cloning system, the two plasmids pUSER2-
dCas9::ΔACT-orf1NT1 and pUSER2-dCas9::ΔACT-orf1NT2 were constructed and 
used to generate the mutants A3(2)::ΔACT-orf1NT1 and A3(2)::ΔACT-orf1NT2, 
respectively. Two negative controls were included in the PoC as well; the non-target 
negative control A3(2)::ΔACT-nontarget, containing a 20 bp spacers targeting outside 
the ACT biosynthetic gene cluster (BGC), and the wild type strain S. coelicolor 
A3(2). The efficiency of the optimised USER assembly method was evident from the 
many positive clones in the colony PCR (see the gel in Fig. 3). 
Disruption of the KS had previously been shown to lead to loss of the blue pigment in 
CRISPR-Cas9-generated mutants17. Therefore, for the initial PoC, the evaluation was 
based on visual examinations of the mutant strains and negative controls grown on 
ISP2 plates containing 1 µg/mL thiostrepton for the induction of dCas9 (Fig. 3). After 
seven days, visual examination of the streaked clones of A3(2)::ΔACT-orf1NT1 and 
A3(2)::ΔACT-orf1NT2 revealed a lack of ACT production as evident from the 
missing blue pigmentation (see Supplementary Fig. S3). Removal of the pUSER2-
dCas9 plasmids by heat stressing resulted in restored blue pigmentation in the two 
ACT mutants (data not shown) and it was concluded that the loss of pigmentation was 
a result of the dCas9 gene repression of actIorf1 involved in ACT biosynthesis in S. 
coelicolor A3(2).  
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Undecylprodigiosin (in the following referred to as RED) is another pigmented 
compound known to be produced by S. coelicolor A3(2). Again the pUSER2-dCas9 
vector was chosen for knock-down of RED. This time, the 20 bp spacer was designed 
for redX (SCO5878), which encodes the two contiguous KSs, which have previously 
been proven essential for RED production in S. coelicolor A3(2)33. Similar to the 
previous approach, non-target and wild type negative controls were also included in 
the assay.  
RED remains in the mycelium of S. coelicolor A3(2) and therefore only this was 
subjected to methanol extraction of the red-coloured pigment from the mutants and 
wild type32. The acidified (0.5 M HCl) methanol extracts were analysed by UHPLC – 
high-resolution mass spectrometry (HRMS). During the 30 min chromatographic run, 
RED appeared at 17.4 min (Fig. 4) with an m/z value of 393.565, corresponding to a 
molecular formula of C25H35N3O. Based on this information, we could confirm 
successful knock-down of RED production in three biological replicates of 
A3(2)::ΔRED-RedX-NT (NT.a, NT.b, NT.c) when compared to the wild type sample. 
Figure 3 Proof-of-concept established using pUSER2-dCas9 for knock-down of actinorhodin (ACT) 
biosynthesis in Streptomyces coelicolor A3(2). a) The two 20 bp spacers NT1 and NT2, targeting the non-
template strand of actIorf1, were designed and tested. b) pUSER2-dCas9 constructs were verified by colony 
PCR. The last two wells in the agarose gel are ddH2O controls, otherwise all clones are positive. c) Pictures of 
the two mutants and the two negative controls grown on ISP2 with 1 µg/mL thiostrepton induction of dCas9 
for seven days. The non-target 20 bp spacer was designed to guide the dCas9 outside the ACT cluster, hence, 
serving as a negative control. The wild type strain S. coelicolor A3(2) served as the second control. NT, non-
template; orf, open reading frame. 
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Comparing the peak intensities (table in Fig. 4) revealed an average reduction in RED 
of 74 % in the mutant replicates compared to wild type. Furthermore, A3(2)::ΔRED-
nontarget maintained RED production and it was concluded that the CRISPR/Cas9 
strategy did not have polar effects on the RED BGC.    
 
 
Figure 4 Evaluation of undecylprodigiosin (RED) production in three biological replicates of A3(2)::ΔRED-
RedX-NT (NT.a, NT.b, and NT.c). The 20 bp spacer was designed to target the non-template strand of redX, a 
core gene involved in RED biosynthesis in Streptomyces coelicolor A3(2). RED production inhibition was 
determined both by visual examination and HPLC-HRMS. The two negative controls include S. coelicolor 
A3(2) wild type (WT) and a non-target control, in which the 20 bp spacer was designed to guide the dCas9 
outside of the RED cluster. Furthermore, RED production was evaluated based on recorded intensities and 
percentage (%) intensity compared to WT RED production (table). NT, non-template; WT, wild type. 
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Discussion 
Genome engineering can be an efficient way of changing properties of streptomycetes 
and improving their production of secondary metabolites. In this context, the 
development of a CRISPR-Cas9 genome engineering tool for actinomycetes has 
revitalised our efforts. Here, we report the expansion of an existing CRISPR-Cas9 
editing toolbox30 through the development of an optimised USER-assembly system 
for construction of CRISPR-(d)Cas9 plasmids. The new workflow allows for faster 
and cheaper plasmid construction, and furthermore, is compatible with a high-
throughput semi-automatic platform. 
In this study, we used the properties of pUSER2-dCas9-catalysed gene repression for 
fast and easy evaluation of ACT and RED production in S. coelicolor A3(2) mutants. 
However, for actual gene and gene cluster deletions we also have available in our 
group the destination vectors pUSER2-Cas9 and pUSER2-Cas9/ScaLigD. The 
properties of these two vectors allow for construction of not only gene specific 
deletion constructs, but could also can aid in fast construction of genome-minimised 
Streptomyces hosts in a multiplexing manner15. The incentive to construct genome-
minimised Streptomyces hosts includes the potential of such strains to become 
scaffolds for heterologous expression of otherwise silent gene clusters, originating 
from strains, that are not easily cultivated under standard laboratory conditions. 
Removing non-essential parts of the chromosome, most often dedicated to secondary 
metabolism, can relieve precursors for more desired pathways, and hence, serve as an 
important field of research when it comes to production of novel compounds or titer 
improvements34.  
Furthermore, the general applicability of the CRISPR-Cas9 system also allows for its 
use in engineering efforts to induce production of secondary metabolites in 
streptomycetes. In this case, both dCas9 and Cas9 can be used to target regulatory 
elements, such as repressors or promoters, found in silent BGCs in an attempt to 
induce production of potentially novel compounds. Recently, an example of taking 
advantage of this alternative approach was reported by Zhang et al.19, who used the 
CRISPR-Cas9 system for knock-in of constitutive promoters in front of several BGCs 
in different Streptomyces hosts, triggering the production of new metabolites from 
otherwise silent BGCs.  
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Our improved pUSER2 vector toolbox is compatible with a semi-automatic high-
throughput platform. In practise, the entire USER assembly can be automated in that 
it only requires the primers with USER-overhangs, templates for the PfuX7 PCRs, 
and the linearised vectors. In this case, the PCR-amplified fragments can even be used 
directly for the USER assembly without any prior purification needed35 (Fig. 5).  
To further strengthen the applicability of the USER-CRISPR-Cas9 cloning platform, 
the inclusion of a chromogenic selection marker could aid in selection of correct 
clones. One such system could be the GusA reporter system, which has already been 
optimised for Streptomyces genome engineering36. The gene gusA encodes a β-
glucoronidase, which can cleave the chromogenic substrate 5-bromo-4-chloro-3-
indolyl-β-D-glucuronide (X-Gluc) into the blue precipitate 5,5’-dibromo-4,4’-
dichloro-indigo. Including the gusA gene in the pUSER2 plasmids would allow for 
quick selection of Streptomyces clones harbouring the plasmid and further would 
reduce the time spent screening for clones having lost the plasmids after Cas9/dCas9 
induction has occurred.  
ACT and RED production can be readily monitored in S. coelicolor A3(2) due to the 
visible change in pigmentation, and, therefore, presents two highly applicable 
biological systems for PoC studies. However, since most secondary metabolites lack 
visual markers, the analytics required in screening for these desired or new 
compounds presents a time-limiting factor. In such cases, an untargeted metabolomics 
approach, which is the complete analysis of all metabolites detectable in a sample37, 
might be employed for evaluation of the genome engineering strategy. This 
methodology allows for detection of not only expected compounds, but also 
potentially novel ones. Several databases exist for dereplication of natural products in 
complex sample mixtures, including the open-access Global Natural Products Social 
Molecular Networking (GNPS) knowledge base, which contains community-derived 
MS libraries of raw, processed, and identified tandem mass (MS/MS) spectrometry 
data38, or alternatively, the Global Alignment for natural-products chemInformatiCs 
(GARLIC) and Generalized Retrobiosynthetic Assembly Prediction Engine (GRAPE) 
platform, which combines compound mining with automated compound 
characterisation39. Linking the output from the engineering efforts to a community-
driven compound database would allow for constant re-evaluation of the sample 
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mixtures and could improve dereplication efforts on the long haul as the database is 
expected to undergo constant expansion.  
In this study, the overall workflow of the USER-CRISPR-Cas9 system was tested and 
verified manually by genetic manipulation of the ACT and RED clusters in S. 
coelicolor A3(2). The next step now is implementation of the system in a robotic 
setting to evaluate the potential of the workflow for high-throughput plasmid 
construction. If successful, we believe that the optimised system can greatly improve 
our future genome engineering efforts. Implementation of the extensions and 
improvements discussed above could further improve the versatility of the system, 
although we believe that the current USER-CRISPR-Cas9 cloning system, reported in 
this study, already serves as a nice tool for future strain engineering efforts and 
ultimately could improve our ability to harness the potential of streptomycetes for 
secondary metabolite production.  
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Figure 5 Proposed semi-automatic high-throughput workflow for the USER-assembly of pUSER2 vectors. 
Inputs, supplied externally by the user, are displayed on the right side of the workflow and output, in this case 
CRISPR-vectors ready for introduction into streptomyces hosts of choice, on the left side. The individual steps 
presented in the middle of the workflow should be automated to ensure a high-throughput output. AMUSER, 
automated DNA modifications with USER cloning. CRISPR, clustered regulatory interspaced short 
palindromic repeats; IDT, Integrated DNA Technologies; gDNA, genomic DNA; USER, uracil-specific 
excision reagent. 
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Table S1: Plasmids and strains used in the study 
Source Description/Genotype Reference 
E. coli strains 
One Shot® ccdB 
Survival™ 2 T1R 
chemically competent 
cells 
F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 
ΔlacX74 recA1 araΔ139 Δ(ara-leu)7697 galU 
galK rpsL (StrR) endA1 nupG fhuA::IS2 
Thermo Fisher 
Scientific 
E. coli DH5-α 
fhuA2, Δ(argF-lacZ)U169, phoA, glnV44, Φ80, 
Δ(lacZ)M15, gyrA96, recA1, relA1, endA1, thi-1, 
hsdR17 
New England 
Biolabs 
E. coli 
ET12567(pUZ8002) 
dam13::Tn9(ChlR), dcm-6, hsdM, hsdR, recF143, 
zjj-201::Tn10, galK2, galT22, ara14, lacY1, xyl-5, 
leuB6, thi-1, tonA31, rpsL136, hisG4, tsx-78, mtlI, 
glnV44. pUZ8002(KanR) 
1 
Streptomyces strains 
Streptomyces 
coelicolor A3(2) Wild type strain 
2 
A3(2)::ΔACT-
orf1NT1 
S. coelicolor A3(2) harbouring pUSER2-
dCas9::ACT-orf1NT1. ApraR This study 
A3(2)::ΔACT-
orf1NT2 
S. coelicolor A3(2) harbouring pUSER2-
dCas9::ACT-orf1NT2. ApraR This study 
A3(2)::ΔACT-
nontarget 
S. coelicolor A3(2) harbouring pUSER2-
dCas9::ACT-nontarget. ApraR This study 
A3(2)::ΔRED-RedX-
NT 
S. coelicolor A3(2) harbouring pUSER2-
dCas9::RED-RedX-NT. ApraR This study 
A3(2)::ΔRED-
nontarget 
S. coelicolor A3(2) harbouring pUSER2-
dCas9::RED-nontarget. ApraR This study 
Plasmids 
pUSER1-Cas9 
USER-compatible destination vector, which is a 
derivative of pGM1190 with Cas9 under the 
control of TipA promoter. Contains USER cassette 
with ccdB suicide gene and chloramphenicol 
resistance marker. ApraR, CmR 
3 
pUSER1-dCas9 
USER-compatible destination vector, which is a 
derivative of pGM1190 with dCas9 under the 
control of TipA promoter. Contains USER cassette 
with ccdB suicide gene and chloramphenicol 
resistance marker. ApraR, CmR 
3 
pUSER1-
Cas9/ScaLigD 
USER-compatible destination vector, which is a 
derivative of pGM1190 with Cas9 under the 
control of TipA promoter and ScaLigD under the 
control of ermE* promoter. Contains USER 
cassette with ccdB suicide gene and 
chloramphenicol resistance marker. ApraR, CmR 
3 
pUSER2-Cas9 
USER-compatible destination vector, which is a 
derivative of pUSER1 with Cas9 under the control 
of TipA promoter. Contains USER cassette with 
sgRNA, ccdB suicide gene, and chloramphenicol 
resistance marker. ApraR, CmR 
This study 
pUSER2-dCas9 
USER-compatible destination vector, which is a 
derivative of pUSER1 with dCas9 under the control 
of TipA promoter. Contains USER cassette with 
This study 
 76 
sgRNA, ccdB suicide gene, and chloramphenicol 
resistance marker. ApraR, CmR 
pUSER2-
Cas9/ScaLigD 
USER-compatible destination vector, which is a 
derivative of pUSER1 with Cas9 under the control 
of TipA promoter and ScaLigD under the control 
of ermE* promoter. Contains USER cassette with 
sgRNA, ccdB suicide gene, and chloramphenicol 
resistance marker. ApraR, CmR. 
This study 
pUSER2-dCas9:: 
ACT-orf1NT1 
pUSER2-dCas9 with USER cassette exchanged 
with sgRNA with 20 bp recognition sequence for 
non-template (NT) 1 for ActIorf1 (SCO5087) 
involved in actinorhodin biosynthesis. ApraR 
This study 
pUSER2-dCas9:: 
ACT-orf1NT2 
pUSER2-dCas9 with USER cassette exchanged 
with sgRNA with 20 bp recognition sequence non-
template (NT) 2 for ActIorf1 (SCO5087) involved 
in actinorhodin biosynthesis. ApraR 
This study 
pUSER2-dCas9:: 
ACT-nontarget 
pUSER2-dCas9 with USER cassette exchanged 
with sgRNA with a 20 bp recognition sequence, 
which does not target (non target) genes involved 
in actinorhodin biosynthesis. ApraR 
This study 
pUSER2-dCas9:: 
RED-RedX-NT 
pUSER2-dCas9 with USER cassette exchanged 
with sgRNA with 20 bp recognition sequence for 
RedX (SCO5878) involved in undecylprodigiosin 
biosynthesis. ApraR 
This study 
pUSER2-dCas9:: 
RED-nontarget 
pUSER2-dCas9 with USER cassette exchanged 
with sgRNA with a 20 bp recognition sequence, 
which does not target (non target) genes involved 
in undecylprodigiosin biosynthesis. ApraR 
This study 
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Table S2: Primers used in this study  
Primer 
ID Primer name Sequence (5' - 3') 
PCR 
program 
UP1 UC2_MreI_FW AAAACGCCGGCGGCTAGCAAAGCGGTCGATCTTGACGGCTG 
1. 98°C, 0:30 min 
2. 98°C, 0:10 min 
3. 70°C, 0:30 min 
4. 72°C, 1:10 min 
5. 72°C, 5:00 min 
(Steps 2-4 × 34) UP2 UC2_Bsp120I_RV 
AAAAGGGCCCGAATGCACGCGAT
CGCTGCGCCG 
UP3 UC2_intseq_FW GTCGTTCGGCTTCATCTGGATTTTCAG 
1. 95°C, 3:00 min 
2. 95°C, 0:30 min 
3. 64°C, 0:30 min 
4. 72°C, 1:00 min 
5. 72°C, 5:00 min 
(Steps 2-4 × 40) UP4 UC2_intseq_RV GGCGTGTTACGGTGAAAACCTGG 
UP6 ActIorf1-NT1_FW CGTGCGAUGTGGCTCGAAGGAGGCTCGAGTTTTAGAGCTAGAAATAG 
1. 98°C, 0:30 min 
2. 98°C, 0:10 min 
3. 68°C, 0:30 min 
4. 72°C, 0:15 min 
5. 72°C, 5:00 min 
(Steps 2-4 × 34) 
UP7 ActIorf1-NT2_FW CGTGCGAUATCGACTTGATCGAGCTGACGTTTTAGAGCTAGAAATAG 
UP8 ActI-nontarget_FW CGTGCGAUGTCCGGGTCGAGCCCGCTGGGTTTTAGAGCTAGAAATAG 
UP9 RedX-NT1_FW CGTGCGAUGTGGGTGTGTCCGTGGCTGTGTTTTAGAGCTAGAAATAG 
UP10 RedX-nontarget_FW 
CGTGCGAUCTTCGGCAGTTCCAA
CATCAGTTTTAGAGCTAGAAATAG 
UP11 sgRNA_RV CACGCGAUCCTCAGGTGACCTCAGAACTCCATCTG 
UP12 USERseq_FW GTTCGAGGTCATGTCCGAGGAG 
1. 95°C, 3:00 min 
2. 95°C, 0:30 min 
3. 64°C, 0:30 min 
4. 72°C, 1:00 min 
5. 72°C, 5:00 min 
(Steps 2-4 × 40) 
UP13 USERseq_RV CCGTCTGACGCCCGATCACG 
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Figure S1: Verification of pUSER2-dCas9 clones by colony PCR  
Colony PCR was carried out to verify correct USER assembly of sgRNAs, amplified 
with primer containing new 20 bp recognition sequences placed in front of the core 
sgRNA, in pUSER2-dCas9. Correct clones (1) yield an amplified fragment of 1.1 kb 
whereas religated pUSER-dCas9 plasmid (2) yields a 2.5 kb fragment. The two 
scenarios are shown in the gel on the right in the figure below. GeneRuler 1 kb DNA 
Ladder (L) was used as marker in which the two intense bands correspond to 1 
(lower) and 3 (upper) kb.  
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Figure S2-I – S2-II: CRISPy-web prediction of spacers for 
SCO5087 (ACT) and SCO5878 (RED) in Streptomyces coelicolor 
A3(2) 
Screendumps of CRISPY-web4 prediction of 20 bp protospacer sequences specific for 
(I) SCO5087, a core gene involved in actinorhodin (ACT) biosynthesis, and (II) 
SCO5878, a core gene of undecylprodigiosin (RED) biosynthesis, in Streptomyces 
coelicolor A3(2). The chosen 20 bp spacers are marked with blue on the schematic 
representation of the gene and in the list. For (I), only the NT1 sequence appears in 
the list in the screenshot. The NT2 appears later in the list, but is still marked on the 
gene. NT1 binds at position 52 – 75 and NT2 at position 385 – 408 on the non-
template strand of SCO5087. For (II), one NT was chosen for SCO5878 as marked by 
the blue narrow square on the gene and the blue text in the list. This NT binds at 
position 48 – 71 on the non-template strand of SCO5878.  
 
 (I)  
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(II) 
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Figure S3: Actinorhodin (ACT) production over time for 
CRISPRi mutants 
To verify successful CRISPRi silencing of core genes involved in actinorhodin (ACT) 
biosynthesis in Streptomyces coelicolor A3(2), plates of A3(2)::ΔACT-orf1NT1 
(generated using either pUSER1-dCas9 or pUSER2-dCas9) and A3(2)::ΔACT-
nontarget were visually examined at different time points. Pictures were taken at day 
4 (96 h), day 5 (120 h), and day 7 (168 h), revealing the slight onset of actinorhodin 
(ACT) production at day 5. On day 7, plates were evaluated and it was concluded that 
both pUSER1-dCas9 and pUSER2-dCas9 can be used for gene repression of ACT 
production in S. coelicolor A3(2). 
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Note S1: USER cassettes (gBlock® gene fragments)  
UC1 (gBlock® gene fragment) 
 
Schematics 
Original USER cassette (UC1) from Tong et al.3. This cassette contains the ccdB 
suicide gene with the chloramphenicol resistance marker (CmR) directly upstream. 
The cassette is removed from the pUSER1 constructs by a restriction and a nicking 
enzyme. The restriction (orange lines) and nicking (orange triangle) sites of the 
enzymes are marked in the fragment.  
 
Sequence  
GAATGCGTGCGATCGCAGCCTACTCGCTATTGTCCTCAATGCCGTATTAAATCATAAAAAGAAATAA
GAAAAAGAGGTGCGAGCCTCTTTTTTGTGTGACAAAATAAAAACATCTACCTATTCATATACGCTAG
TGTCATAGTCCTGAAAATCATCTGCATCAAGAACAATTTCACAACTCTTATACTTTTCTCTTACAAGT
CGTTCGGCTTCATCTGGATTTTCAGCCTCTATACTTACTAAACGTGATAAAGTTTCTGTAATTTCTACT
GTATCGACCTGCAGACTGGCTGTGTATAAGGGAGCCTGACATTTATATTCCCCAGAACATCAGGTTA
ATGGCGTTTTTGATGTCATTTTCGCGGTGGCTGAGATCAGCCACTTCTTCCCCGATAACGGAGACCGG
CACACTGGCCATATCGGTGGTCATCATGCGCCAGCTTTCATCCCCGATATGCACCACCGGGTAAAGT
TCACGGGAGACTTTATCTGACAGCAGACGTGCACTGGCCAGGGGGATCACCATCCGTCGCCCGGGCG
TGTCAATAATATCACTCTGTACATCCACAAACAGACGATAACGGCTCTCTCTTTTATAGGTGTAAACC
TTAAACTGCATTTCACCAGCCCCTGTTCTCGTCAGCAAAAGAGCCGTTCATTTCAATAAACCGGGCG
ACCTCAGCCATCCCTTCCTGATTTTCCGCTTTCCAGCGTTCGGCACGCAGACGACGGGCTTCATTCTG
CATGGTTGTGCTTACCAGACCGGAGATATTGACATCATATATGCCTTGAGCAACTGATAGCTGTCGCT
GTCAACTGTCACTGTAATACGCTGCTTCATAGCATACCTCTTTTTGACATACTTCGGGTATACATATC
AGTATATATTCTTATACCGCAAAAATCAGCGCGCAAATACGCATACTGTTATCTGGCTTTTAGTAAGC
CGGATCCACGCGGCGTTTACGCCCCGCCCTGCCACTCATCGCAGTACTGTTGTAATTCATTAAGCATT
CTGCCGACATGGAAGCCATCACAGACGGCATGATGAACCTGAATCGCCAGCGGCATCAGCACCTTGT
CGCCTTGCGTATAATATTTGCCCATGGTGAAAACGGGGGCGAAGAAGTTGTCCATATTGGCCACGTT
TAAATCAAAACTGGTGAAACTCACCCAGGGATTGGCTGAGACGAAAAACATATTCTCAATAAACCCT
TTAGGGAAATAGGCCAGGTTTTCACCGTAACACGCCACATCTTGCGAATATATGTGTAGAAACTGCC
GGAAATCGTCGTGGTATTCACTCCAGAGCGATGAAAACGTTTCAGTTTGCTCATGGAAAACGGTGTA
ACAAGGGTGAACACTATCCCATATCACCAGCTCACCGTCTTTCATTGCCATACGGAATTCCGGATGA
GCATTCATCAGGCGGGCAAGAATGTGAATAAAGGCCGGATAAAACTTGTGCTTATTTTTCTTTACGG
TCTTTAAAAAGGCCGTAATATCCAGCTGAACGGTCTGGTTATAGGTACATTGAGCAACTGACTGAAA
TGCCTCAAAATGTTCTTTACGATGCCATTGGGATATATCAACGGTGGTATATCCAGTGATTTTTTTCTC
CATTTTAGCTTCCTTAGCTCCTGAAAATCTCGATAACTCAAAAAATACGCCCGGTAGTGATCTTATTT
CATTATGGTGAAAGTTGGAACCTCTTACGTGCCGATCAACGTCTCATTTTCGCCAAAAGTTGGCCCAG
GGCTTCCCGGTATCAACAGGGACACCAGGATTTATTTATTCTGCGAAGTGATCTTCCGTCACAGGTAT
TTATTCGGCGCAGCGATCGCGTGCATTC 
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UC2 (gBlock® gene fragment) 
 
Schematics 
New USER cassette (UC2) ordered as a gBlock® gene fragment. UC2 contains the 
suicide gene ccdB with the chloramphenicol resistance marker (CmR) upstream. 
Additionally, the core sgRNA flanked by the ermE* promoter and to terminator has 
been included in this fragment as well. The cassette is removed from the vector by a 
restriction and a nicking enzymes of which the restriction sites are marked in the 
gBlock® gene fragment (orange) below.   
 
Sequence 
GCTAGCAAAGCGGTCGATCTTGACGGCTGGCGAGAGGTGCGGGGAGGATCTGACCGACGCGGTCCA
CACGTGGCACCGCGATGCTGTTGTGGGCACAATCGTGCCGGTTGGTAGGATCGACGGACTAGGAATG
CGTGCGATCGCGTGGCTCGAAGGAGGCTCGAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCT
AGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTTACCCTAGGAAAAGCTACGAT
GTTCCGGGGACTGCTGATCCGGTCAGCAGGTGGAAGAGGGACTGGATTCCAAAGTTCTCAATGCTGC
TTGCTGTTCTTGAATGGGGGGTCGTTGACGACGACATGGCTCGATTGGCGCGACAAGTTGCTGCGAT
TCTCACCAATAAAAAACGCCCGGCGGCAACGCAGCGTTCTGAACAAATCCAGATGGAGTTCTGAGGT
CACCTGAGGAGCCTACTCGCTATTGTCCTCAATGCCGTATTAAATCATAAAAAGAAATAAGAAAAAG
AGGTGCGAGCCTCTTTTTTGTGTGACAAAATAAAAACATCTACCTATTCATATACGCTAGTGTCATAG
TCCTGAAAATCATCTGCATCAAGAACAATTTCACAACTCTTATACTTTTCTCTTACAAGTCGTTCGGC
TTCATCTGGATTTTCAGCCTCTATACTTACTAAACGTGATAAAGTTTCTGTAATTTCTACTGTATCGAC
CTGCAGACTGGCTGTGTATAAGGGAGCCTGACATTTATATTCCCCAGAACATCAGGTTAATGGCGTTT
TTGATGTCATTTTCGCGGTGGCTGAGATCAGCCACTTCTTCCCCGATAACGGAGACCGGCACACTGG
CCATATCGGTGGTCATCATGCGCCAGCTTTCATCCCCGATATGCACCACCGGGTAAAGTTCACGGGA
GACTTTATCTGACAGCAGACGTGCACTGGCCAGGGGGATCACCATCCGTCGCCCGGGCGTGTCAATA
ATATCACTCTGTACATCCACAAACAGACGATAACGGCTCTCTCTTTTATAGGTGTAAACCTTAAACTG
CATTTCACCAGCCCCTGTTCTCGTCAGCAAAAGAGCCGTTCATTTCAATAAACCGGGCGACCTCAGC
CATCCCTTCCTGATTTTCCGCTTTCCAGCGTTCGGCACGCAGACGACGGGCTTCATTCTGCATGGTTG
TGCTTACCAGACCGGAGATATTGACATCATATATGCCTTGAGCAACTGATAGCTGTCGCTGTCAACTG
TCACTGTAATACGCTGCTTCATAGCATACCTCTTTTTGACATACTTCGGGTATACATATCAGTATATAT
TCTTATACCGCAAAAATCAGCGCGCAAATACGCATACTGTTATCTGGCTTTTAGTAAGCCGGATCCAC
GCGGCGTTTACGCCCCGCCCTGCCACTCATCGCAGTACTGTTGTAATTCATTAAGCATTCTGCCGACA
TGGAAGCCATCACAGACGGCATGATGAACCTGAATCGCCAGCGGCATCAGCACCTTGTCGCCTTGCG
TATAATATTTGCCCATGGTGAAAACGGGGGCGAAGAAGTTGTCCATATTGGCCACGTTTAAATCAAA
ACTGGTGAAACTCACCCAGGGATTGGCTGAGACGAAAAACATATTCTCAATAAACCCTTTAGGGAAA
TAGGCCAGGTTTTCACCGTAACACGCCACATCTTGCGAATATATGTGTAGAAACTGCCGGAAATCGT
CGTGGTATTCACTCCAGAGCGATGAAAACGTTTCAGTTTGCTCATGGAAAACGGTGTAACAAGGGTG
AACACTATCCCATATCACCAGCTCACCGTCTTTCATTGCCATACGGAATTCCGGATGAGCATTCATCA
GGCGGGCAAGAATGTGAATAAAGGCCGGATAAAACTTGTGCTTATTTTTCTTTACGGTCTTTAAAAA
GGCCGTAATATCCAGCTGAACGGTCTGGTTATAGGTACATTGAGCAACTGACTGAAATGCCTCAAAA
TGTTCTTTACGATGCCATTGGGATATATCAACGGTGGTATATCCAGTGATTTTTTTCTCCATTTTAGCT
TCCTTAGCTCCTGAAAATCTCGATAACTCAAAAAATACGCCCGGTAGTGATCTTATTTCATTATGGTG
AAAGTTGGAACCTCTTACGTGCCGATCAACGTCTCATTTTCGCCAAAAGTTGGCCCAGGGCTTCCCG
GTATCAACAGGGACACCAGGATTTATTTATTCTGCGAAGTGATCTTCCGTCACAGGTATTTATTCGGC
GCAGCGATCGCGTGCATTC  
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Note S2: Plasmid maps 
pUSER1-dCas9 
 
 
 
pUSER2-dCas9 
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pUSER2-Cas9/ScaLigD 
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Manuscript IV 
Genetic perturbations caused by CRISPR-Cas9 genetic engineering of 
Streptomyces collinus Tü 365 
Despite the advantages of implementing the CRISPR-Cas9 strategy for genome 
engineering in streptomycetes, the fact that the system is still in its infancy brings 
about certain limitations to its use. We experienced one such limitation of the 
technology when construction a kirN-deletion (ΔkirN) mutant of the kirromycin-
producer strain Streptomyces collinus Tü 365. kirN encodes a crotonyl-CoA 
reductase/carboxylase (CCR), which is predicted to be responsible for provision of 
the ethylmalonyl-CoA extender units, incorporated at the C28 position in kirromycin 
(Fig. 5). CCRs are known to be involved in the assimilation of acetyl-CoA through an 
alternative glyoxylate pathway82, and thus, we expected an isoenzyme of KirN from 
primary metabolism to partially complement its function. This should result in 
lowered kirromycin biosynthesis, but not complete loss of production in the ΔkirN 
mutant. However, to our surprise the CRISPR-Cas9-generated mutant of ΔkirN 
completely lost its ability to produce kirromycin (Fig. 11).  
 
Figure 11 UV-Vis profiles of Streptomyces collinus Tü 365 wild type (top) and ΔkirN mutant (bottom). The 
asterisk marks kirromycin. No kirromycin-associated compounds were detected in the ΔkirN mutant. 
Using Breseq83 for whole genome sequence (WGS) analysis of the mutant, the results 
revealed an unexpected genotype, in which the CRISPR-Cas9 strategy had led to two 
large-scale deletions on both chromosomal arms of S. collinus Tü 365. The deletions 
of 0.79 Mb (left arm) and 0.63 Mb (right arm) explain why kirromycin production 
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was lost in the mutant, in that the BGC of kirromycin is present in two identical 
copies on the long terminal inverted repeats (TIRs) of the chromosomal arms49,50 (see 
Appendix 2 and 3). 
Several features characteristic for streptomycetes could provide hints to why this 
chromosome rearrangement was observed in the ΔkirN mutant. Chromosome 
replication in Streptomyces species is a bidirectional process starting from the 
centrally located oriC84,85. Core genes involved in primary metabolism are situated 
near the central region of the chromosome, whereas genes and gene clusters involved 
in secondary metabolism can be distributed across the chromosomes86. The natural 
habitat of streptomycetes can present a very competitive environment, in which the 
ability of the strain to quickly adapt to new growth conditions, including nutrient 
depletion or competing organism, is important for survival. Besides sporulation, the 
capability of streptomycetes to undergo recombination could provide a survival 
benefit in that exchange of genetic material, such as clusters encoding secondary 
metabolites, can result in mutants with novel phenotypes87. In addition, mutation rates 
have been reported to be inherently high (> 0.1 % mutants observed for colony-
forming spores) in these organisms88,89. Chloramphenicol-sensitive (CmlS) mutants of 
Streptomyces lividans 66 TK64 was found to arise at a 0.8 % average frequency in 
spores. This mutation in the CmlS strains gave rise to increased instability, which 
resulted in 25 % arginine-auxothrophic mutants90. Spontaneous mutations have also 
been reported for Streptomyces ambofaciens DSM 40697, affecting its overall 
pigmentation with 17 % frequency. The pigment-deficient mutants displayed 
hypervariability, which could be further linked to large chromosomal deletions 
ranging from 250 – 2000 kb88, all confined within the same genomic region.   
The natural instability at the telomeres might provide hints to the observed genotype 
of the ΔkirN mutant. Several hypotheses exist trying to explain this instability, 
including the presence of transposon at the TIRs, which allow for intermolecular 
transposition between chromosomes and an exchange of the TIRs91. Alternatively, 
collapsed replication forks at single-strand DNA breaks are repaired by homologous 
recombination (HR). In the lack of suitable templates for HR, illegitimate 
recombination can result in deletions in or rearrangement of the chromosome92,93.     
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Due to the unintended side effects of using the CRISPR-Cas9 technology for 
construction of genetic mutants in the duplicated kirromycin BGC of S. collinus Tü 
365, an alternative strategy was undertaken to manipulate putative genes involved in 
kirromycin biosynthesis. Two of the mutants, ΔkirOI and ΔkirOII, included in our 
studies, was previously constructed by Kristina J. Laiple and David Worbs under the 
supervision of Tilmann Weber and Wolfgang Wohlleben at Tübingen University. The 
findings of our studies have resulted in manuscript IV presented in the following 
section.  
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Abstract 
Kirromycin is the main product of the soil-dwelling Streptomyces collinus Tü 365. 
The elucidation of the biosynthetic pathway revealed that the antibiotic is synthesized 
via a unique combination of trans-/cis-AT type I polyketide synthases and non-
ribosomal peptide synthetases (PKS I/NRPS). This was the first example of an 
assembly line integrating the three biosynthetic principles in one pathway. However, 
information about other enzymes involved in kirromycin biosynthesis remained 
scarce.  
In this study, genes encoding tailoring enzymes KirM, KirHVI, KirOI, and KirOII, 
and the putative crotonyl-CoA reductase/carboxylase KirN were deleted, 
complemented, and the emerged products analysed. Derivatives were identified in 
mutants ΔkirM, ΔkirHVI, ΔkirOI, and ΔkirOII, of which the products of ΔkirOII and 
ΔkirHVI were subjected to NMR as well. Our efforts enabled functional assignment 
of the enzymes, demonstrating their involvement in kirromycin tailoring. In ΔkirN, 
the production of kirromycin was significantly decreased, which is advantageous for 
the production and purification of kirromycin analogues. The obtained data enabled 
us to clarify the putative roles of the studied enzymes, ultimately allowing us to fill 
many of the missing gaps in the biosynthesis of the complex antibiotic. Furthermore, 
this collection of mutants can serve as a toolbox for generation of new kirromycins. 
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Introduction 
Streptomycetes are known for their profound ability to produce a diverse set of 
secondary metabolites with relevant pharmaceutical properties, including, but not 
limited to, antibiotics, anti-fungals, immunosuppressant, and antitumor agents. 
Polyketides comprise a noteworthy subset of these metabolites. They played and still 
play an important role in the clinic1,2, hence highlighting the importance of their 
discovery.  
Many complex polyketides are synthesized by megaenzyme complexes termed 
modular polyketide synthases (PKSs), which catalyse the controlled initiation and 
elongation of simple carboxylic acid monomers into polyketide chains. One example 
of a complex polyketide is the narrow-spectrum antibiotic kirromycin. The compound 
was first isolated from the soil-dwelling Streptomyces collinus Tü 365 in 19723. The 
linear molecule is composed of three internal ring structures: a pyridone ring, a 
central tetrahydrofuran (THF) group, and a sugar-like moiety, also referred as 
goldinonic acid lactone4 (Fig. 1). All three molecule structures are involved in the 
binding of the antibiotic kirromycin to the elongation factor (EF) Tu in prokaryotes5,6. 
This interaction prevents the conformational change between the GTP and GDP-
bound form of the EF Tu, which results in stalling of protein biosynthesis. Although 
the structure and activity of kirromycin were known since the early 70s, most of the 
biosynthetic steps remained unexplored. First after the 82 kb kirromycin cluster (Fig. 
2), encoding 28 genes, was identified and described4, more details on the assembly of 
the compound were obtained. The hypothetical pathway of kirromycin indicated that 
the biosynthetic steps involve non-ribosomal peptide synthetases (NRPSs), 
acyltransferase (AT)-harbouring PKSs (cis-AT PKSs), AT-less PKSs (trans-AT 
PKSs), and several tailoring enzymes. This first description of a biosynthetic pathway 
involving three different types of multi-modular enzymes has made the assembly line 
a relevant model for studying complex cis-/trans-AT PKS/NRPS pathways.  
 
 
Figure 1 Structure of kirromycin. The molecule is composed of three intramolecular ring structures; a 
pyridone ring, a central tetrahydrofuran (THF) ring, and a sugar-like moiety termed goldinonic acid6. 
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Directly upstream of the PKS/NRPS genes in the BGC of kirromycin, the Sfp-type 
phosphopantetheinyl transferase (PPTase), encoded by kirP, is found. The enzyme 
KirP catalyses the post-translational activation of the acyl carrier proteins (ACPs) and 
peptidyl carrier proteins (PCPs) and has a relaxed CoA substrate specificity, allowing 
it to accept both malonyl- and methylmalonyl-CoA7. The core PKS/NRPS enzymes in 
kirromycin are encoded by kirAI – kirAVI and kirB4. Closer examinations of the PKS-
related genes and their products revealed KirAVI to be the only cis-AT PKS in the 
assembly line. The KirAVI PKS contains two AT domains (KirAVI-AT1 and 
KirAVI-AT2). ATs are responsible for the recognition, binding, and loading of 
extender units onto the acceptor proteins, the ACPs, in the PKS. According to the 
kirromycin structure and conserved amino acid (aa) sequence motives, the KirAVI-
AT1 incorporates methylmalonate, while KirAVI-AT2 is responsible for introduction 
of malonate into the kirromycin polyketide backbone. The upstream PKSs, KirAI – 
KirAV, lack the integrated ATs. For these modules, extender units are provided by 
the discrete ATs8. The enzyme KirCI provides malonyl-CoA to several ACPs of the 
assembly line9, whereas KirCII specifically recognizes only one ACP (KirAII-ACP5) 
and delivers the non-malonate precursor ethylmalonyl-CoA to module five, leading to 
the branched moiety at C28 of kirromycin10. Furthermore, it was demonstrated that 
KirCII loads both allyl- and propargyl-derived units onto its cognate ACP11,12. These 
features were exploited to generate kirromycin analogues with allyl and propargyl 
side chains in vivo13. The propargyl side chains can be utilized as educts for "click" 
chemistry reactions, which highlights the potential of the KirCII-ACP5 tool for the 
production of not only kirromycin derivatives, but also new polyketide products 
whenever the tool can be adapted to a heterologous assembly line. 
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kirB encodes the last core enzyme of the PKS I/NRPS assembly line of kirromycin, 
and has been found to be responsible for incorporation of the precursor β-alanine4, 
which is biosynthesised by the aspartate-α-decarboxylase encoded by kirD14. Upon 
release from the assembly line this precursor is cyclized to form the pyridone ring4. 
Interestingly, no genes encoding a typical thioesterase (TE) were identified in the 
genome of the producer strain. Recently, Gui et al.15 reported the discovery of a new 
group of Dieckmann cyclases involved in the biosynthesis of tetramic acid and 
pyridone scaffolds. A member of this new family of enzymes is also found in the 
kirromycin biosynthetic gene cluster (BGC). KirHI, previously assigned with a 
hypothetical function4, was found to catalyse pyridone ring closure and the co-
occurring release of the molecule chain from the PKS I/NRPS assembly line.  
While the precursor loading of the PKS I/NRPS modules and the kirromycin 
polyketide chain elongation are well investigated (Fig. 3A), only limited knowledge 
about the provision of ethylmalonyl-CoA and the final tailoring reactions is available 
for this pathway. To date, the underlying reactions leading to closing of the THF ring, 
the introduction of hydroxyl groups at C16 and C30, methylation of the oxygen at 
O42, and the formation of the double bond between C5 and C6 in the pyridone ring 
have remained elusive. These enzymatic reactions cannot be explained from the 
enzymatic domains encoded within the PKS I/NRPS complex and thus, it was 
speculated that those product modifications are achieved through tailoring reactions.  
In this study, the genes kirM, kirHVI, kirOI, kirOII, kirHIV, kirHV and kirN, which 
are encoded in the kirromycin BGC, but have no experimentally determined function, 
were examined by genetic inactivation and gene complementation. The compounds 
produced by the gene inactivation mutants were analysed and characterized by high 
performance liquid chromatography (HPLC)–high-resolution mass spectrometry 
(HRMS), and MS/MS. In addition, nuclear magnetic resonance (NMR) was employed 
for structural elucidation of the derivative produced by ΔkirOII and ΔkirHVI.  
Figure 2 Schematic representation of the biosynthetic gene cluster encoding kirromycin. Black, hypothetical 
proteins; Blue, NRPS-related genes; Red, PKS-related genes; Orange, dehydrogenases and hydroxylases; 
Light blue, genes involved in precursor supply; Light brown, O-methyltransferase; Light green, transport-
related genes; Purple, resistance-related genes; Light grey, genes putatively not involved in kirromycin 
biosynthesis (modified graphics from Weber et al.4). 
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Figure 3 The hybrid PKS I/NRPS assembly line for kirromycin biosynthesis in Streptomyces collinus Tü 365. 
A) The mechanism behind the PKS I/NRPS chain elongation. Modified from Weber et al.4. B) Tailoring 
enzymes involved in the biosynthesis of kirromycin. ACP, acyl carrier protein; AT, acyltransferase; KS, 
ketosynthase; DH, dehydrogenase; KR, ketoreductase; ER, enoylreductase; MT, methyltransferase; C, 
condensation domain; A, adenylation domain; PCP, peptidyl carrier protein; KirCI/KirCII, trans-ATs; kirHI, 
Dieckmann cyclase; kirM, O-methyltransferase; kirHVI, phytanoyl-CoA dioxygenase; kirOI/kirOII, 
cytochrome P450-dependent hydroxylases. 
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Methods 
Bacterial strains and general growth conditions  
Plasmids and strains used in this study are listed in Supplementary Table S1. 
Wild type strain Streptomyces collinus Tü 365 was obtained from the “Tübinger 
Stammsammlung”. For routine cultivations of mutants, complemented mutants, and 
wild type strain, Tryptic Soy Broth (TSB) supplemented with nalidixic acid was used. 
Furthermore, mutants, into which the inactivated gene was introduced, were 
propagated in the presence of apramycin. Sporulation of wild type and mutant strains 
was performed on modified SFM agar (2 % mannitol, 2 % full fat soy flour, 20mM 
MgCl2, 20mM CaCl2, tap water). Escherichia coli DH5-α was used for standard 
cloning procedure of pGUSA21, pDrive, pA18mob, pJet1.2/blunt, pGM1190 and 
pRM4 constructs. Transformation was carried out according to the manufacturer's 
specifications and including a 1 h recovery step in Super Optimal broth with 
Catabolite repression (S.O.C.) medium. E. coli was grown at 37°C (200 rpm) in Luria 
Broth (LB) medium supplemented with appropriate antibiotics. In order to introduce 
the construct into streptomycetes, plasmid DNA was introduced into E. coli ET12567 
(pUZ8002) by calcium chloride transformation. ET12567 strains were grown in LB 
supplemented with apramycin, chloramphenicol, and kanamycin for 16 hours, 
shaking at 200 rpm at 37°C.  
 
Construction of kirM, kirN, kirHIV and kirHV gene inactivation plasmids 
All primers used in this study are listed in Supplementary Table S2. A 2.1 kb 
cassette, containing pErmE* flanked by two 1 kb-fragments up- and downstream of 
the genes kirM, kirHIV, kirHV, and kirN, were amplified from pCRISPR-
Cas9_USER- kirM/kirHIV/kirHV/kirN, which were constructed based on a previously 
described method16 (see Supplementary Table S1). For the assembly, primers KP1 – 
KP8 and PCR programs listed in Supplementary Table S2 were used. Each of the kir 
cassettes were assembled in pGUS A21 by Gibson cloning carried out at 50°C for 30 
min. Correct clones of pHR1 – pHR4 were identified by control PCR and confirmed 
by Sanger sequencing with KP37/KP42. 
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Construction of kirHVI gene inactivation plasmid 
To generate the kirHVI gene inactivation plasmid pHR2, 1 kb fragments, flanking the 
target gene, were amplified from the cosmid 2K05 DNA4 using primers KP9/KP10 
and KP13/KP14. pErmE* was amplified from plasmid pCRISPR-Cas917 with primers 
KP11/KP12. 1 M betaine was added to the PCRs to improve amplification of GC-rich 
stretches. Upon gel purification, the three fragments were assembled in pGUS A2118 
by Gibson cloning carried out at 50°C for 30 min, yielding pHR5. Correct clones of 
pHR5 were identified by control PCR and Sanger sequencing with KP37/KP38. 
 
Construction of kirOI and kirOII gene inactivation plasmids 
To construct pTL-kirOI, 1.2 kb of the flanking regions of the gene were amplified by 
PCR with primer pairs KP15/KP16 and KP17/KP18 using the PCR programs listed in 
Supplementary Table S2. For construction of pDW-kirOII, 2 kb of the flanking 
regions of kirOII were amplified by PCR with primers KP21/KP22 and KP23/KP24 
using the PCR program listed in the Supplementary Table S2. 
The left and right fragments, up- and downstream of kirOI and kirOII, were cloned 
into pA18mob resulting in the plasmids pTL-kirOI and pDW-kirOII, respectively. 
The thiostrepton resistance cassette (1.1 kb) was amplified from plasmid pSLE6119 
with primers KP19/KP20. The 1.1 kb fragment was first cloned into pDrive (Qiagen, 
Hilden, Germany) and then inserted via the XbaI sites into pTL-kirOI and pDW-
kirOII, resulting in the plasmids pTL-kirOI-thio and pDW-kirOII-thio, respectively. 
The gene replacement mutants were confirmed by control PCRs targeting the 
apramycin and thiostrepton resistance cassettes with the primer pairs KP39/KP40 and 
KP19/KP20, respectively. 
To distinguish between wild type and single/double crossover mutants, the primer 
pairs KP41/KP42 and KP43/KP44 were used for amplification of an internal region of 
(wild type) kirOI/kirOII or the thiostrepton resistance marker (single- or double 
crossover mutant).  
In addition to PCR, Southern Blot analysis was used to confirm correct mutants of 
kirOI and kirOII. Here, the DIG-labelled probe for Southern Blot experiments was 
amplified from cosmid 1C24 DNA4 with the primer pairs KP41/KP42 (kirOI) or 
KP43/KP44 (kirOII), using a 10X DIG DNA labelling mix (Roche, Mannheim, 
Germany). Genomic DNA preparation from the streptomycetes was performed with 
the NucleoSpin® Tissue Kit from Macherey-Nagel, Düren, Germany. 
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Intergeneric conjugation in S. collinus Tü 365 
To introduce the gene inactivation plasmids into S. collinus Tü 365, a standard 
protocol for intergeneric conjugation was used20. Single crossover mutants were 
selected based on blue-white screening18 in which spore dilution plates were overlaid 
with 20 mM X-Gluc (5-bromo-4-chloro-3-indolyl-β-D-glucuronic acid). Control PCR 
was used to verify the single crossovers using primers KP72/KP73. For induction of 
the double crossover event, two days-old cultures of single crossover mutants, 
cultivated in TSB medium, were stressed for 24 h at 37°C, shaking at 160 rpm. Spore 
dilution plates were overlaid with 20 mM X-Gluc and white clones were picked for 
control PCRs with primers KP45 – KP58 (see Supplementary Fig. S6).   
 
Construction of complementation plasmids for kirromycin kir mutants 
kir genes were PCR amplified using the cosmid 2K05 (kirM, kirHVI, kirOI, kirOII, 
and kirN)4 as template and the primers KP27 – KP36. 1M betaine was added to the 
PCRs to improve amplification of the GC-rich stretches. The DNA encoding the kir 
genes was purified from gel and cloned into blunt end pJet1.2 vector as instructed by 
the manufacturer. Correct clones were verified by control PCR and Sanger 
sequencing with primers KP59/KP60.  
pJet1.2 clones of kirM, kirHVI, and kirN were subjected to restriction digestions with 
NdeI and HindIII together with DNA of integrative plasmid pRM4. The pJet1.2 clone 
of kirOII was subjected to restriction digestion with NheI and HindIII together with 
pRM4. Finally, pJet1.2-kirOI was subjected to restriction digestion with HindIII and 
EcoRI together with replicative plasmid pGM1190. The genes purified from gel and 
linearized vectors were ligated using T4 DNA Ligase and introduced into E. coli 
DH5-α competent cells according to manufacturer’s instructions. The 
complementation plasmids of pGM1190 and pRM4 were verified by control PCR and 
Sanger sequencing with primers KP61/KP62 and KP63/KP64, respectively, and 
transferred to S. collinus mutant strains by standard intergeneric conjugation20. 
 
Kirromycin production assay, HPLC-HRMS, and MS/MS analyses  
For the fermentations, 5 mL of two days-old precultures (grown in TSB), normalized 
according to weight, were used for inoculation of 95 mL kirromycin production 
medium composed of 1 % full-fat soy flour, 1 % D-mannitol, and 0.5 % CaCO3 
dissolved in tap water and pH adjusted to 7.4 prior to autoclaving. Fermentations were 
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carried out for six days at 30°C in a rotary shaker at 160 rpm. Cultures were extracted 
with 1:1 ethyl acetate for 90 minutes and evaporated in a Büchi® Rotavapor® RII 
evaporator equipped with jack and water bath. Dried extracts were redissolved in 500 
µL methanol. HPLC–HRMS analysis was carried out with an Orbitrap Fusion 
connected to a Dionex Ultimate 3000 UHPLC pumping system (ThermoFisher 
Scientific, Waltham, MA, USA). UV-Vis detection was done using a DAD-3000 set 
to the range 200 – 600 nm. Samples were kept at 10.0°C in the autosampler during the 
analysis. 2 µL of each sample was injected into a C18 Acquity UPLC F5-3 HPLC 
column (2.1 × 100 mm, 1.8 µm,) at a flow rate of 0.4 mL/min, 30.0°C. Mobile phases 
A and B were 0.1 % formic acid in water and acetonitrile, respectively. Elution was 
done with a 30 min multistep system. After 5 % B for 1 min, a linear gradient started 
from 5 % B to 100 % B in 21 min, which was held for another 5 min and followed by 
re-equilibration to 5 % B until 30 min. Data was collected in both positive and 
negative ion modes with a scan range of (m/z) = 200 – 2000. MS/MS fragmentation 
was carried out using Ion Trap using collision-induced dissociation (CID) with the 
collision energy (30 %), RF Lens 60 %, AGC target 5.0e4, and scan range (m/z) 230 
– 800. Data analyses were performed with the software Xcalibur 3.0.63 (Thermo 
Fisher Scientific Inc.).   
 
NMR of kirromycin-HVI and kirromycin-OII derivatives 
To confirm the structure of the kirromycin-OII derivative (5), a 2L-fermentation of 
the ΔkirOII mutant was carried out. Pure compound 5 (2.2 mg) was obtained by 
separation on a semi-preparative RP-18 column by HPLC. 1D and 2D NMR were 
acquired using standard pulse sequences on an 800 MHz Bruker Avance spectrometer 
with a 5 mm TCI cryo probe at NMR Center, Danish Technology University. CD3OD 
was applied as solvent. Chemical shifts were usually expressed in parts per million 
(ppm, δ) relative to internal standard tetramethylsilane. In addition, kirromycin-HVI 
(3), kirromycin-OI (4), and 5 were analysed at the Institut für Organische Chemie in 
Tübingen University.   
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Results 
Sequence analysis of genes and encoded products presumably involved in 
kirromycin biosynthesis in S. collinus Tü 365 
The genes kirM, kirHVI, kirOI, kirOII, kirHIV, kirHV and kirN are located in the 
kirromycin gene cluster and thus a potential function of their gene products was 
postulated based on sequence analysis, using the sequence aligner DIAMOND against 
the MIBiG database.  
For the tailoring enzymes, the closest homolog of KirM was the O-methyltransferase 
RapM (75 % aa identity and 87 % similarity), involved in rapamycin biosynthesis in 
Streptomyces hygroscopicus NRRL 549121. With 31 % aa identity and 55 % 
similarity, the hydroxylase Fum3p involved in C5 hydroxylation in fumonisin 
biosynthesis in Gibberella fujikuroi22 was the best hit for KirHVI. When the protein 
sequence of KirHVI was aligned against the Uniprot/Swissprot database, most of the 
hits were members of the phytanoyl-CoA dioxygenases enzyme family. KirOI and 
KirOII were putatively assigned to cytochrome P450 hydroxylases. KirOI displayed 
49 % aa identity and 64 % similarity to the previously characterized cytochrome P450 
hydroxylase TiaP2, responsible for hydroxylation of the C20 residue during 
Tiacumicin B biosynthesis23. For KirOII, the closest characterised homolog (40 % aa 
identity/59 % similarity) was found to be the 6-deoxyerythronolide_B hydroxylase 
encoded by eryF, which is involved in biosynthesis of erythromycin in 
Saccharopolyspora erythraea24. 
Additional proteins downstream of the PKS/NRPS biosynthetic core have remained 
assigned with hypothetical function, as it is the case for KirHIV and KirHV. The 
sequence analyses of KirHIV and KirHV, using DIAMOND alignment against the 
MIBiG database, did not yield any significant hits. Furthermore, based on the 
alignment against the UniProtKB/Swiss-Prot database, KirHIV and KirHV displayed 
similarity only to proteins with uncharacterized functions. Here, the best match for 
KirHIV (76 % aa identity and 88 % similarity) was an uncharacterized protein found 
in Frankia sp. BMG5.23. KirHV displayed the highest aa identity and similarity (71 
and 80 %) to an uncharacterized protein from Streptomyces sp. CB00455. Hence, in 
respect of the sequence analyses, the functions of KirHIV and KirHV remained 
elusive.   
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The gene kirN is located downstream of the PKS I/NRPS-encoding region in the BGC 
(see Supplementary Table S3) and shows 76 % aa identity and 86 % similarity to the 
crotonyl-CoA reductase/carboxylase (CCR) SfaR from the sanglifehrin BGC25. In 
addition to this, the sequence analysis revealed that kirN displays between 70 to 76 % 
aa identity with several other CCRs found in other Streptomyces species. 
 
Gene inactivations of kirM, kirHVI, kirOI, and kirOII result in production of 
kirromycin derivatives 
To determine the role of the six genes presumed to be involved in tailoring reactions, 
two different gene replacement strategies were carried out. For the mutants in kirM, 
kirHVI, kirHIV and kirHV, the respective gene was replaced by the ermE* promoter, 
whereas for kirOI and kirOII, a thiostrepton gene cassette together with the ermE* 
promoter were used to replace the genes. Mutants were verified by control PCRs (see 
Supplementary Fig. S6), which resulted in either the expected bands or no product 
when the primers targeted internal regions of the deleted gene. The confirmed mutant 
clones were subjected to fermentation experiments carried out in parallel batches with 
wild type S. collinus Tü 365 as reference strain. The cultures were extracted with 
ethyl acetate, concentrated, and the extracts, including kirromycin and its derivatives, 
were dissolved in methanol. The samples were analysed by HRMS. 
In the 30 min chromatographic method used for separation of kirromycin (1) and its 
derivatives, 1 appeared at 12.2 min with the main ion m/z = 795.4110 [M-H]- (Fig. 4). 
Furthermore, MS/MS fragmentation of the derivatives was carried out to gain insights 
into differences in the chemical formulas (see Supplementary Fig. S2). Kirromycin 
derivatives were detected in the mutants of ΔkirM, ΔkirHVI, ΔkirOI, and ΔkirOII (see 
Fig. 4 and Supplementary Table S3). Gene inactivations of the hypothetical proteins 
encoded by kirHIV and kirHV did not affect the production of kirromycin and resulted 
in HPLC-HRMS data similar to the wild type (see Supplementary Fig. S1-I and S1-
II). Thus, it was concluded that these proteins are not directly involved in kirromycin 
biosynthesis. 
Gene inactivation of kirM resulted in the complete loss of production of 1, and instead 
a new derivative, kirromycin-M (2), with the chemical formula C42H58N2O12 appeared 
in the chromatogram at 11.2 min with m/z = 781.3953 [M-H]- (Fig. 4 and 
Supplementary Table S3). The MS/MS fragmentation of 2 gave rise to a fragment 
ion of m/z = 485.2292 [M-H]- (see Supplementary Fig S2-II). Compared to the 
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fragment ion of 1, which was m/z = 499.2451 [M-H]-, the difference of Δ14 
corresponds to a difference of CH2. This is in accordance with the predicted mass of a 
methyl group and gives strong evidence that KirM catalyses the O-methylation at the 
C20 position in the kirromycin precursor. The derivative produced by the ΔkirM 
mutant was thereby determined to be 20-O-demethyl-kirromycin, which for simplicity 
was referred to as 2. 
Similar to the ∆kirM mutant, the extracts of ∆kirHVI, ∆kirOI, and ∆kirOII were 
analysed using HPLC-HRMS and MS/MS. The chromatograms of these mutants 
revealed new prominent peaks, which were only detected with weak intensities in the 
extract of the wild type S. collinus Tü 365. Gene inactivation of kirHVI led to the 
production of kirromycin-HVI (3). Based on HRMS data (Fig. 4 and Supplementary 
Table S3), the chemical formula of 3 was calculated to be C43H60N2O11 and the 
corresponding ion m/z = 779.4177 [M-H]- appeared at 12.3 min. This derivative was 
already observed in the chromatogram of the WT. In this case, the presence of 3 in the 
wild type extract was concluded to be a shunt product from biosynthetic pathway and 
the result of incomplete biosynthesis of kirromycin. MS/MS fragmentation patterns 
for 1 and 3 yielded the same main fragment ion with m/z = 499.2457 [M-H]- (see 
Supplementary Fig. S2-I and S2-III). Because 1 is fragmented at the peptide bond of 
glycine at C2713 and one of the detected peaks is that of the pyridine-containing 
fragment, this indicated that the sugar-containing fragment is missing a hydroxyl 
group on C30 of 3 in the ΔkirHVI mutant. Furthermore, 1H- and 13C-NMR 
corroborated the putative proposed structure of 3, which could also be referred to as 
30-deoxy-kirromycin (see Supplementary Table S4 and Fig. S4-IA/B). 
Gene inactivations of the putative P450-dependent hydroxylases encoded by kirOI 
and kirOII resulted in detection of the two derivatives kirromycin-OI (4) and 
kirromycin-OII (5) with m/z 797.4286 [M-H]- and 763.4213 [M-H]-, which eluted at 
13.6 min and 13.5 min, respectively (Fig. 4 and Supplementary Table S3). Chemical 
formulas of 4 and 5 were calculated to be C43H62N2O12 and C43H60N2O10, respectively. 
This information together with the fragmentation data allowed for the assignment of 
KirOI to the double bond in the pyridone ring. Furthermore, the fragment ion of 4 of 
m/z = 501.26 [M-H]-, which is the respective fragment of m/z = 499.2451 [M-H]- of 
1, showed a mass unit difference of Δ2 and could be assigned to the loss of two 
hydrogen atoms. The chemical name of 4 should therefore be 5,6-dihydro-kirromycin 
(see Supplementary Fig. S2-I, S2-IV, and Supplementary Table S4). 
 102 
In the case of KirOII, the difference of two oxygen atoms underlined the hypothesis 
of the enzyme being involved in oxidation at C16 and presumably preparing the ring 
closure to the THF ring. MS/MS fragmentation of 5 yielded the fragment ion of m/z = 
469.2548 [M+H]+, which failed to give insight into the exact chemical structure of the 
derivative (see Supplementary Fig. S2-V). Therefore, NMR analyses, including 
1HNMR, 13CNMR, COSY, HSQC, and HMBC were undertaken to gain more insight 
into the structure of this derivative (see Supplementary Table S4, Supplementary 
Fig. S4-IIA/B, and Fig. S5). To elucidate the structure of 5, a 2 L-fermentation of the 
ΔkirOII mutant was carried out. Pure compound 5 (2.2 mg) was obtained by 
separation on a semi-preparative RP-18 column by HPLC. 13CNMR spectrum showed 
the loss of signals for three oxygen-bearing carbons indicating opening of the furan 
ring and corroborated the chemical nomenclature 30-hydroxy-5,6-dehydro-1-N-
demethyl-16-deoxy-kirromycin (see Supplementary Table S4 and Fig. S5-A).  
 
 
To rule out polar effects caused by disruption of the kirromycin BGC, gene 
complementations for each of the mutants, ΔkirM, ΔkirHVI, and ΔkirOII, were 
carried out using conjugation and the integrative plasmid pRM4, and for ΔkirOI using 
the replicative plasmid pGM1190 (see Supplementary Fig. S3-I – S3-IV). The 
complemented mutants were fermented in kirromycin production medium, extracted, 
and the extracts analysed by HPLC-HRMS. The complementation of the ΔkirM 
mutant resulted in similar kirromycin production levels compared to the wild type 
Figure 4 HPLC-ESI chromatograms and MS spectra for kirromycin, produced by the wild type strain, and 
derivatives produced by the mutants. 
 103 
(100 %). For the complementation of the ΔkirHVI mutant, approximately 30 % of the 
wild type levels of 1 could be restored, which was confirmed by both MS and UV-Vis 
quantification. The complementation of the ΔkirOI and ΔkirOII mutants resulted in 
only 10 and 20 % restored production of 1 compared to the wild type levels. Although 
there was no full complementation for these two mutants, the retention times and 
molecular masses, as determined by HRMS, clearly indicated that the observed 
effects were due to the inactivation of the individual genes and not due to polar effects 
on the biosynthetic assembly line.  
 
Gene inactivation of kirN gives rise to lowered kirromycin production 
The ΔkirN mutant and complemented mutant were constructed and tested using the 
same methods as described for the mutants above.  The gene kirN encodes a putative 
CCR, which is postulated to provide the ethylmalonyl-CoA extender unit for the 
trans-AT KirCII, which then loads this substrate onto KirAII-ACP5. Unexpectedly, a 
deletion of kirN (ΔkirN) resulted in loss of kirromycin production. Instead the main 
derivative 3, which was observed in the ΔkirHVI mutant, was detected. Genetic 
complementations with both pGM1190 and pRM4 of the ΔkirN mutant failed to 
restore production of 1. However, upon gene complementation of the ΔkirN mutant 
with kirHVI, levels of 1 were partially restored to ~30 % of wild type levels. Since the 
replacement of kirN with the ermE* promoter was expected to drive expression 
through the downstream gene kirHVI, we instead examined the genetic organisation. 
This revealed overlapping open reading frames (ORFs) of kirN and kirHVI and it was 
concluded that the genetic inactivation of kirN led to the disruption of downstream 
gene kirHVI. To test if production of 1 could be fully restored, pRM4 harbouring a 
copy of both kirN and kirHVI was constructed and used for complementation of 
ΔkirN. This resulted in a restoration of 1 in the ΔkirN mutant, reaching between 40 – 
100 % of wild type levels (see Supplementary Fig. S3-V and S3-VI). Together, this 
data confirmed that the downstream gene kirHVI was affected by the gene 
inactivation of kirN and a full recovery of production of 1 was only possible when 
kirN and its neighbouring gene kirHVI were encoded on the complementation 
construct.
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Discussion 
In this study, the involvement of the seven genes, kirM, kirHVI, kirOI, kirOII, kirHIV, 
kirHV, and kirN in the biosynthesis of kirromycin in S. collinus Tü 365 was 
investigated experimentally based on gene inactivations, complementations, and 
product analyses by HPLC-HRMS, MS/MS, and NMR.  
Our studies provide experimental evidence that KirM acts as an O-methyltransferase, 
giving rise to the methyl group on O42 in kirromycin. This finding is further 
strengthened by comparison of the role of the close homolog RapM in rapamycin 
biosynthesis Streptomyces hygroscopicus NRRL 5491. Gene complementation with 
rapM of the deletion mutant MG2-10 (ΔrapKIJMNOQL) resulted in the restored O-
methylation at the C16 position in this molecule. Furthermore, it was found that 
altering the level of O-methylation in rapamycin resulted in the production of 
rapamycin analogues with altered properties, including increased solubility and 
improved Caco-2 permeability21. Although bioactivity assays have not yet been 
carried out for 2 in this study, it would be interesting to test if the missing methyl 
group results in a kirromycin derivative with altered pharmacokinetic properties. Such 
assays are planned for the future.  
Based on the MS/MS (see Supplementary Fig. S2-III) and NMR analysis (see 
Supplementary Table S4 and S4-IA/B), the main derivative 3 produced by ΔkirHVI 
lacks a hydroxyl group at position C30 in the kirromycin analogue. From the 
sequence-based alignment against the MIBiG database, KirHVI displays similarity to 
the hydroxylase Fum3p, which is responsible for attachment of a hydroxyl group at 
the C5 position in fumonisin B, produced by Gibberella fujikuroi22. Heterologous 
expression of Fum3p in Saccharomyces cerevisiae was previously conducted to 
clarify the enzymatic function of the protein and based on in vitro and in vivo findings 
it was possible to determine Fum3p to be a 2-ketoglutarate-dependent dioxygenase26. 
Since most protein hits from the UniProtKB/Swiss-Prot sequence alignment of 
KirHVI belonged to the family of phytanoyl Co-A dioxygenases it can be postulated 
that the hydroxylation catalysed by KirHVI in kirromycin biosynthesis occurs in a 
similar fashion (see Supplementary Fig. S7-I).  
Furthermore, the function of KirOI and KirOII has been analysed in this study. The 
ΔkirOI mutant produces a kirromycin derivative, which is undoubtedly missing the 
double bond in the pyridone ring (see Supplementary Table S4). Here, the predicted 
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cytochrome P450 hydroxylase KirOI most likely forms a hydroxylated intermediate 
which then undergoes dehydrogenation giving rise the fully unsaturated pyridone ring 
(see Supplementary Fig. S7-II). 
Our HRMS and MS/MS analyses failed to provide data suitable for clear structure 
prediction of the derivative 5 produced by the ΔkirOII mutant. Therefore, 5 was 
subjected to NMR studies, which enabled us to uncover a kirromycin analogue 
missing the THF ring structure and both hydroxyl groups at positions C15 and C16 
(see Supplementary Table S4, Fig. S4-IIA/B, and Fig. S5). Based on our current 
hypothesis, the biosynthesis of kirromycin from 5 might be explained by a mechanism 
similar to that of the cytochrome P450 monooxygenase AurH, which is involved in 
conversion of deoxyaureothin to aureothin, through the formation of two C-O bonds, 
ultimately giving rise to a THF ring27,28. Similar to AurH, KirOII could introduce two 
hydroxyl groups at C14 and C16. Allylic substitution of the hydroxyl system could 
then lead to the formation of the THF ring system at the expense of H2O. The 
alternative enzymatic pathway is found in Supplementary Fig. S7-III. In the future, 
enzymatic in vitro assays are necessary to fully establish the enzymatic reaction 
catalysed by KirOII. 
Finally, we have studied the putative CCR encoded by kirN, which is expected to be 
involved in biosynthesis of the ethylmalonyl-CoA extender unit incorporated in 
kirromycin at the C28 position4. Studies on the involvement of CCRs in both primary 
and secondary metabolism have led to a revision of their function and today these 
enzymes are known for their involvement in acetyl-CoA assimilation through an 
alternative pathway distinct from the glyoxylate pathway29,30. Furthermore, sequence 
analysis of actinomycetes has revealed a tendency of co-clustering of CCRs with 
PKSs. This suggests an important role of the CCRs in polyketide derivatization in that 
they can facilitate the incorporation of polyketide extender units alternative to 
butyrate30,31. The putative role of KirN is furthered strengthened by the 13CNMR 
studies on the N-methylated kirromycin analogue aurodox, in which Liu et al.32,33 
confirmed the incorporation of an intact butyrate unit at the C28 position in the 
molecule. The presence of an additional copy of the CCR, mainly involved in primary 
metabolism, in the genome of S. collinus Tü 365 gives rise to an inherent 
complementation of ΔkirN and, therefore, complete abolishment of kirromycin 
production was not expected. Surprisingly, the ΔkirN mutant generated in this study 
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gave rise to production of 3 instead of the expected lowered production of 1. 
Examination of the genetic organization of the kirromycin BGC revealed the ORF of 
kirN to overlap with that of kirHVI, hence leading to disruption of the latter gene and 
production of 3. Partial and full restoration of kirromycin production was achieved by 
genetic complementation of ΔkirN with kirHVI separately and with kirN and kirHVI 
together, respectively (see Supplementary Fig. S3-V and S3-VI). The observed 
phenomenon should be kept in mind for future BGC engineering efforts to account for 
polar effects in these often tightly regulated systems.  
In our study, we demonstrated that the enzymes KirM, KirHVI, KirOI and KirOII 
play important roles in late stages of the biosynthesis of kirromycin. Derivatives of 1 
were detected in all mutants, expect for ΔkirN, ΔkirHIV, and ΔkirHV. Although the 
genes kirHIV and kirHV are located in the kirromycin BGC, their inactivation had no 
effect on kirromycin biosynthesis and resulted in similar production profiles in both 
the wild type and mutant clones. Consequently, the data suggest that these 
hypothetical proteins are not directly involved in kirromycin biosynthesis. For the 
ΔkirN mutant, we observed a reduced production of 1. While the ΔkirM mutant 
produces a derivative missing a methyl group at the O42 position, the main derivative 
produced by the ΔkirHVI mutant lacks the hydroxyl group at the C30 position in the 
goldinonic acid lactone. Finally, gene inactivations of the kirOI and kirOII, encoding 
the two cytochrome P450 hydroxylases, result in a missing double bond in the 
pyridine ring and no THF ring closure, respectively. These results and the new 
knowledge have allowed us to close some of the missing gaps in the biosynthetic 
pathway of kirromycin (Fig. 3B). Our studies does not allow for determining a 
defined sequence of the tailoring reactions. However, based on our findings, it could 
be argued that the enzymes act in an independent manner.   
The better understanding of the complex kirromycin assembly line, which can be 
regarded as model for hybrid cis-/trans-AT PKS I/NRPSs, provides new incentive to 
the development of novel strategies for the production of polyketide derivatives, 
which might result in novel bioactive compounds. Our previous reports presented the 
use of the trans-AT KirCII, which accepts non-natural malonate-derived extender 
units, as a potential tool for polyketide engineering. The expression of a modified 
malonyl-CoA synthase T207G/M306I MatB and external feeding of the kirromycin 
producer strain with allyl- or propargylmalonic acid resulted in the production of 
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allyl- and propargyl-kirromycin13. However, the reported yields of propargyl-
kirromycin were low compared to the production of the wild type kirromycin (22 % 
propargyl-kirromycin compared to 78 % kirromycin). In particular the ΔkirN mutant, 
generated and analysed in this study, will support the applicability of the MatB-
KirCII-ACP5 system as the production of kirromycin is significantly reduced in this 
mutant. Hence, the use of the ΔkirN mutant as scaffold for production of kirromycin 
derivatives might result in improved yields and an easier accessibility of the desired 
compounds.  
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Table S1: Strains and plasmids in this study 
 
Source Description/Genotype Reference 
E. coli strains 
E. coli DH5-α fhuA2, Δ(argF-lacZ)U169, phoA, glnV44, Φ80, Δ(lacZ)M15, gyrA96, recA1, relA1, endA1, thi-1, hsdR17 
New England 
Biolabs 
E. coli ET12567 
(pUZ8002) 
dam13::Tn9(ChlR), dcm-6, hsdM, hsdR, recF143, zjj-
201::Tn10, galK2, galT22, ara14, lacY1, xyl-5, leuB6, thi-1, 
tonA31, rpsL136, hisG4, tsx-78, mtlI, glnV44. 
pUZ8002(KanR) 
1 
Streptomyces strains 
S. collinus Tü 
365  Wild type Streptomyces collinus Tü 365 
2 
ΔkirM  S. collinus Tü 365 deletion mutant in kirM This study 
ΔkirHVI S. collinus Tü 365 deletion mutant in kirHVI This study 
ΔkirOI 
S. collinus gene replacement mutant in which kirOI is 
replaced by the thiostrepton resistance cassette with the 
ermE* promoter downstream, ThioR 
This study 
ΔkirOII 
S. collinus gene replacement mutant in which kirOII is 
replaced by the thiostrepton resistance cassette with the 
ermE* promoter downstream, ThioR 
This study 
ΔkirHIV S. collinus Tü 365 deletion mutant in kirHIV This study 
ΔkirHV S. collinus Tü 365 deletion mutant in kirHV This study 
ΔkirN S. collinus Tü 365 deletion mutant in kirN This study 
ΔkirOI- 
pGM1190 
ΔkirOI complemented with replicative plasmid pGM1190-
kirOI. ApraR, ThioR This study 
ΔkirM-pRM4 ΔkirM complemented with integrative plasmid pRM4-kirM. ApraR This study 
ΔkirHVI-pRM4 ΔkirHVI complemented with integrative plasmid pRM4-kirHVI. ApraR This study 
ΔkirOII-pRM4 ΔkirOII complemented with integrative plasmid pRM4-kirOII. ApraR, ThioR This study 
ΔkirN-pRM4_1 ΔkirN complemented with integrative plasmid pRM4-kirHVI. ApraR This study 
ΔkirN-pRM4_2 ΔkirN complemented with integrative plasmid pRM4-kirN+HVI. ApraR This study 
Cosmids 
1C24 pOJ436 cosmid vector with a fragment of the genome of kirromycin producer Streptomyces collinus Tü 365 
3 
2K05 pOJ436 cosmid vector with a fragment of the genome of kirromycin producer Streptomyces collinus Tü 365 
3 
 
Plasmids 
pJet1.2/blunt 
rep(pMB1), bla(AmpR), eco47IR, PlacUV5, T7 RNA 
polymerase promoter. Part of the CloneJET™ PCR Cloning 
Kit used for high efficiency cloning of PCR products  
Thermo Fisher 
Scientific Inc. 
pDrive 
T7 RNA polymerase promoter, LacZα, SP6 RNA 
polymerase promoter, AmpR, KanR, pUC origin, phage f1 
origin of replication. For construction of ΔkirOI and ΔkirOII 
gene inactivation plasmids 
Qiagen 
pGUS A21  
Promoter probe vector, pSETGUS with deleted KpnI 
fragment containing TipA promoter. gusA, Δint, ΔattB, MCS 
from pUC21. Used for gene inactivation 
4 
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pGM1190 
pGM190 derivative in which the kanamycin resistance 
cassette is exchanged with the apramycin resistance gene 
aac3(3)IV. TipA promoter, ApraR, ThioR. Used for 
complementation of the kir mutant kirOI 
G. Muth (personal 
communication) 
pRM4 
pSET152ermEp derivative with an artificial RBS, ΦC31 
integration vector, pErmE*, ApraR. Used for 
complementation of the kir mutants 
5 
pA18mob 
pK18mob derivative in which aphII is replaced with the 
apramycin resistance cassette. oriT, lacZα, ApraR. Used for 
construction of gene replacement mutants of kirOI and 
kirOII. 
3 
pSLE61 pUC19 derivative. lacZα, oriI, pSG5 replicon, AmpR, ThioR. For amplification of thiostrepton resistance cassette 
6 
pCRISPR-Cas9 Derivative of pGM1190 with Cas9 under the control of TipA promoter 
7 
pCRISPR-
Cas9_USER- 
ΔkirM 
USER-compatible destination vector, which is a derivative of 
pGM1190 with Cas9 under the control of TipA promoter. 
Cloned with pErmE* between sgRNA and 1 kb flanking 
regions right and left of kirM inserted in the USER cassette. 
ApraR 
7,8 
pCRISPR-
Cas9_USER- 
ΔkirHIV 
USER-compatible destination vector, which is a derivative of 
pGM1190 with Cas9 under the control of TipA promoter. 
Cloned with pErmE* between sgRNA and 1 kb flanking 
regions right and left of kirHIV inserted in the USER 
cassette. ApraR 
7,8 
pCRISPR-
Cas9_USER- 
ΔkirHV 
USER-compatible destination vector, which is a derivative of 
pGM1190 with Cas9 under the control of TipA promoter. 
Cloned with pErmE* between sgRNA and 1 kb flanking 
regions right and left of kirHV inserted in the USER cassette. 
ApraR 
7,8 
pCRISPR-
Cas9_USER- 
ΔkirN 
USER-compatible destination vector, which is a derivative of 
pGM1190 with Cas9 under the control of TipA promoter. 
Cloned with pErmE* between sgRNA and 1 kb flanking 
regions right and left of kirN inserted in the USER cassette. 
ApraR 
7,8 
pHR1 
pGUS A21 deletion plasmid of kirM cloned with pErmE* 
between 1kb flanking regions of the gene. 2.1 kb construct 
cloned from pCRISPR-Cas9_USER-kirM. ApraR 
This study 
pHR2 pGUS A21 deletion plasmid of kirHVI cloned with pErmE* between 1kb flanking regions of the gene. ApraR This study 
pHR3 
pGUS A21 deletion plasmid of kirHIV cloned with pErmE* 
between 1kb flanking regions of the gene. 2.1 kb construct 
cloned from pCRISPR-Cas9_USER-kirHIV. ApraR 
This study 
pHR4 
pGUS A21 deletion plasmid of kirHV cloned with pErmE* 
between 1kb flanking regions of the gene. 2.1 kb construct 
cloned from pCRISPR-Cas9_USER-kirHV. ApraR 
This study 
pHR5 
pGUS A21 deletion plasmid of kirN cloned with pErmE* 
between 1kb flanking regions of the gene. 2.1 kb construct 
cloned from pCRISPR-Cas9_USER-kirN. ApraR 
This study 
pTL-kirOI 1.2 kb flanking regions left and right of kirOI cloned in pA18mob. ApraR This study 
pTL-kirOI-thio pTL-kirOI cloned with thiostrepton resistance cassette inserted in XbaI site. ApraR, ThioR This study 
pDW-kirOII 2 kb flanking regions left and right of kirOI cloned in pA18mob. ApraR This study 
pDW-kirOII-
thio 
pDW-kirOII cloned with thiostrepton resistance cassette 
inserted in the XbaI site. ApraR, ThioR This study 
pJet1.2-kirM pJet1.2/blunt with kirM cloned in the MCS. AmpR This study 
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pJet1.2-kirHVI pJet1.2/blunt with kirHVI cloned in the MCS. AmpR This study 
pJet1.2-kirOI pJet1.2/blunt with kirOI cloned in the MCS. AmpR This study 
pJet1.2-kirOII pJet1.2/blunt with kirOII cloned in the MCS. AmpR This study 
pJet1.2-kirN pJet1.2/blunt with kirN cloned in the MCS. AmpR This study 
pJet1.2-
kirN+HVI pJet1.2/blunt with kirN+HVI cloned in the MCS. AmpR 
This study 
pGM1190-kirOI Complementation plasmid of kirOI cloned in HindIII + EcoRI site This study 
pRM4-kirM Complementation plasmid of kirM cloned in NdeI + HindIII site This study 
pRM4-kirHVI Complementation plasmid of kirHVI cloned in NdeI + HindIII site This study 
pRM4-kirOII Complementation plasmid of kirOII cloned in NheI + HindIII site This study 
pRM4-kirN Complementation plasmid of kirN cloned in NdeI + HindIII site This study 
pRM-kirN+HVI Complementation plasmid of kirN+kirHVI cloned in NdeI + HindIII site This study 
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Table S2: Primers used in this study 
 
ID Primer name Sequence (5' - 3') PCR program 
kirM, kirN, kirHIV, and kirHV inactivation mutants 
KP1 kirM_pGUS_left_FW CTGCAGACGCGTCGACGTCAAGCGACGAGGAGCTGGCG 
1. 98°C, 0:30 min 
2. 98°C, 0:10 min 
3. 73°C, 0:30 min 
4. 72°C, 1:00 min 
5. 72°C, 5:00 min 
(Steps 2-4 × 34) KP2 kirM_pGUS_left_RV ATTACCCTGTTATCCCTAGTTAGTACGCGGGCCCCAGG 
KP3 kirN_pGUS_left_FW 
GGAGCTCGAATTCGAAGCTTCTG
CAGACGCGTCGACGTCATATGCG
ACCCCGACCAGGA 
1. 98°C, 0:30 min 
2. 98°C, 0:10 min 
3. 75°C, 0:30 min 
4. 72°C, 1:00 min 
5. 72°C, 5:00 min 
(Steps 2-4 × 34) KP4 kirN_pGUS_right_RV 
GCGGGAAGCAGTGATAAGCATT
ACCCTGTTATCCCTAGTTCTAGA
ATCTCCGACGACGCGT 
KP5 kirHIV_pGUS_left_FW GCAGACGCGTCGACGTCACTGCTCAAGTACTTCGACTCGAC 
1. 98°C, 0:30 min 
2. 98°C, 0:10 min 
3. 70°C, 0:30 min 
4. 72°C, 1:00 min 
5. 72°C, 5:00 min 
(Steps 2-4 × 34) KP6 kirHIV_pGUS_right_RV ATTACCCTGTTATCCCTAGTTTGACCAGCGCCAGTTGTG 
KP7 kirHV_pGUS_left_FW CTGCAGACGCGTCGACGTCAGCTCAGCTTCGCCGC 
1. 98°C, 0:30 min 
2. 98°C, 0:10 min 
3. 73°C, 0:30 min 
4. 72°C, 1:00 min 
5. 72°C, 5:00 min 
(Steps 2-4 × 34) KP8 kirHV_pGUS_right_RV ATTACCCTGTTATCCCTAGTTGACGATGTCGGGATCCTCCC 
kirHVI inactivation mutant 
KP9 kirHVI_pGUS_left_FW GACGCGTCGACGTCACCGGAGTCGTGCTG 
1. 98°C, 0:30 min 
2. 98°C, 0:10 min 
3. 72°C, 0:30 min 
4. 72°C, 0:30 min 
5. 72°C, 5:00 min 
(Steps 2-4 × 34) KP10 kirHVI_pGUS_left_RV GTCAAGATCGACCGCTTGTTTCCCTTCCCTG 
KP11 kirHVI_pGUS_ermE_FW CTACAGGGAAGGGAAACAAGCGGTCGATCTTGACG 
1. 98°C, 0:30 min 
2. 98°C, 0:10 min 
3. 74°C, 0:10 min 
4. 72°C, 1:00 min 
5. 72°C, 5:00 min 
(Steps 2-4 × 34) KP12 kirHVI_pGUS_ermE_RV CGACGGGCGGCTCGCCGTCGATCCTACCAA 
KP13 kirHVI_pGUS_right_FW GGTAGGATCGACGGCGAGCCGCCCGTCG 
1. 98°C, 0:30 min 
2. 98°C, 0:10 min 
3. 75°C, 0:30 min 
4. 72°C, 0:30 min 
5. 72°C, 5:00 min 
(Steps 2-4 × 34) 
 
KP14 kirHVI_pGUS_right_RV ATTACCCTGTTATCCCTAGTTGGACGCGACCAGGCCGC 
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kirOI and kirOII inactivation mutants 
KP15 1ldOxy5 AACTGCAGTCAACATCACCTACGACC 
1. 94°C, 2:00 min 
2. 94°C, 1:15 min 
3. 60°C, 1:30 min 
4. 72°C, 1:30 min 
5. 72°C, 5:00 min 
(Steps 2-4 × 30) 
KP16 1ldOxy3 AATCTAGACTCGTCGTAGCCGGTG  
KP17 1rdOxy5 AATCTAGAGTCGGCCAGCAACTGG  
KP18 1rdOxy3 AAGAATTCGAACACGTCGATGTGCG 
KP19 thio-up ACTCTAGATCACTGACGAATCGAGGTCGAGGA  
KP20 thio-low AATCTAGAGGCGAATACTTCATATGCGGGGAT  
KP21 leftOIIeco5 GAATTCGTGCCAGGAGGTGATCC 
1. 94°C, 2:00 min 
2. 94°C, 1:15 min 
3. 60°C, 1:30 min 
4. 72°C, 2:00 min 
5. 72°C, 5:00 min 
(Steps 2-4 × 30) 
KP22 leftOIIxba3 TCTAGACTCGACGTCCGTCCAATC 
KP23 rightOIIxba5 TCTAGAGGCCCGCGCTTCCTGAAAG 
KP24 rightOIIhind3 AAGCTTCAGCGCGAACTGCGTCG 
Complementation plasmids 
KP27 kirN_NdeI_FW AAACATATGCAAGACATCATCGACGCCG  
1. 98°C, 0:30 min 
2. 98°C, 0:10 min 
3. 60°C, 0:30 min 
4. 72°C, * 
5. 72°C, 5:00 min 
(Steps 2-4 × 34) 
KP28 kirN_HindIII_RV AAAAAGCTTTCATTTGTTTCCCTTCCCTGTAGG  
KP29 kirM_NdeI_FW AAACATATGAGCCAACCCGATGTGATGACC  
KP30 kirM_HindIII_RV AAAAAGCTTTCAGACTCGGACGGCGAC 
KP31 kirHVI_NdeI_FW AAACATATGACCGACGAAGACCTCGTCACG 
KP32 kirHVI_HindIII_RV AAAAAGCTTTCAACCGGCGCGCTCGG 
KP33 kirOI_ HindIII_pGM1190_FW 
AAAAAGCTTGTGTCCGAGACCGT
TCGTCCCG 
KP34 kirOI_ EcoRI_pGM1190_RV 
AAAGAATTCTCACCATGTCACCG
GCAGCTCG 
KP35 kirOII_NheI_FW AAAGCTAGCGTGACCGGAACATTCGATTGGACG 
KP36 kirOII_HindIII_RV AAAAAGCTTTCACACGAGCTGGACGGGCAG 
Control PCRs and sequencing 
KP37 kirLEFT_ pGUS_seq_FW GCTCGAATTCGAAGCTTCTGCAG 
1. 95°C, 3:00 min 
2. 95°C, 0:30 min 
3. 61°C, 0:30 min 
4. 72°C, 2:15 min 
5. 72°C, 5:00 min 
(Steps 2-4 × 40) KP38 
kirRIGHT_ 
pGUS_seq_RV 
GATAAGCATTACCCTGTTATCCC
TAG 
KP39 apra-up AGCTTCTCAACCTTGG 
1. 94°C, 2:00 min 
2. 94°C, 1:00 min 
3. 50°C, 1:00 min 
4. 72°C, 1:00 min 
5. 72°C, 5:00 min 
(Steps 2-4 × 30) 
KP40 apra-low TCCGCCAAGGCAAAGC 
KP41 oxy1 GCAAAGGAGAGCGTTGTGTC    
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KP42 oxy2 TGGTCTCCGTTCACCATGTC 
1. 94°C, 2:00 min 
2. 94°C, 1:00 min 
3. 60°C, 1:00 min 
4. 72°C, 1:10 min 
5. 72°C, 5:00 min 
(Steps 2-4 × 30) 
KP43 kirOII_check_FW GCGATTGGGGATCTTGGTGA 
KP44 kirOII_check_RV ATGGAAACGGTGGTCACACG 
KP45 kirM_int-500bp_FW CCACCCTGTCCGGTCGCGG 
1. 95°C, 3:00 min 
2. 95°C, 0:30 min 
3. 64°C, 0:30 min 
4. 72°C, 2:30 min 
5. 72°C, 5:00 min 
(Steps 2-4 × 40) 
KP46 kirM_int-500bp_RV GCATCGTCCGCAGCCGCTG 
KP47 kirN_int-500bp_FW GTGTTCGCGTGGAACCCCGG 
KP48 kirN_int-500bp_RV GGGATCCTCCCCACCCGTG 
KP49 kirHIV_int-500bp_FW CCTGGTGGAGGCCGACAACG 
KP50 kirHIV_int-500bp_RV CGCCTCGGCGAGTTCGGCG 
KP51 kirHV_int-500bp_FW GCATGAACTCCGTGCCCCAGG 
KP52 kirHV_int-500bp_RV GCCGCCCGGTCAGTGCACG 
KP53 kirHVI_int-500bp_FW TGGAGGAGTTCCTGGACCCCG 
KP54 kirHVI_int-500bp_RV CGCCGTGATACAGACCGCCG 
KP55 kirOI_int-500bp_FW CGAGGAAGGCGGACCCACCG 
KP56 kirOI_int-500bp_RV GCGTCTCCCTCGGTGAAGTGGTG 
KP57 kirOII_int-500bp_FW GACGGACCTCGTCGCCGGG 
KP58 kirOII_int-500bp_RV GAGCTGGATCTGGCCGTCCTTG 
KP59 pJet_check_FW CGACTCACTATAGGGAGAGCGGC 
1. 95°C, 3:00 min 
2. 95°C, 0:30 min 
3. 60°C, 0:30 min 
4. 72°C,  ** 
5. 72°C, 5:00 min 
(Steps 2-4 × 40) 
KP60 pJet_check_RV AAGAACATCGATTTTCCATGGCAG 
KP61 pGM1190_seq_FW CACGCGGAACGTCCGGG  
KP62 pGM1190_seq_RV CCGCTGAAACTGTTGAAAGTTGTTTAGC 
KP63 pRM4_seq_FW CAGTCACGACGTTGTAAAACGACGG 
KP64 pRM4_seq_RV GGCACCGCGATGCTGTTGTG 
*   0:15 min for kirHV. 0:30 min for kirM/kirHIV/kirHVI. 0:45 min for kirN/kirOI/kirOII. 
** 1:00 min for kirM/kirHVI. 1:30 min for kirN/kirOI/kirOII. 
 
  
 121 
Table S3: HPLC-ESI-HRMS data for kirromycin and derivatives  
 
Compound RT (min) 
m/z for 
[M-H-] 
Chemical 
Formula 
MS/MS 
fragment 
(m/z [M-H-]) 
MS/MS 
fragment 
(m/z [M+H+]) 
Kirromycin  
  (1)* 12.2 795.4110 C43H60N2O12 499.2451 501.2578 
Kirromycin-M 
(2) 11.2 781.3953 C42H58N2O12 485.2292 487.2292 
Kirromycin-HVI 
(3) 12.3 779.4177 C43H60N2O11 499.2457 501.2586 
Kirromycin-OI 
(4) 13.6 797.4286 C43H62N2O12 501.26 503.2768 
Kirromycin-OII 
(5) 13.5 763.4213 C43H60N2O10 467.2548 469.2698 
*ΔkirN(kirHVI-complemented), ΔkirHIV, and ΔkirHV have similar chromatograms and MS profiles to 
those of the wild type kirromycin (1), albeit production is lowered in ΔkirN(kirHVI-complemented).   
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Table S4: 1HNMR spectra and assignments 
1H NMR data (A) and 13C NMR data (B) for 5,6-dihydro-kirromycin (4 from ∆kirOI), 
30-hydroxy-5,6-dehydro-1-N-desmethyl-16-deoxy-kirrothricin (5, from ∆kirOII), and 
30-deoxy-kirromycin (3 from ∆kirHVI) in CD3OD at resonance frequency 1)600 resp. 
150.8 MHz or 2)700 resp. 176.1 MHz. The chemical shifts, obtained from nuclear 
magnetic resonance (NMR) spectroscopy analysis, are represented by Δ ppm. 
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 5,6-dihydro-kirromycin (4, from ∆kirOI)  
30-hydroxy-5,6-dehydro-1-N-demethyl-16-
deoxy-kirrothricin (5, from ∆kirOII)  
30-deoxy-kirromycin 
(3, from ∆kirHVI)  
Position δH [ppm] (Integral, Type, J in Hz)1) 
δC 
[ppm] δH [ppm] (Integral, Type, J in Hz)
2) δC [ppm] δH [ppm] (Integral, Type, J in Hz)
2) δC [ppm] 
1 - - - -  - 
2 - n.d. - 164.5  164.5 
3 - 79.500 - 112.72 112.64 - 112.5 
4 - 169.8 - 169.18, 169.01 - 169.4 
5 2.54, 1H, dd, J = 7.0 (br) 37.3 (br)# 6.12, 1H, d, J = 7.4 102.0 6.11, 1H, s, br 102.1 
6 3.42, 1H, m, J = 7.0 (br) 37.9 7.40, 1H, d, J = 7.4 137.8 7.39, 1H, br 137.8 
7 - n.d. - 198.55, 198.63 - 198.9 
8 - 138.800 - 142.9 - 141.4 
9 6.20, m 134.300 6.97, 1H, ddd, J = 11.4, 5.3, 1.2 143.3 6.94, 1H, br 142.5 
10 6.56, m00 129.3 6.73, 1H, dd, J = 11.4, 14.7 129.5 6.69, 1H, b, dd, J = 12.5, 12.5 129.4 
11 6.56, m00 137.200 6.67, 1H, d, J = 14.7, 10.7 142.3 6.07, 1H, dd, J = 15.1, 7.2 137.0 
12 6.40, 1H, J = 11.5, 15.0 133.9 (br) 6.61, 1H, dd, J = 14.7, 10.7 142.5 6.45, 1H, dd, J = 15.0, 11.0 133.6 
13 5.99, m 135.1 (br) 
6.46, 1H, dd, J = 10.5, 5.9 
6.44, 1H, dd, J = 10.6, 5.7 
138.7 
134.0 6.52, 1H, m (with 24) 136.1 
14 4.25, 1H, dd, J = 12.5 81.8 6.37, 0.6 H, dd, J = 14.7, 10.5 132.1 4.31, 1H, m 81.6 
15 4.28, 1H, dd, J = 12.5 75.0 
5.90, 0.4 H, dt, J = 14.9, 7.4; 
6.26, 0.6H dd, J = 14.8, 10.4 
(also 6.21, dd, J = 11.3, 11.3, 5.67, m,; 6.78, 
m) 
136.02 
133.50 
(131.1, 
132.2, 
133.5) 
4.32, 1H, m 75.0 
16 4.17, 1H, dd, J = 4.4 74.0 2.25, m 40.0, 4.19, 1H, dd, J = 4.4 74.0 
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 5,6-dihydro-kirromycin (4, from ∆kirOI)  
30-hydroxy-5,6-dehydro-1-N-demethyl-16-
deoxy-kirrothricin (5, from ∆kirOII)  
30-deoxy-kirromycin 
(3, from ∆kirHVI)  
Position δH [ppm] (Integral, Type, J in Hz)1) 
δC 
[ppm] δH [ppm] (Integral, Type, J in Hz)
2) δC [ppm] δH [ppm] (Integral, Type, J in Hz)
2) δC [ppm] 
2.40, m 
2.43, m 
40.7, 
34.8 
 
17 3.68, 1H, dd, J = 4.0, 7.5 84.9 4.06, 1H, m 70.9 3.71, 1H, dd, 7.3, 4.1 85.0 
18 - - - - - - 
19 2.16, 1H, ddq, J = 2.0, 7.0 36.8 1.69, 1H, m 40.8 2.20, 1H, m 36.8 
20 3.32, s 91.9 3.46, 1H, d, J = 10.1 90.0 3.34, 1H, d, 9.2 91.9 
21 - 136.0 - 136.7 - 136.1 
22 5.96, 1H, d (br), J = 10 130.9 5.99, 1H, d, J = 10.5 130.4 5.69, 1H, dd, J = 15.0, 6.0 130.8 
23 6.49, 1H, m, J = 11.0, 16.0 128.3 6.51, 1H, dd, J = 15.2, 11.0 128.3 6.56, 1H, dd, J = 15.2, 11.0 128.0 
24 5.67, 1H, m, J = 6.0, 16.0 131.0 5.66, 1H, m (with 35) 130.6 6.53, 1H, dd, J = 15.2, 11.0 128.2 
25a 3.86, 1H, dd, J = 6.5, 15.0 42.0 3.89, 1H, dd, J = 15.8, 5.5 42.1 3.90, 1H, dd, J = 15.8, 5.8 42.0 
25b 3.93, 1H, dd, J = 6.5, 15.0 3.95, 1H, dd, J = 15.8, 6.7 3.95, 1H, dd, J = 15.8, 5.9 
26-N - - - - - - 
27 - 177.9 - 177.9 - 176.9 
28 2.82, 1H, dd, J = 4.0, 11.0 52.5 2.84, 1H, dd, J = 11.0, 4.5 52.5 2.39, 1H, dd, J = 11.1, 4.2 58.3 
29 - 101.0 - 101.0 - 99.5 
30 3.65, 1H, d, J = 4.0 71.4 3.68, 1H, d, J = 3.6 71.4 1.95, 1H, dd, J = 12.6, 4.6 1.48, 1H, dd, J = 12.6, 12.5 38.3 
31 3.57, 1H, d, J = 4.0 74.0 3.60, 1H, d, J = 3.6 74.0 3.74, 1H, d, J = 12.5, 4.6 72.6 
32 - 40.0 - 39.9 - 40.3 
33 4.21, 1H, d, J = 6.0 77.3 4.24, 1H, t, J = 5.8 77.3 4.17, 1H, d, J = 6.0 77.7 
34-O - -   - - 
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 5,6-dihydro-kirromycin (4, from ∆kirOI)  
30-hydroxy-5,6-dehydro-1-N-demethyl-16-
deoxy-kirrothricin (5, from ∆kirOII)  
30-deoxy-kirromycin 
(3, from ∆kirHVI)  
Position δH [ppm] (Integral, Type, J in Hz)1) 
δC 
[ppm] δH [ppm] (Integral, Type, J in Hz)
2) δC [ppm] δH [ppm] (Integral, Type, J in Hz)
2) δC [ppm] 
35 5.62, 1H, dd, J = 6.0, 15.0 130.5 5.66, 1H, m (with 24) 130.6 5.64, 1H, m (with 24) 130.3 
36 6.54, m 127.7 6.58, 1H, dd, J = 14.8, 11.8 127.7 6.55, 1H, m (with 24) 127.9 
37 5.99, m 130.6 6.01, 1H, ddd, J = 10.8, 10.8, 1.5 130.5 6.01, 1H, ddd, J = 10.8, 10.8, 1.0 130.4 
38 5.44, 1H, dq, J = 7.0, 11.0 126.4 5.49, 1H, dq, J = 11.0, 7.0 126.4 5.49, 1H, dq, J = 11.0, 6.9 126.5 
39 1.73, 3H, dd, J = 2.0, 7.0 13.7 1.77, 3H, dm, J = 7.0 13.7 1.77, 3H, dd, J = 7.1, 1.5 13.7 
40 1.95, s (br) 14.4 (br) 2.00, 2.04, 3H, d, J = 0.9 11.61, 11.68 2.01, 3H, 11.7 
41 0.81, 1H, d, J = 7.0 13.9 0.69, 3H, d, J = 7.0 9.49, 9.57 0.84, 3H, d, J = 6.8 13.9 
42 3.15, 3H, s (sh) 56.2 3.17, 3H, s 56.32 3.18, 3H, s 56.2 
43 1.66, 3H, s (sh) 11.2 1.63, 3H, s 11.0 (sh) 1.69, 3H, s 11.2 
44 1.70, m 21.1 1.73, 2H, m 21.1 1.73, 2H, m 21.6 
45 0.92, 3H, t, J = 7.5 12.3 0.95, 3H, t, J = 7.4 12.3 0.95, 3H, t, J = 7.3 12.4 
46 0.89, 3H, s00 15.9 0.92, 3H, s 15.9 0.77, 3H, s 12.4 
47 0.89, 3H, s00 24.6 0.92, 3H, s 24.6 0.94, 3H, s 23.0 
#: assigned due to HSQC correlations. 00: not unambiguously assigned due to tautomerization, missing 2D correlations, or overlaying signals. 
n.d.: not detected. n.a.: not assigned. 
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Figure S1-I – S1-II: UV-VIS profiles of ΔkirHIV and ΔkirHV mutants 
The ΔkirHIV and ΔkirHV mutants were grown in parallel with Streptomyces collinus 
Tü 365 (wild type) in kirromycin production medium and extracted with ethyl acetate. 
The extracts were dried, redissolved and analysed using HPLC-ESI-HRMS. The 
recorded UV profiles of ΔkirHIV (I) and ΔkirHV (II) (black chromatograms) were 
similar to those of the wild type (red chromatograms). These results indicate that the 
two genes kirHIV and kirHV are not directly involved in biosynthesis of kirromycin. 
In the case of ΔkirHV (II), we suspect that the lower intensity of the peak at 12.3 min 
is due to an almost complete assembly of kirromycin molecules and with that fewer 
shunt products.  
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Figure S2-I – S2-V: MS/MS spectra of kirromycin and derivatives 
MS/MS spectra for (I) kirromycin (1), (II) kirromycin-M (2), (III) kirromycin-HVI 
(3), (IV) kirromycin-OI (4), and (V) kirromycin-OII (5). Recorded in negative mode 
(ESI-) with higher-energy collisional dissociation (HCD) of 25 eV for 1, 2, 3, and 5 
and collision-induced dissociation (CID) of 30eV for 4.  
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Figure S3-I – S3-VI: HPLC-ESI-UV-Vis profiles of the wild type 
(WT), Δkir mutants, and complemented mutants 
UV-Vis profiles of Streptomyces collinus Tü 365 (WT) compared to mutants (I) 
ΔkirM, (II) ΔkirHVI, (III) ΔkirOI, and, (IV) ΔkirOII, along with their respective 
complementations. The ΔkirN mutant and its single (kirHVI) and double (kirN+HVI) 
complementations are shown in (V) and (VI), respectively.  
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Figure S4-IA/B – S4-IIA/B:  1HNMR and 13CNMR data and 
assignment for kirromycin-HVI and kirromycin-OII  
(A) 1HNMR and (B) 13CNMR of (I) kirromycin-HVI (3) and  (II) kirromycin-OII (5) 
derivatives (CD3OD, 298 K). Resonance frequency 1) 600 resp. 150.8 MHz, 2) 700 
resp. 176.1 MHz).  
(IA) 
 
(IB) 
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Figure S5-I – S5-III: 2D NMR of kirromycin-OII (5) derivative 
(I) Homonuclear correlation spectroscopy (COSY) spectrum established the partial 
structure for the disrupted furan part (Fig. S5-A) in the kirromycin-OII (5) derivative 
isolated from the ΔkirOII mutant. H17 (δ 4.05) exhibited correlations with both H18 
(δ 1.69) and H16 (δ 2.42, δ 2.25). H16 exhibited further correlations to an olefinic 
proton H15 (δ 5.65), which confirmed the location of the extra double bond. (III) 
Heteronuclear multiple bond correlation (HMBC spectrum) showed correlations 
between H18, Me41, Me43 and C19 (δ 88.7) and corroborated the final structure. The 
red shifted UV-Vis spectrum for 5 could be explained by the elongation of the double 
bond chain. Additional 2D NMR spectra included: (II) (Heteronuclear single quantum 
correlation) HSQC. 
 
 
Figure S5-A Selected COSY (double arrowed) and HMBC (single arrowed) correlations for compound 5. 
(I)
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(II)
 
(III)
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Figure S6-I – S6-II: Verification of Δkir mutants by control PCRs 
Control PCRs on genomic DNA (gDNA) of ΔkirM, ΔkirHVI, ΔkirOI, ΔkirOII, 
ΔkirHIV, ΔkirHV, and ΔkirN were carried out to confirm successful double crossover 
(II). The use of primers (KP43 – KP56) targeting an internal 500 bp region of each 
gene in question (I) allowed for verification of correct mutants by the absence of 
bands (gene replaced by ermE* promoter). Streptomyces collinus Tü 365 (positive) 
(1) and water (negative) (2) controls were included for each primer pair. GeneRuler™ 
1 kb DNA ladder (Fisher Scientific) (L) was used as marker.  
 
(I) 
 
 
(II) 
 
  
 138 
Figure S7-I – S7-III: Putative enzymatic reaction catalysed by 
tailoring enzymes KirHVI, KirOI, and KirOII 
Genetic inactivation studies and NMR analysis enabled the prediction of the putative 
enzymatic reactions catalysed by the phytanoyl-CoA dioxygenase KirHVI (encoded 
by kirHVI) (I) and the two P450-dependent hydroxylases KirOI and KirOII (encoded 
by kirOI (II) and kirOII (III). 
 
 
(I)  
Based on similarity to the hydroxylase Fum3p in fumonisin B9, KirHVI is postulated 
to induce α-ketoglutarate (α-KG)/Fe(II)-dependent hydroxylation at the C30 position 
in the sugar-like moiety in kirromycin. 
 
 
 
 
(II) 
The cytochrome P450-dependent hydroxylase KirOI catalyses hydroxylation of either 
C5 or C6 in the pyridone ring in kirromycin. The intermediate can then undergo 
dehydration, which might be facilitated by a yet uncharacterised enzyme or a trans-
acting dehydrogenase (DH), to form the double bond between C5 and C6. 
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(III) 
Our data suggests KirOII to be involved in formation of the tetrahydrofuran (THF) 
ring in the centre of the kirromycin molecule.  
In case of kirromycin biosynthesis the PKS-derived precursor molecule of kirromycin 
could undergo dual CH2-hydroxylation at C14 and C16, possibly catalysed by the 
cytochrome P450 monooxygenase KirOII. The hypothesis is strengthened from the 
sequence comparison of KirOII to AurH (31 % identity and 49 % similarity). The 
cytochrome P450 monooxygenase AurH has been found to be involved in formation 
of the THF ring in the antifungal compound aureothin produced by Streptomyces 
thioluteus10,11 through the introduction of two C-O bonds. In a similar fashion, KirOII 
might catalyse the following step including a classical ring-closing dehydration 
reaction under formation of the THF ring moiety in kirromycin. This conversion is 
favoured in kirromycin because of increased nucleophilicity of C17-hydroxyl group 
as a result of the hydrogen bonding in a cyclic 6-membered ring including the C20 
carbonyl group. From the ΔkirOII mutant, the tetraene product 4, named 30-hydroxy-
5,6-dehydro-1-N-demethyl-16-deoxy-kirrothricin, is isolated from the culture broth 
due to chemically favoured dehydration to the stable extended conjugated double 
bond system between C6 and C15. 
While this is a plausible enzymatic reaction, the scheme currently lacks an additional 
enzyme responsible for catalysing the reduction of C=O to C-OH at the C20 position 
in kirromycin. Such an enzyme remains to be identified and characterized. 
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Discussion & Perspectives 
The overall aim of this thesis was the development and application of genome 
engineering tools for improved secondary metabolite production in streptomycetes, 
which are organisms known for their ability to produce a range of different clinically 
relevant compounds, including antibiotics.  
Most antibiotics used in clinics today are based on synthetic or semi-synthetic natural 
product-derived compounds94, however, with the increase in multidrug resistant 
pathogens, the need for new antibiotic classes are greater than ever. Fortunately, 
streptomycete genomes harbour several silent BGCs, which potentially could encode 
novel compound classes. With the discovery of these silent gene clusters and 
improvements of molecular tools for genome engineering, both small- and large-scale 
engineering of natural and heterologous Streptomyces hosts are becoming routine 
practice in many laboratories. A comprehensive review on the recent progress 
experienced within the field of streptomycetes engineering is presented in 
manuscript I64 of this thesis.  
In 2015, the CRISPR-Cas9 system was adapted for actinomycetes genome 
engineering75–77. Compared to the at that time existing molecular tools, the CRISPR-
Cas9 system presented a relatively simple and efficient tool for manipulating 
actinomycetal DNA to refactor production of secondary metabolites. Reports of gene 
and gene cluster inactivations75–77, gene silencing77, and gene induction80, using this 
system alone, have accelerated engineering efforts within the field.  
A toolkit for CRISPR-Cas9 genome engineering of actinomycetes was recently 
developed by our group as a part of our compound discovery platform77. To 
encourage its application, our group extended the system into a more comprehensive 
toolkit, which has been included as manuscript II95 in this thesis. The extended 
toolkit includes a software for sgRNA identification96, a CRISPR-Cas9 toolbox for 
different genome engineering efforts, and an adapted uracil-specific excision reagent 
(USER)-cloning strategy and protocol for simple and efficient CRISPR plasmid 
construction. The CRISPR-Cas9 toolbox encompass different genome engineering 
tools, one of which relies on CRISPR-Cas9 plasmids for construction of random size 
libraries, which can be beneficial for gene function studies and for the generation of 
genome-minimised hosts77. Furthermore, the addition of HR templates in the 
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CRISPR-Cas9 vectors allows for scar-less gene deletions or gene insertions at defined 
sites in the host genome. Finally, the catalytically inactive dCas9 is included in the 
toolbox and represents a need tool for reversible gene repression. In this context, the 
development of a USER-cloning system for construction of the CRISPR-dCas9 
vectors was included in manuscript II to facilitate future implementation of the 
system in an automated setting. In addition to the molecular tools, the CRISPy-web 
software was included. The software allows for computer-aided prediction of 20 bp 
recognition sequences for defined genes with as few mismatches, or off-targets, in the 
target genome as possible. 
Further improvement to the USER-cloning system is reported in manuscript III of 
the thesis. While the genome engineering is based on the same principles as those in 
manuscript II, the major difference lies in the improved workflow for plasmid 
construction and its applicability in semi-automatic high throughput approaches. The 
new system includes the plasmids pUSER2-Cas9, pUSER2-dCas9, and pUSER2-
Cas9/ScaLigD, which are all compatible with robotic equipment, in which the USER-
assembly and clone verification can be automated with minimal operator interference. 
The assembled vectors can be directly transferred to Streptomyces or Actinomyces 
hosts.  
The improved cloning system was verified in two manual proof-of-concept studies 
using pUSER-dCas9 for gene repression of core genes involved in actinorhodin 
(ACT) and undecylprodigiosin (RED) biosynthesis in Streptomyces coelicolor A3(2). 
While ACT and RED production could be easily evaluated due to the blue and red 
pigments, respectively, we realise that for future applications of the system, providing 
an additional link to local or global compound databases would improve dereplication 
of the complex sample mixtures substantially in terms of identifying novel 
compounds.  
The feasibility of implementing a cloning system in a high-throughput platform has 
recently been explored for the construction of a library of transcription activator-like 
effector nucleases (TALENs) in an automated setting97. The synthesis platform was 
implemented on the programmable iBioFAB (Illinois Biofoundry for Advanced 
Biomanufacturing) system, which consists of single operational units capable of a 
range of molecular tasks, including PCR, DNA assembly, and transformation. Based 
on very limited operator interference, consisting of only reagents and consumables 
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supply, the automated workflow allowed for the high-throughput construction of a 
library of 192 TALEN constructs to be used for further testing. 
The simplicity behind the USER assembly protocol allows for the same level of 
automation and would enable the fast and easy construction of a library of sgRNA-
harbouring CRISPR constructs, requiring only limited operator interactions. The 
multiple applications of the CRISPR-Cas9 toolbox brings even more versatility to our 
system in that simple modifications, such as the exchange of destination vector or the 
inclusion of HR templates, give rise to entirely new constructs with different 
applications. In this sense, our platform does not restrict itself to single purposes, 
which further strengthens the incentive to implement the system on robotic 
equipment.   
We believe that the combined efforts of manuscript II and III present a unique 
workflow with a high value for future engineering efforts, especially keeping in mind 
the ease of automation. In practise, our automated workflow would present itself as 
follows; First, the gifted strains entering the pipeline would undergo genome mining, 
using a tool such as antiSMASH14,98, to predict and list gene targets for engineering. 
Some operator interference is expected at this stage in order to evaluate the output of 
the in silico prediction. Next, the chosen gene(s) would enter the CRISPy-web 
software for the automated prediction of 20 bp protospacers with as few off-targets as 
possible. The standardised USER-primer construction and ordering can be 
programmed as well. Supplying of the primers, templates, and linearised vectors is the 
last operator action needed for the plasmid construction. The assembled constructs 
can then be directly used for targeted gene inactivation or gene silencing. 
The ability to generate several sgRNAs, both for single and multiple genes, would 
improve further downstream engineering efforts and could increase odds of a positive 
outcome in our compound discovery platform. On that note, it should be mentioned 
that in high-throughput settings, the robustness and consistency of the implemented 
protocol is of high importance in terms of reducing the screening required to obtain 
correct mutants. The current CRISPy-web software tool, implemented in our 
workflow, allows for prediction and evaluation of sgRNAs based on their number of 
off-targets. In the future, the prediction capabilities of our tool might be optimised to 
account for additional thermodynamic properties, which could improve efficacy of the 
sgRNA and with that the Cas9 cleavage99,100. As more studies are undertaken to 
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evaluate the specificity and efficiency of larger pools of sgRNAs, the applicability of 
the in silico prediction tools, such as the CRISPy-web, are expected to improve and 
expand. Being only recently implemented as a tool for genome engineering of 
streptomycetes, more systematic, large-scale studies on the individual components of 
the CRISPR-Cas9 system are expected in the future. 
Streptomyces collinus Tü 365 is a known producer of the narrow-spectrum antibiotic 
kirromycin, which is produced from a hybrid PKS I/NRPS system25. Prior to our 
development of the optimised USER-CRISPR-Cas9 platform, the CRISPR-Cas9 
editing tool77 was tested for construction of a genetic variant of the original strain. 
The interest in using the CRISPR-Cas9 system for gene knockout in S. collinus Tü 
365 was sparked from recent studies on the two discrete trans-AT enzymes KirCI and 
KirCII, which are involved in the supply of extender units to the assembly line of 
kirromycin25–27. The fact that KirCII can recognise and incorporate non-natural 
extender units, alternative to the ethylmalonyl-CoA, in the kirromycin precursor has 
led to the development of a system for polyketide bioderivatization52. Using this 
KirCII-ACP5 tool, the derivatives allyl- and propargyl-kirromycin was produced in 
the wild type strain S. collinus Tü 365. The major limitation of the system, however, 
remained in the lower production yields of the kirromycin derivatives compared to 
kirromycin, which presented a bottleneck for downstream processes, such as 
purification and pharmacokinetic studies. Since the pathway-specific CCR, encoded 
by kirN, is expected to be involved in supply of the ethylmalonyl-CoA, the first part 
of the thesis set out to investigate the role of this gene.  
Unfortunately, our initial attempts to use the CRISPR-Cas9 system for gene 
inactivation of kirN resulted in unexpected genome deletions, in which both 
chromosomal arms of S. collinus Tü 365 were lost. As a consequence, both BGCs of 
kirromycin, found on the TIRs of the chromosome49,50, were lost and kirromycin 
production abolished.  
Chromosome instability in streptomycetes is not an uncommon phenomenon and has 
previously been linked with spontaneous mutations88–90. The mutations caused by the 
CRISPR-Cas9 or any other gene editing strategy are thus expected to give rise to 
instability, which might lead to aberrant reactions, such as those observed for the 
ΔkirN mutant. Furthermore, the natural instability at the telomeric regions on the 
chromosome of streptomycetes might provide additional explanation to the observed 
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phenotype of the ΔkirN mutant in that the BGC of kirromycin is found on the TIRs in 
the chromosome of S. collinus Tü 365. With our current data, it is not possible to 
exactly determine the series of events leading to the loss of both kirromycin BGCs in 
the ΔkirN mutant, but we suspect that the massive stress of the CRISPR-Cas9 
mediated DSBs, that likely happen simultaneously on both TIRs, may lead to 
cyclisation of the chromosomes around the DSBs. This type of DSB-induced 
cyclisation has been reported previously for other streptomycetes, including 
Streptomyces griseus101, Streptomyces lividans 66102, and Streptomyces 
ambofaciens103.  
The growth of the ΔkirN mutant strain was unaffected compared to the wild type 
strain, which fits to previous reports of cyclised mutants growing with comparable 
efficiency to that of the parental strain104. A plausible explanation for this might be 
found in the unique organisation of the chromosomes of streptomycetes, in which 
genes monitoring core functions are located close to the oriC, located in the middle of 
the chromosome. However, in this respect it should be noted that circular 
chromosomes do not necessarily display higher stability than the linear93,105.  
As more laboratories start employing the CRISPR-Cas9 technology, reports 
describing this instability and possible explanations as to why it occurs might be 
something we see more of in the near future. 
Due to the unexpected side effects of using the CRISPR-Cas9 system for genetic 
editing in S. collinus Tü 365, an alternative classical engineering method was 
selected, which makes use of a GusA reporter gene to indicate plasmid integration 
and loss. In continuation of the works of this thesis, our study on kirromycin 
biosynthesis was expanded to include not only kirN, but also genes putatively 
involved in tailoring reactions, as these were yet to be characterised. Six additional 
genes, kirM, kirHVI, kirOI, kirOII, kirHIV, and kirHV were included in the genetic 
study reported in manuscript IV.  
Our studies on the genes involved in tailoring reactions in kirromycin biosynthesis 
allowed us to close most of the missing gaps in the biosynthetic pathway. For the 
genes kirM, kirHVI, kirOI, and kirOII, genetic inactivations led to the production of 
derivatives of kirromycin, which allowed for assigning the functions of the enzymes 
encoded by the genes. As a result, kirM was confirmed to encode an O-
methyltransferase, responsible for installation of the methyl group at the O42 position 
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in kirromycin, and the dioxygenase kirHVI was found to be responsible for 
hydroxylation at the C30 position in the sugar-like moiety of the molecule. 
Furthermore, the cytochrome P450 hydroxylases, encoded by kirOI and kirOII, were 
found to be involved in double bond formation in the pyridone ring and for formation 
of the tetrahydrofuran (THF) ring, respectively. In respect to KirOII, our genetic and 
structural examinations of the kirromycin-OII derivative could open up for new 
studies on the role of hydroxylases in THF ring closure in the molecule. From our 
current data, the putative enzymatic function of KirOII is believed to be similar to that 
of the AurH, which is a cytochrome P450 monooxygenase responsible for installation 
of two C-O bonds during aureothin biosynthesis in Streptomyces thioluteus HKI-
227106,107. To determine the exact enzymatic function of KirOII, the next step will be 
to carry out in vivo and/or in vitro enzymatic assays.   
Using our alternative gene inactivation strategy, we also obtained a correct mutant in 
kirN with lowered kirromycin production compared to the wild type strain. This not 
only confirmed the role of kirN as a CCR, but also yielded a mutant suitable for the 
bioderivatization platform. We hypothesise that the reduction in ethylmalonyl-CoA in 
the ΔkirN mutant can give rise to a larger pool of precursors for the alternative 
malonyl-CoA extender units, such as propargylmalonyl-CoA. Using the KirCII-ACP5 
tool with the ΔkirN mutant presents a future engineering scaffold to improve yields of 
propargyl-kirromycin or other derivatives. Propargyl-kirromycin is of special interest 
in that it can form the basis for further molecular derivatization based on Copper(I)-
catalysed azide/alkyne cycloaddition (CuAAC), or “click” chemistry52, to produce 
novel derivatives of kirromycin.  
In addition to the derivatives generated with the ΔkirN scaffold, our studies on the 
four genes involved in tailoring reactions in kirromycin biosynthesis also provide us 
with a toolbox of four kirromycin derivatives. In the future, these new derivatives 
should be included in mode-of-action studies to test for potentially improved 
properties.  
Recently, the Global Antibiotic Research & Development Partnership (GARDP), a 
joint initiative between the Drugs for Neglected Diseases initiative (DNDi) and World 
Health Organisation (WHO), was launched to deliver new treatments for bacterial 
infections with emerging or present drug resistances108. One of the main parts of the 
initiative includes development of solutions to address the increase in sexually 
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transmitted infections (STIs) caused by the gram-negative pathogen N. 
gonorrhoeae109. Kirromycin has a reported MIC of 0.06 µg/mL41 against N. 
gonorrhoea, but suffers from poor pharmacokinetic properties, which has thus far 
inhibited its used in the clinics. In this respect, the collection of new kirromycin 
derivatives, reported in our study, should be tested for improved pharmacokinetic 
properties. In addition, the ΔkirN mutant, with reduced kirromycin production, can be 
applied to the bioderivatization method to produce new kirromycin analogous with 
higher yields. 
 
 
 
 
Conclusion 
Engineering of secondary metabolism in streptomycetes has witnessed a great 
progress in recent years. As more whole genome sequence (WGS) projects are 
undertaken, our understanding of the potential of these gifted microorganisms for 
production of valuable compounds is increased. Furthermore, improvements to 
existing molecular cloning methods along with the development of entirely new ones 
are opening up for more rational and efficient engineering efforts.  
This thesis contributes to the field of genome engineering of streptomycetes by the 
development of an improved USER-cloning methodology for our CRISPR-Cas9 
toolbox, allowing for implementation of the system in a high-throughput semi-
automatic setting. Lessons learned from the unintended side effects of using the 
CRISPR-Cas9 system for genetic inactivation in S. collinus Tü 365, has helped to 
uncover an area which should be subjected to more studies in the future. The fact that 
the molecular toolbox for genome engineering of streptomycetes continues to expand, 
allowed us to still study genes involved in tailoring reactions and ethylmalonyl-CoA 
supply in kirromycin biosynthesis in S. collinus Tü 365. This leaves us with a 
collection of mutants, which now can be tested for improved properties, especially in 
relation to treatment of infections caused by multidrug resistant N. gonorrhoeae 
isolates.   
 148 
References 
1. Chater, K. F. A Morphological and Genetic Mapping Study of White Colony Mutants of 
Streptomyces coelicolor. J. Gen. Microbiol. 72, 9–28 (1972). 
2. Wildermuth, H. & Hopwood, D. A. Septation During Sporulation in Streptomyces coelicolor. 
J. Gen. Microbiol. 60, 51–59 (1970). 
3. Claessen, D., Rozen, D. E., Kuipers, O. P., Søgaard-Andersen, L. & van Wezel, G. P. Bacterial 
solutions to multicellularity: a tale of biofilms, filaments and fruiting bodies. Nat. Rev. 
Microbiol. 12, 115–124 (2014). 
4. Claessen, D. et al. The formation of the rodlet layer of streptomycetes is the result of the 
interplay between rodlins and chaplins. Mol. Microbiol. 53, 433–443 (2004). 
5. Flärdh, K. & Buttner, M. J. Streptomyces morphogenetics: dissecting differentiation in a 
filamentous bacterium. Nat. Rev. Microbiol. 7, 36–49 (2009). 
6. Barka, E. A. et al. Taxonomy, Physiology, and Natural Products of Actinobacteria. Microbiol. 
Mol. Biol. Rev. 80, 1–43 (2016). 
7. Williams, S. T. & Vickers, J. C. in Biology of actinomycetes (eds. Okami, Y., Beppu, T. & 
Ogawara, H.) 165–270 (Japan Scientific Societies Press, 1988). 
8. Demain, A. L. & Sanchez, S. Microbial drug discovery: 80 years of progress. J. Antibiot. 
(Tokyo). 62, 5–16 (2009). 
9. Bérdy, J. Bioactive microbial metabolites. J. Antibiot.  58, 1–26 (2005). 
10. Bentley, S. D. et al. Complete genome sequence of the model actinomycete Streptomyces 
coelicolor A3(2). Nature 417, 141–147 (2002). 
11. Zerikly, M. & Challis, G. L. Strategies for the Discovery of New Natural Products by Genome 
Mining. ChemBioChem 10, 625–633 (2009). 
12. Weber, T. In silico tools for the analysis of antibiotic biosynthetic pathways. Int. J. Med. 
Microbiol. 304, 230–235 (2014). 
13. Medema, M. H. & Fischbach, M. A. Computational approaches to natural product discovery. 
Nat. Chem. Biol. 11, 639–648 (2015). 
14. Blin, K. et al. antiSMASH 4.0—improvements in chemistry prediction and gene cluster 
boundary identification. Nucleic Acids Res. 45, W36–W41 (2017). 
15. Skinnider, M. A., Merwin, N. J., Johnston, C. W. & Magarvey, N. A. PRISM 3: expanded 
prediction of natural product chemical structures from microbial genomes. Nucleic Acids Res. 
(2017). doi:10.1093/nar/gkx320 
16. Weber, T. in Encyclopedia of Industrial Biotechnology (John Wiley & Sons, Inc., 2010). 
doi:10.1002/9780470054581.eib040 
 149 
17. Weissman, K. J. in Methods in Enzymology 459, 3–16 (2009). 
18. Shen, B. Polyketide biosynthesis beyond the type I, II and III polyketide synthase paradigms. 
Curr. Opin. Chem. Biol. 7, 285–295 (2003). 
19. Hertweck, C. The Biosynthetic Logic of Polyketide Diversity. Angew. Chemie Int. Ed. 48, 
4688–4716 (2009). 
20. Whicher, J. R. et al. Structural rearrangements of a polyketide synthase module during its 
catalytic cycle. Nature 510, 560–564 (2014). 
21. Dutta, S. et al. Structure of a modular polyketide synthase. Nature 510, 512–517 (2014). 
22. Weissman, K. J. The structural biology of biosynthetic megaenzymes. Nat. Chem. Biol. 11, 
660–670 (2015). 
23. Schwecke, T. et al. The biosynthetic gene cluster for the polyketide immunosuppressant 
rapamycin. Proc. Natl. Acad. Sci. 92, 7839–7843 (1995). 
24. Aparicio, J. F. et al. Organization of the biosynthetic gene cluster for rapamycin in 
Streptomyces hygroscopicus: Analysis of the enzymatic domains in the modular polyketide 
synthase. Gene 169, 9–16 (1996). 
25. Weber, T. et al. Molecular Analysis of the Kirromycin Biosynthetic Gene Cluster Revealed β-
Alanine as Precursor of the Pyridone Moiety. Chem. Biol. 15, 175–188 (2008). 
26. Musiol, E. M. et al. Supramolecular Templating in Kirromycin Biosynthesis: The 
Acyltransferase KirCII Loads Ethylmalonyl-CoA Extender onto a Specific ACP of the trans-
AT PKS. Chem. Biol. 18, 438–444 (2011). 
27. Musiol, E. M. et al. The AT(2) domain of KirCI loads malonyl extender units to the ACPs of 
the kirromycin PKS. Chembiochem 14, 1343–1352 (2013). 
28. Fernández-Moreno, M. A., Martínez, E., Boto, L., Hopwood, D. A. & Malpartida, F. 
Nucleotide-sequence and deduced functions of a set of cotranscribed genes of Streptomyces 
coelicolor A3(2) including the polyketide synthase for the antibiotic actinorhodin. J. Biol. 
Chem. 267, 19278–19290 (1992). 
29. Grimm, A., Madduri, K., Ali, A. & Hutchinson, C. R. Characterization of the Streptomyces 
peucetius ATCC 29050 genes encoding doxorubicin polyketide synthase. Gene 151, 1–10 
(1994). 
30. Revill, W. P., Bibb, M. J. & Hopwood, D. A. Purification of a malonyltransferase from 
Streptomyces coelicolor A3(2) and analysis of its genetic determinant. J. Bacteriol. 177, 3946–
3952 (1995). 
31. Arthur, C. J. et al. Self-Malonylation Is an Intrinsic Property of a Chemically Synthesized Type 
II Polyketide Synthase Acyl Carrier Protein. Biochemistry 44, 15414–15421 (2005). 
32. Pfeifer, V. et al. A Polyketide Synthase in Glycopeptide Biosynthesis. J. Biol. Chem. 276, 
 150 
38370–38377 (2001). 
33. Austin, M. B. & Noel, J. P. The chalcone synthase superfamily of type III polyketide 
synthases. Nat. Prod. Rep. 20, 79–110 (2003). 
34. Funa, N. et al. A new pathway for polyketide synthesis in microorganisms. Nature 400, 897–
899 (1999). 
35. Walsh, C. T. Insights into the chemical logic and enzymatic machinery of NRPS assembly 
lines. Nat. Prod. Rep. 33, 127–135 (2016). 
36. Drake, E. J. et al. Structures of two distinct conformations of holo-non-ribosomal peptide 
synthetases. Nature 529, 235–238 (2016). 
37. Gatto, G. J., McLoughlin, S. M., Kelleher, N. L. & Walsh, C. T. Elucidating the Substrate 
Specificity and Condensation Domain Activity of FkbP, the FK520 Pipecolate-Incorporating 
Enzyme. Biochemistry 44, 5993–6002 (2005). 
38. Du, L., Sánchez, C., Chen, M., Edwards, D. J. & Shen, B. The biosynthetic gene cluster for the 
antitumor drug bleomycin from Streptomyces verticillus ATCC15003 supporting functional 
interactions between nonribosomal peptide synthetases and a polyketide synthase. Chem. Biol. 
7, 623–642 (2000). 
39. Fischbach, M. A. & Walsh, C. T. Assembly-Line Enzymology for Polyketide and 
Nonribosomal Peptide Antibiotics: Logic, Machinery, and Mechanisms. ChemInform 37, 
3468–3496 (2006). 
40. Wolf, H. & Zähner, H. Stoffwechselprodukte von Mikroorganismen. Arch. Mikrobiol. 83, 147–
154 (1972). 
41. Tavecchia, P. et al. Synthesis and biological evaluation of new fragments from kirromycin 
antibiotic. J. Antibiot. (Tokyo). 49, 1249–1257 (1996). 
42. Clough, B., Rangachari, K., Strath, M., Preiser, P. R. & Wilson, R. J. Antibiotic inhibitors of 
organellar protein synthesis in Plasmodium falciparum. Protist 150, 189–195 (1999). 
43. Leeds, J. A. et al. In Vitro and In Vivo Activities of Novel, Semisynthetic Thiopeptide 
Inhibitors of Bacterial Elongation Factor Tu. Antimicrob. Agents Chemother. 55, 5277–5283 
(2011). 
44. Prezioso, S. M., Brown, N. E. & Goldberg, J. B. Elfamycins: inhibitors of elongation factor-
Tu. Mol. Microbiol. 106, 22–34 (2017). 
45. Schmid, B., Anke, T. & Wolf, H. Action of pulvomycin and kirromycin on eukaryotic cells. 
FEBS Lett. 96, 189–191 (1978). 
46. Pingoud, A., Urbank, C., Wolf, H. & Maass, G. The Binding of Kirromycin to Elongation 
Factor Tu. Structural Alterations are Responsible for the Inhibitory Action. Eur. J. Biochem. 
86, 153–157 (1978). 
 151 
47. Vogeley, L., Palm, G. J., Mesters, J. R. & Hilgenfeld, R. Conformational change of elongation 
factor Tu (EF-Tu) induced by antibiotic binding. Crystal structure of the complex between EF-
Tu. GDP and aurodox. J. Biol. Chem. 276, 17149–17155 (2001). 
48. Carelli, J. D. et al. Ternatin and improved synthetic variants kill cancer cells by targeting the 
elongation factor-1A ternary complex. Elife 4, e10222 (2015). 
49. Rückert, C. et al. Complete genome sequence of the kirromycin producer  Streptomyces 
collinus Tü 365 consisting of a linear chromosome and two linear plasmids. J. Biotechnol. 168, 
739–740 (2013). 
50. Iftime, D. et al. Identification and activation of novel biosynthetic gene clusters by genome 
mining in the kirromycin producer Streptomyces collinus Tü 365. J. Ind. Microbiol. Biotechnol. 
43, 277–291 (2016). 
51. Pavlidou, M. et al. The phosphopantetheinyl transferase KirP activates the ACP and PCP 
domains of the kirromycin NRPS/PKS of Streptomyces collinus Tü 365. FEMS Microbiol. 
Lett. 319, 26–33 (2011). 
52. Musiol-Kroll, E. M. et al. Polyketide Bioderivatization Using the Promiscuous Acyltransferase 
KirCII. ACS Synth. Biol. 6, 421–427 (2017). 
53. Gui, C. et al. Discovery of a New Family of Dieckmann Cyclases Essential to Tetramic Acid 
and Pyridone-Based Natural Products Biosynthesis. Org. Lett. 17, 628–631 (2015). 
54. Olsthoorn-Tieleman, L. N., Palstra, R.-J. T. S., van Wezel, G. P., Bibb, M. J. & Pleij, C. W. A. 
Elongation factor Tu3 (EF-Tu3) from the kirromycin producer Streptomyces ramocissimus is 
resistant to three classes of EF-Tu-specific inhibitors. J. Bacteriol. 189, 3581–3590 (2007). 
55. Bode, H. B., Bethe, B., Höfs, R. & Zeeck, A. Big Effects from Small Changes: Possible Ways 
to Explore Nature’s Chemical Diversity. ChemBioChem 3, 619–627 (2002). 
56. Baltz, R. H. Genetic methods and strategies for secondary metabolite yield improvement in 
actinomycetes. Antonie Van Leeuwenhoek 79, 251–259 (2001). 
57. Stephanopoulos, G. Metabolic Fluxes and Metabolic Engineering. Metab. Eng. 1, 1–11 (1999). 
58. Ro, D.-K. et al. Production of the antimalarial drug precursor artemisinic acid in engineered 
yeast. Nature 440, 940–943 (2006). 
59. Murli, S., Kennedy, J., Dayem, L. C., Carney, J. R. & Kealey, J. T. Metabolic engineering of 
Escherichia coli for improved 6-deoxyerythronolide B production. J. Ind. Microbiol. 
Biotechnol. 30, 500–509 (2003). 
60. Hong, K.-K. & Nielsen, J. Metabolic engineering of Saccharomyces cerevisiae: a key cell 
factory platform for future biorefineries. Cell. Mol. Life Sci. 69, 2671–2690 (2012). 
61. Cho, C., Choi, S. Y., Luo, Z. W. & Lee, S. Y. Recent advances in microbial production of fuels 
and chemicals using tools and strategies of systems metabolic engineering. Biotechnol. Adv. 
 152 
33, 1455–1466 (2015). 
62. Fang, L., Zhang, G. & Pfeifer, B. A. in Functional Metagenomics: Tools and Applications 
(eds. Charles, T. C., Liles, M. R. & Sessitsch, A.) 45–63 (Springer International Publishing, 
2017). doi:10.1007/978-3-319-61510-3_3 
63. Baltz, R. H. Genetic manipulation of secondary metabolite biosynthesis for improved 
production in Streptomyces and other actinomycetes. J. Ind. Microbiol. Biotechnol. 43, 343–
370 (2016). 
64. Robertsen, H. L., Weber, T., Kim, H. U. & Lee, S. Y. Towards systems metabolic engineering 
of streptomycetes for secondary metabolites production. Biotechnol. J. 1700465 (2017). 
doi:10.1002/biot.201700465 
65. Barrangou, R. et al. CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes. 
Science (80-. ). 315, 1709–1712 (2007). 
66. Bhaya, D., Davison, M. & Barrangou, R. CRISPR-Cas Systems in Bacteria and Archaea: 
Versatile Small RNAs for Adaptive Defense and Regulation. Annu. Rev. Genet. 45, 273–297 
(2011). 
67. Wiedenheft, B., Sternberg, S. H. & Doudna, J. A. RNA-guided genetic silencing systems in 
bacteria and archaea. Nature 482, 331–338 (2012). 
68. Jinek, M. et al. A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial 
Immunity. Science (80-. ). 337, 816–821 (2012). 
69. Makarova, K. S., Aravind, L., Wolf, Y. I. & Koonin, E. V. Unification of Cas protein families 
and a simple scenario for the origin and evolution of CRISPR-Cas systems. Biol. Direct 6, 38 
(2011). 
70. Deltcheva, E. et al. CRISPR RNA maturation by trans-encoded small RNA and host factor 
RNase III. Nature 471, 602–607 (2011). 
71. Nishimasu, H. Crystal Structure of Cas9 in Complex with Guide RNA and Target DNA. Cell 
156, 935–949 (2014). 
72. Hsu, P. D., Lander, E. S. & Zhang, F. Development and Applications of CRISPR-Cas9 for 
Genome Engineering. Cell 157, 1262–1278 (2014). 
73. Sander, J. D. & Joung, J. K. CRISPR-Cas systems for editing, regulating and targeting 
genomes. Nat. Biotechnol. 32, 347–355 (2014). 
74. Garneau, J. E. et al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and 
plasmid DNA. Nature 468, 67–71 (2010). 
75. Cobb, R. E., Wang, Y. & Zhao, H. High-Efficiency Multiplex Genome Editing of Streptomyces 
Species Using an Engineered CRISPR/Cas System. ACS Synth. Biol. 4, 723–728 (2015). 
76. Huang, H., Zheng, G., Jiang, W., Hu, H. & Lu, Y. One-step high-efficiency CRISPR/Cas9-
 153 
mediated genome editing in Streptomyces. Acta Biochim. Biophys. Sin. (Shanghai). 47, 231–
243 (2015). 
77. Tong, Y., Charusanti, P., Zhang, L., Weber, T. & Lee, S. Y. CRISPR-Cas9 Based Engineering 
of Actinomycetal Genomes. ACS Synth. Biol. 4, 1020–1029 (2015). 
78. Qin, Z. et al. Formicamycins, antibacterial polyketides produced by Streptomyces formicae 
isolated from African Tetraponera plant-ants. Chem. Sci. 8, 3218–3227 (2017). 
79. Wolf, T. et al. Targeted genome editing in the rare actinomycete Actinoplanes sp. SE50/110 by 
using the CRISPR/Cas9 System. J. Biotechnol. 231, 122–128 (2016). 
80. Zhang, M. M. et al. CRISPR–Cas9 strategy for activation of silent Streptomyces biosynthetic 
gene clusters. Nat. Chem. Biol. 13, 607–609 (2017). 
81. Jia, H. et al. Development of a CRISPR/Cas9-mediated gene-editing tool in Streptomyces 
rimosus. Microbiology 163, 1148–1155 (2017). 
82. Wilson, M. C. & Moore, B. S. Beyond ethylmalonyl-CoA: The functional role of crotonyl-
CoA carboxylase/reductase homologs in expanding polyketide diversity. Nat. Prod. Rep. 29, 
72–86 (2012). 
83. Deatherage, D. E. & Barrick, J. E. in Methods in Molecular Biology 1151, 165–188 (2014). 
84. Zakrzewska-Czerwińska, J. & Schrempf, H. Characterization of an autonomously replicating 
region from the Streptomyces lividans chromosome. J. Bacteriol. 174, 2688–2693 (1992). 
85. Musialowski, M. S. Functional evidence that the principal DNA replication origin of the 
Streptomyces coelicolor chromosome is close to the dnaA-gyrB region. J. Bacteriol. 176, 
5123–5125 (1994). 
86. Choulet, F. et al. Evolution of the Terminal Regions of the Streptomyces Linear Chromosome. 
Mol. Biol. Evol. 23, 2361–2369 (2006). 
87. Perry, J. A. & Wright, G. D. The antibiotic resistance ‘mobilome’: searching for the link 
between environment and clinic. Front. Microbiol. 4, 138 (2013). 
88. Leblond, P. & Decaris, B. New insights into the genetic instability of Streptomyces. FEMS 
Microbiol. Lett. 123, 225–232 (1994). 
89. Dharmalingam, K. & Cullum, J. Genetic instability in Streptomyces. J. Biosci. 21, 433–444 
(1996). 
90. Altenbuchner, J. & Cullum, J. DNA amplification and an unstable arginine gene in 
Streptomyces lividans 66. MGG Mol. Gen. Genet. 195, 134–138 (1984). 
91. Chen, C. W. et al. The Linear Chromosomes of Streptomyces: Structure and Dynamics. 
Actinomycetologica 8, 103–112 (1994). 
92. Volff, J. N. & Altenbuchner, J. Influence of disruption of the recA gene on genetic instability 
and genome rearrangement in Streptomyces lividans. J. Bacteriol. 179, 2440–2445 (1997). 
 154 
93. Volff, J. N., Viell, P. & Altenbuchner, J. Artificial circularization of the chromosome with 
concomitant deletion of its terminal inverted repeats enhances genetic instability and genome 
rearrangement in Streptomyces lividans. Mol. Gen. Genet. MGG 253, 753–760 (1997). 
94. Newman, D. J. & Cragg, G. M. Natural Products as Sources of New Drugs over the Last 25 
Years. J. Nat. Prod. 70, 461–477 (2007). 
95. Tong, Y., Robertsen, H. L., Blin, K., Weber, T. & Lee, S. Y. in Methods in Molecular Biology 
1671, 163–184 (2018). 
96. Blin, K. CRISPy-web: An online resource to design sgRNAs for CRISPR applications. Synth. 
Syst. Biotechnol. 1, 118–121 (2016). 
97. Chao, R. et al. Fully Automated One-Step Synthesis of Single-Transcript TALEN Pairs Using 
a Biological Foundry. ACS Synth. Biol. 6, 678–685 (2017). 
98. Medema, M. H. et al. antiSMASH: rapid identification, annotation and analysis of secondary 
metabolite biosynthesis gene clusters in bacterial and fungal genome sequences. Nucleic Acids 
Res. 39, W339-46 (2011). 
99. Doudna, J. A. & Charpentier, E. The new frontier of genome engineering with CRISPR-Cas9. 
Science (80-. ). 346, 1258096–1258096 (2014). 
100. Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target 
effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184–191 (2016). 
101. Kameoka, D. et al. Analysis of fusion junctions of circularized chromosomes in Streptomyces 
griseus. J. Bacteriol. 181, 5711–5717 (1999). 
102. Redenbach, M. et al. The Streptomyces lividans 66 chromosome contains a 1 MB deletogenic 
region flanked by two amplifiable regions. MGG Mol. Gen. Genet. 241, 255–262 (1993). 
103. Leblond, P. et al. The unstable region of Streptomyces ambofaciens includes 210 kb terminal 
inverted repeats flanking the extremities of the linear chromosomal DNA. Mol. Microbiol. 19, 
261–271 (1996). 
104. Chen, C. W., Huang, C.-H., Lee, H.-H., Tsai, H.-H. & Kirby, R. Once the circle has been 
broken: dynamics and evolution of Streptomyces chromosomes. Trends Genet. 18, 522–529 
(2002). 
105. Fischer, G., Decaris, B. & Leblond, P. Occurrence of deletions, associated with genetic 
instability in Streptomyces ambofaciens, is independent of the linearity of the chromosomal 
DNA. J. Bacteriol. 179, 4553–4558 (1997). 
106. He, J. & Hertweck, C. Iteration as Programmed Event during Polyketide Assembly; Molecular 
Analysis of the Aureothin Biosynthesis Gene Cluster. Chem. Biol. 10, 1225–1232 (2003). 
107. Richter, M. E. A., Traitcheva, N., Knüpfer, U. & Hertweck, C. Sequential Asymmetric 
Polyketide Heterocyclization Catalyzed by a Single Cytochrome P450 Monooxygenase 
 155 
(AurH). Angew. Chemie 120, 9004–9007 (2008). 
108. Alirol, E. et al. Multidrug-resistant gonorrhea: A research and development roadmap to 
discover new medicines. PLOS Med. 14, e1002366 (2017). 
109. Unemo, M. & Shafer, W. M. Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st 
Century: Past, Evolution, and Future. Clin. Microbiol. Rev. 27, 587–613 (2014). 
  
 156 
Appendix 
1. Abbreviations ............................................................................................................... 157 
2. Artemis evaluation of the ΔkirN mutant of Streptomyces collinus Tü 365 .............. 159 
3. Breseq analysis of the ΔkirN mutant of Streptomyces collinus Tü 365 .................... 160 
  
 157 
1. Abbreviations 
A   adenylation 
aa   amino acid 
ACP   acyl carrier protein 
ACT   actinorhodin 
ARO   aromatase 
AT   acyltransferase 
BGC   biosynthetic gene cluster 
C   condensation 
Cas   CRISPR-associated 
CCR   crotonyl-CoA reductase/carboxylase 
CID   collision-induced dissociation 
CmR   chloramphenicol resistance marker 
CRISPR  clustered regularly interspaced short palindromic repeats 
crRNA   CRISPR RNA 
Cryo-EM  cryogenic electron microscopy 
CuAAC  Copper-dependent azide-alkyne cycloaddition 
CYC   cyclase 
dCas9   catalytically inactive Cas9 
DH   dehydratase 
DSB   double stranded break 
dU   uracil base 
E   epimerisation 
EF   elongation factor 
ER   enoyl reductase 
FA   fatty acid 
GNAT   Gcn5-related N-acetyltransferase 
GOI   gene of interest 
HDR   homology directed repair 
HR   homologous recombination 
HRMS   high-resolution mass spectrometry 
IC50   half maximal inhibitory concentration 
KR   ketoreductase 
KS   ketosynthase 
LB   Luria broth 
MCAT   malonyl-CoA:ACP transferase 
MIC   minimal inhibitory concentration 
MS/MS  tandem mass spectrometry 
MT   methyltransferase 
NHEJ   non-homologous end joining 
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NMR   nuclear magnetic resonance 
NRPS   non-ribosomal peptide synthetase 
nt   nucleotide 
ORF   open reading frame 
OSMAC  One strain-Many compounds 
PAM   protospacer associated motif 
PCP   peptidyl carrier protein 
PCR   polymerase chain reaction 
PKS   Polyketide synthase 
PoC   proof-of-concept 
ppm   parts per million 
PPTase  Sfp-type phosphopantetheinyl transferase 
pre-crRNA  precursor CRISPR RNA 
PS   pyran synthase 
RED   undecylprodigiosin 
S.O.C.   Super Optimal broth with Catabolite repression 
SFM   soy flour-mannitol medium 
sgRNA  single guide RNA 
T   thiolation 
Ta   annealing temperature 
TE   thioesterase 
TIR   terminal inverted repeat 
tracrRNA  trans-activating crRNA 
TSB   tryptic soy broth 
UHPLC  ultra high performance liquid chromatography 
USER   uracil-specific excision reagent 
WGS   whole genome sequence 
WT   wild type 
X-Gluc  5-bromo-4-chloro-3-indolyl-β-D-glucuronic acid 
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2. Artemis evaluation of the ΔkirN mutant of Streptomyces collinus Tü 365 
An installable version of the free genome browser Artemis 
(http://www.sanger.ac.uk/science/tools/artemis) was used to align the reads obtained 
from Illumina MiSeq sequencing of the ΔkirN mutant against the reference genome of 
Streptomyces collinus Tü 365. The two screenshots below display the zoom-in (2AI) 
and zoom-out (2AII) of the bam-sorted alignment. As seen in both (2AI) and (2AII), 
the loss of the both the chromosomal arms in the mutant are evident from the missing 
read coverage. The zoom-in (2AI) is on the left arm of the chromosome of ΔkirN 
mutant.   
(2AI) 
 
(2AII) 
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 3. Breseq analysis of the ΔkirN mutant of Streptomyces collinus Tü 365 
The open-source computational pipeline Breseq has been developed for identification 
and annotation of genetic differences in mutants based on the mapping of data, 
obtained from next-generation sequencing technology, against a high-quality 
reference genome83. Using this tool, the Illumina MiSeq reads of the ΔkirN mutant 
was mapped against the reference genome of Streptomyces collinus Tü 365. The 
output data was a HTML file containing a list of all mutations found in the mutant. A 
modified version of the list, in which only the large deletions are listed, is presented in 
Fig. 3AI below. As seen from the list, both arms of the chromosome of the ΔkirN 
mutant were lost. The list include start and end positions of the two large deletions in 
addition to their sizes, which are of 787,795 and 630,478 bp. Genes involved in 
kirromycin biosynthesis has been underlined (in red) in the figure.  
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(3AI) 
 
